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Synopsis 
Telomeres are repetitive nucleotide sequences located at the ends of chromosomes 
that, together with the binding of a group of proteins known as ‘shelterin’, serve to maintain 
the integrity of genomic DNA, and to distinguish natural DNA ends from DNA damage sites. 
The semi-conservative nature of DNA replication results in telomeric DNA shortening after 
every round of cell division, culminating in cellular senescence and aging. Cancer is a class of 
disease characterised by unlimited cellular proliferation, in contradiction to the regulation 
conferred by this ‘mitotic clock’. This resistance to the inherent cellular limit on proliferation 
can only be achieved by lengthening telomeres, either by the ribonucleoprotein telomerase 
or a recombination-based telomere extension mechanism termed ‘Alternative Lengthening 
of Telomeres’ or ‘ALT’. Telomerase is a ribonucleoprotein that was first discovered in the 
mid-1980s in the ciliated protozoan Tetrahymena thermophila. Human telomerase consists 
of a minimal catalytic complex of hTERT, hTR and the protein dyskerin. Studies into 
telomerase regulation have suggested that phosphorylation can mediate this process, 
possibly by modulating active site accessibility, cellular localisation, protein structure and 
protein – protein interactions. The protein kinase C and Akt kinase pathways have been 
shown to affect telomerase activity, although the mechanistic understanding of how these 
events lead to changes in telomerase regulation remains poor.  
The involvement of DNA damage proteins in telomere length regulation was first 
observed in humans containing a defective Ataxia Telangiectasia Mutated (ATM) gene. ATM 
and ATR are two members of a family of serine/ threonine kinases termed the 
Phosphatidylinositol 3-kinase-related kinases (PIKK) that coordinates cellular responses to 
stress. Patients with a defective ATM gene display short telomeres as well as symptoms 
including increased incidence of cancers, diabetes and premature aging or fragility of the 
skin, nails and hair. Subsequent studies in yeast models demonstrated the requirements for 
Tel1 (the yeast homolog of ATM) and Rad3 (the yeast homolog of ATR) in phosphorylating 
telomere binding proteins to mediate telomerase recruitment to telomeres. Studies in 
murine models have indicated that ATM is dispensable for the recruitment of telomerase to 
the shortest telomeres. In human cells, ATM can phosphorylate the mammalian double 
stranded telomere specific binding protein TRF1 at multiple residues. ATM phosphorylation 
of TRF1 at S367 mediates proteosomal directed degradation of TRF1. This coincides with an 
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increase in telomere length, although these studies did not examine whether telomere 
lengthening can be directly attributed to increases in telomerase recruitment to telomeres.  
These data demonstrated the universal importance of phosphorylation in mediating 
different aspects of telomerase regulation, which underpins the general aims for this PhD 
project: to understand the role of phosphorylation in regulating the activities, recruitment, 
assembly and primer binding of telomerase. 
The first major aim of this work (Chapter 3) involved the identification and 
characterisation of novel hTERT phosphorylation sites. These phosphorylation sites were 
identified from published phospho-proteomic studies (T1113 and S1125), and via phospho-
enrichment and mass spectrometry performed by Dr. Scott Cohen (S206 and S523). Various 
biochemical and molecular biology techniques were used to characterise telomerase 
containing either non-phosphorylated or phospho-mimetic hTERT. None of the residues 
examined displayed any biologically significant differences that could be attributed to 
phosphorylation. There are several possible explanations for these observations, including 
potential artefacts from protein over-expression, or the possible involvement of these 
phosphorylation sites in mediating a telomerase-independent function of hTERT. Chapters 3 
and 6 discuss these possibilities, and future work that should be carried out to address these 
observations. 
While the need for ATM and ATR homologues in telomerase recruitment has been 
demonstrated in yeast model systems, whether human telomerase recruitment to 
telomeres is regulated by ATM or ATR is unknown. The second aim of this work was to 
investigate the requirement for ATM and ATR in human telomerase recruitment to 
telomeres. By directly visualising cellular telomerase localisation using a fluorescence in situ 
hybridisation assay with probes for both telomeres and hTR, chapter 4 directly 
demonstrated the essential role of ATM and ATR kinase activity in mediating this process. 
Depletion of either kinase abolished telomerase recruitment across all phases of the cell 
cycle, while TRF1 was identified as one of the downstream substrates of ATM. Depletion of 
TRF1 led to the deregulation of telomerase recruitment and elevated levels of telomerase at 
the telomere outside of S phase, in particular in G2/M phase. Phospho-mimetic mutations 
of TRF1 at S367 resulted in the dissociation of TRF1 from telomeres, and directly resulted in 
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increased telomerase presence at the telomere, illustrating the negative regulatory 
feedback between TRF1 telomere occupancy and telomerase recruitment. Chapter 4 also 
demonstrated that stalled replication forks and the resulting ATR activation induce 
telomerase recruitment in human cells, providing the first mechanistic explanation for the 
observation of increasing telomere lengths after replication fork stalling and replication 
stress. 
The third aim of this project involved identifying novel ways with which ATM and 
ATR can mediate telomerase regulation independently of telomere recruitment and TRF1 
(Chapter 5). By measuring the levels of hTR in HEK 293T cells before and after hTERT 
immunoprecipitation, chapter 5 demonstrated the requirement for both ATM and ATR in 
mediating telomerase complex assembly, and that ATM-mediated telomerase assembly 
occurs in a TRF1-independent manner. This discovery of ATM and ATR involvement in the 
regulation of telomerase assembly represents a novel insight into telomerase biogenesis. 
Overall, the work presented in this thesis highlighted the similar requirements for 
both DNA damage proteins ATM and ATR in mediating telomerase recruitment in humans 
and yeast, as well as the importance of phosphorylation in regulating different stages of 
telomerase biogenesis. Our current working model supports the notion that ATM 
phosphorylation of TRF1 during S phase triggers TRF1 telomeric dissociation. This induces 
replication fork stalling and activates ATR signalling to mediate telomerase recruitment. A 
second regulatory pathway involves the role of ATM and ATR in facilitating telomerase 
assembly to contribute to telomerase-mediated telomere length regulation. This PhD thesis 
presents the vital requirements of both the process of phosphorylation and the process of 
DNA damage signalling for optimal telomerase recruitment and assembly. Increasing our 
knowledge of how DNA damage proteins and the process of phosphorylation can be 
exploited to regulate telomerase action at telomeres can potentially lead to new avenues in 
efforts for finding better cancer therapeutics.  
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Introduction  
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1. Introduction 
1.1 Cancer 
According to data from Cancer Council Australia, cancer is one of the leading causes 
of death in Australia (Feletto et al., 2013). It is vital to understand the biogenesis of cancer 
as well as its regulating pathways, in order to identify new targets for potential therapeutic 
intervention. This knowledge can potentially give rise to treatments with higher specificity, 
without the associated side effects and toxicity currently endured with conventional 
treatments such as chemotherapy and radiation therapy.   
Cancer is a class of disease characterised by the uncontrolled proliferation of cells. 
Cancer cells have been described as exhibiting six ‘hallmarks’, combinations of which must 
be acquired for malignant transformation. They include sustained angiogenesis, tissue 
invasion and metastasis, unlimited replicative potential, apoptosis evasion, self-sufficiency 
in growth signals and insensitivity to anti-growth signals (Hanahan and Weinberg, 2000). 
Advances in the understanding of cancer biogenesis as well as conceptual progress 
prompted a re-examination of the characteristics that allow tumour formation and cancer 
progression. Two new enabling characteristics were included: genome instability and 
mutation, as well as tumour-promoting inflammation. In addition, two new hallmarks were 
also introduced to the canonical list: the deregulation of cellular energetics and the ability to 
avoid immune destruction (Hanahan and Weinberg, 2011) (Figure 1.1).  
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Figure 1.1: The hallmarks of cancer. The hallmarks of cancer cells as reviewed by 
Hanahan and Weinberg 2011. The eight cancer hallmarks and two enabling characteristics 
represent gain of function mutations that must be acquired in various combinations to 
facilitate tumourigenesis and hence, cancer development. (Hanahan and Weinberg, 2011).  
The eight cancer hallmarks and two enabling characteristics are factors that facilitate 
the uncoupling of cell cycle regulation from external stimuli, and confer cells with the 
potential to proliferate in a different tissue or cellular context through the manipulation of 
oxygen supply and vital nutrients. They also allow evasion from immunological detection, to 
facilitate unregulated cellular proliferation as well as facilitating the process of acquiring 
additional hallmarks by equipping cells with genetic alterations that predispose them to 
tumour progression. However, these deregulated conditions and gain of function mutations 
are in principle insufficient to permit uncontrolled cellular growth, due to the ‘Hayflick limit’. 
The Hayflick limit was termed following observations made by Leonard Hayflick, who 
demonstrated that cells cultured in vitro have a finite replicative lifespan before ceasing to 
proliferate, an irreversible phenomenon termed ‘cell senescence’ (Hayflick and Moorhead, 
1961).  
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Therefore, the limited replicative capacity of normal cells represents a critical hurdle 
preventing cells from becoming oncogenic. In order to overcome this and achieve 
oncogenesis, cells must find a solution around the DNA ‘end replication problem’. 
1.2 DNA end replication problem 
 
Figure 1.2: The DNA end replication problem. Telomeric DNA ends consist of a single-
stranded 3’ overhang. During replication, the DNA replication machinery, which includes 
DNA helicase and associated proteins, unwind the DNA to allow RNA primers to bind to the 
single stranded DNA and initiate daughter strand synthesis. Due to the inherent nature of 
DNA replication from the 5’ to 3’ direction, the leading strand is synthesised continuously to 
result in blunt ended daughter strands. The lagging strand is synthesised in short sections 
known as Okazaki fragments which are later ligated by DNA ligase following primer 
displacement to form blunt-ended double stranded daughter DNA. The removal of the most 
5’ end RNA primer in the lagging strand, coupled with C-strand fill in, results in the re-
introduction of the 3’ lagging overhang, while Apollo exonuclease activity is required to 
regenerate the 3’ overhang in the leading DNA strand. This 3’ overhang regeneration in the 
leading strand results in the loss of DNA material with each replication cycle.  
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The DNA end replication problem arises due to two factors: the semi-conservative 
nature of DNA synthesis and the maintenance of chromosome ends (telomeres) as single 
stranded 3’ overhangs post-replication (Dionne and Wellinger, 1996; Wright et al., 1997; 
Klobutcher et al., 1981; Henderson and Blackburn, 1989; Wellinger et al., 1993). During DNA 
replication, the duplex DNA is unwound by DNA helicase and accessory proteins at the 
replication fork (Leman and Noguchi, 2013). The 5’ to 3’ directionality of replication results 
in the continuous replication of the leading strand, while the lagging strand is replicated in 
segments known as Okazaki fragments (Okazaki et al., 1968). Following RNA primer 
displacement by the invading DNA polymerase complex from the 5’ end, the fragments are 
ligated by DNA ligase. Due to the non-terminal positioning of the extreme 5’ end RNA 
primer in lagging strand telomere synthesis, as well as the loss of this primer by RNases, the 
single stranded 3’ telomeric DNA overhang is elongated during S phase, and later shortened 
to the correct length by C-strand fill-in (Dai et al., 2010; Wu et al., 2012; Chow et al., 2012). 
The blunt-ended leading daughter strand undergoes excision by Apollo exonuclease to 
regenerate a 3’ telomeric DNA overhang in G2/M phase (Lingner and Cech, 1996; Wu et al., 
2010; Wu et al., 2012; Chow et al., 2012). This mechanism of 3’ overhang generation leads 
to the shortening of telomeric DNA with each round of nucleotide replication, a 
phenomenon termed the ‘end replication problem’. In human fibroblasts, this loss of DNA is 
estimated to be between 50-200 nucleotides per cell division (Harley et al., 1990). Telomeric 
DNA thus limits cells to a finite number of replication cycles without catastrophic deletion of 
DNA coding regions (Figure 1.2).  
1.3 Telomeres 
Human telomeres comprise tandem 5’-TTAGGG-3’ nucleotide repeats located at the 
ends of chromosomes, and confer protection against recombination, end to end fusions and 
the recognition of chromosome ends as double-stranded DNA breaks (Moyzis et al., 1988; 
O'Sullivan and Karlseder, 2010). Termination of human telomeres as single-stranded 3’ G-
rich overhangs (Figure 1.2) (Makarov et al., 1997; Wright et al., 1997) makes them 
susceptible to nucleolytic attack and recombination. To overcome this, telomeric 3’ ends 
have been observed to adopt secondary structures such as G-quadruplexes and T-loops in 
vitro (discussed below), and associate with a group of six telomere specific binding proteins, 
collectively known as the shelterin complex (Bochman et al., 2012; Griffith et al., 1999; de 
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Lange, 2005). While broken chromosomes ends and telomeres devoid of shelterin 
components activate DNA damage responses (DDR), shelterin-bound telomeric ends do not. 
This provides further evidence that adopting various secondary structures and/or 
associating with capping proteins enables telomere ends to distinguish themselves and 
hence evade the activation of DNA damage responses (McClintock, 1941; Sandell and 
Zakian, 1993; Takai et al., 2003; Cesare and Karlseder, 2012; Cesare et al., 2013).   
1.4 Telomeric secondary structure – G-quadruplexes 
One of the first secondary structures discovered using in vitro telomeric DNA 
oligonucleotides is a group of guanine-rich structures called G-quadruplexes. Diffraction 
studies in the 1960s, coupled with an earlier observation that high concentrations of 
guanylic acid form gels, led to the notion that guanosine residues have the ability to form 
tetrameric arrangements (Gellert et al., 1962; Bryan and Baumann, 2011). These 
observations led to the discovery that G-rich sequences, particularly those comprising four 
or more 5’-TTAGGG-3’ repeats, could form structures in which the guanine residues form 
hydrogen bonds with one another forming a planar cyclic array called a ‘G-quartet’. Multiple 
G-quartets stack to form secondary structures termed ‘G-quadruplexes’ (Gellert et al., 1962; 
Williamson et al., 1989), in which interactions between the DNA strands can either be 
intramolecular or intermolecular. G-quadruplexes exhibit wide structural polymorphism, 
dictated in part by the type of metal ion present in solution, and can be grouped into three 
main conformations: parallel, antiparallel and hybrid structures (Wang and Patel, 1993; 
Parkinson et al., 2002; Phan et al., 2007; Dai et al., 2007).  
It is generally accepted that one biological function of G-quadruplexes involves 
inhibition of the telomere extension enzyme telomerase (described later), and thus, 
negative regulation of telomerase-mediated telomere lengthening (Wang et al., 2011; 
Zahler et al., 1991). However, studies performed using ciliates suggested that the biological 
significance of parallel intermolecular G-quadruplexes is more complex. Ciliate telomerase 
has the ability to extend parallel intermolecular G-quadruplexes in vitro (Oganesian et al., 
2006). More recently, it has been demonstrated that human telomerase can co-localise with 
a subset of G-quadruplexes in human cells, and extend parallel, intermolecular G-
quadruplex conformations in vitro (Moye et al., 2015). Why parallel intermolecular G-
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quadruplexes are permissive to telomerase extension while anti-parallel G-quadruplexes are 
not is one aspect of the biological significance of G-quadruplexes that is currently not well 
understood.  
Recent studies have provided direct evidence for the existence of G-quadruplexes in 
vivo. Separate G-quadruplex-specific antibodies demonstrated the presence of G-
quadruplexes in the human genome (Biffi et al., 2013; Henderson et al., 2014). These studies 
support several other lines of evidence indicating that G-quadruplexes may play vital 
biological roles. Firstly, the distribution of G-quadruplexes along the genome appears to be 
non-random. G-rich sequences are concentrated in functionally vital regions including 
telomeres and gene promoters, with oncogenes more likely to contain these sequences 
compared to tumour suppressors (Huppert and Balasubramanian, 2005; Siddiqui-Jain et al., 
2002; Huppert and Balasubramanian, 2007; Smargiasso et al., 2009). In addition, the large 
number of proteins that have been demonstrated to bind G-quadruplexes in in vitro assays 
lends credibility to the notion that G-quadruplexes are not just experimental artefacts, but 
rather, are involved in regulating important biological roles (reviewed in Oganesian, 2007). 
Together, this evidence indicates the presence and biological importance of G-quadruplexes 
in vivo.  
1.5 Shelterin components, telomeric ‘t-loops’ and the suppression of DNA damage 
Human telomeres are bound by a group of six telomere-specific binding proteins 
collectively termed the ‘shelterin’ complex (de Lange, 2005). This complex consists of the 
double-stranded DNA binding proteins TRF1 and TRF2, the single-stranded DNA binding 
proteins POT1 and TPP1, the bridging protein TIN2, as well as RAP1.  
TRF1 was first discovered in 1992 as a dimeric double-stranded TTAGGG-specific 
binding protein in HeLa cells (Zhong et al., 1992). It contains a C-terminal myb-type DNA 
binding domain, a TRF-homology domain to mediate homodimerization, and an N-terminal 
acidic domain (Broccoli et al., 1997; Bianchi et al., 1997; Fairall et al., 2001; Smith and de 
Lange, 1997). TRF1 is a suppressor of telomere elongation, since over-expression resulted in 
a gradual decrease in telomere length, while a mutant that is defective in telomere binding 
caused progressive telomere elongation (van Steensel and de Lange, 1997; Smogorzewska 
et al., 2000; Ancelin et al., 2002). This role of TRF1 is also supported by studies in 
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Schizosaccharomyces pombe, in which deletion of Taz1, the homolog of human TRF1 and 
TRF2, results in a ~10-fold increase in telomere length (Cooper et al., 1997; Dehe et al., 
2012).  
There are conflicting reports of the role of TRF1 in the progression of DNA 
replication, likely due to the different experimental contexts of these studies. Human, 
murine and yeast telomeric repeats are poor substrates for the canonical DNA replication 
machinery and thus stalled replication forks are a common occurrence (Ivessa et al., 2002; 
Makovets et al., 2004; Fouche et al., 2006; Sfeir et al., 2009). In vitro techniques involving 
baculovirus-expressed TRF1 and TRF2 demonstrated that saturating the telomere with TRF1 
or TRF2 proteins reduces the efficiency of telomeric repeat replication and causes an 
increase in the rate of replication fork stalling (Ohki and Ishikawa, 2004). In contrast, in vivo 
murine and human cell studies have demonstrated the requirement for TRF1 in preventing 
the ATR/ATM mediated activation of the checkpoint kinases CHK1 and CHK2 (Martinez et 
al., 2009), while facilitating the resolution of stalled replication forks for efficient telomere 
replication (Sfeir et al., 2009; McKerlie and Zhu, 2011). This is achieved by recruiting BLM or 
RTEL1 helicases, and TPP1/POT1 to repress ATR signalling (Sfeir et al., 2009; Zimmermann et 
al., 2014). The role of TRF1 in facilitating the efficient progression of the replication fork 
through telomeres is supported by in vivo studies on Taz1, the homologue of TRF1 and TRF2 
in S. pombe, in which the loss of Taz1 results in replication fork stalling, indicating the 
requirement of Taz1 for efficient replication fork progression (Miller et al., 2006).  
In addition to its telomere-specific role, TRF1 also has a telomere-independent role 
in mitosis and chromosome segregation. Knockdown of TRF1 abolishes Aurora-B 
recruitment to the centromeres, resulting in improper microtubule-kinetochore 
attachments and manifesting in aneuploidy in both murine and human diploid cells. This 
role of TRF1 is most likely telomere-independent because over-expressing a mutant TRF1 
defective in telomere binding can also reverse such a phenotype (Ohishi et al., 2014). 
TRF2 is another double-stranded telomeric DNA binding protein that exhibits high 
similarity to TRF1, with the exception that it contains a basic N-terminal domain (Broccoli et 
al., 1997). It is a known negative regulator of telomere length in the context of both murine 
and human models (Smogorzewska et al., 2000; Ancelin et al., 2002; Karlseder et al., 2002). 
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The major role of TRF2 is the suppression of ATM activation and end-to-end chromosome 
fusions (Karlseder et al., 2004; Denchi and de Lange, 2007). TRF2 is able to directly bind to 
and inhibit the activation of ATM through its dimerisation domain (Karlseder et al., 2004). In 
addition, TRF2 has the ability to inhibit the E3 ubiquitin ligase RNF168 via the enzyme BRCC3 
and ubiquitin ligase UBR5 to terminate the propagation of downstream DNA damage 
signalling and prevent chromosome end-to-end fusions (Karlseder et al., 2004; Okamoto et 
al., 2013). TRF2 was also found to interact with the microcephaly syndrome protein 
(MCPH1) and the phosphatase nuclear targeting subunit (PNUTS) (Kim et al., 2009). MCPH1 
binding to TRF2 is required to mediate suppression of ‘telomere dysfunction-induced foci’ 
(TIF), while PNUTS lacking its phosphatase-interacting domain resulted in telomere length 
elongation, suggesting that both proteins have distinct roles in regulating telomere end 
protection and length respectively via TRF2 interaction (Kim et al., 2009).   
The TRF2 protein is involved in the formation and maintenance of the telomeric 
secondary structure termed a ‘t-loop’ in both human and mouse cells (Griffith et al., 1999; 
Doksani et al., 2013). T-loop formation involves the invasion of the single stranded 3’ 
telomeric end back into duplex telomeric repeats to form telomeric loops of varying sizes,  a 
structure that was first observed via electron microscopy of human and mouse purified 
telomeric fragments (Figure 1.3) (Griffith et al., 1999). The study utilised the two earliest 
known TTAGGG repeat-binding factors TRF1 and TRF2 (Chong et al., 1995; Bilaud et al., 
1997; Broccoli et al., 1997) and demonstrated that the direct binding of TRF2 to telomeric 
repeats induces an architectural change, allowing the 3’ telomere end to invade the duplex 
region (Griffith et al., 1999; Stansel et al., 2001). This observation is supported by data from 
a later study on murine telomeres using super-resolution microscopy which indicated that 
TRF2 is the only shelterin component needed for t-loop maintenance (Doksani et al., 2013), 
suggesting that TRF1 is not involved in mediating t-loop formation in either species. The 
formation of telomere t-loops in S. pombe is also mediated by the binding of the double 
stranded telomeric protein Taz1 (homolog of human TRF1 and TRF2). The binding of Taz1 to 
telomeres in vitro has also been observed to be specifically required for telomeric DNA to 
form t-loops with a frequency of ~13% in S. pombe (Tomaska et al., 2004).  
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Figure 1.3: Image of mammalian t-loops in HeLa cells. Human telomeres from HeLa 
cells showed that telomeric ends are able to remodel into a loop structure via a homologous 
recombination mechanism (Griffith et al., 1999).  
Telomere shortening provides the shelterin complex proteins, particularly TRF2, with 
less telomeric repeats with which to bind. This has been postulated to lead to the loss of 
architectural influence of TRF2, culminating in an inability to form t-loops (Griffith et al., 
1999; Stansel et al., 2001; Bianchi et al., 1997; Doksani et al., 2013). A study of telomeric 
DNA damage has proposed a 3 state model of control, whereby progressive loss of TRF2 
shifts telomeres away from a protected to an ‘intermediate state’ that triggers a DNA 
damage response, activating the ATM and p53 pathways to induce cell cycle arrest and 
senescence, but no telomere fusions (Cesare and Karlseder, 2012). With excessive TRF2 loss, 
telomeres become de-protected and fusions or end-joinings are initiated as a means to 
protect telomere ends from further recognition as broken chromosome ends (Figure 1.4).   
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Figure 1.4: Schematic of the three state model of telomere protection. With long 
telomeres, sufficient shelterin components are bound to provide protection against DNA 
damage response and chromosome fusions; this is referred to as a ‘closed-state’ telomere. 
With increasing TRF2 loss, the t-loop structure is compromised, exposing the telomere ends 
to DNA damage responses and the activation of γ-H2AX as well as ATM and p53 to result in 
cell-cycle arrest and senescence, an ‘intermediate-state telomere’. When telomeres become 
critically short or TRF2 gets depleted to a state where insufficient telomere protection can be 
conferred, it is referred to as an ‘uncapped telomere’, where chromosomal fusions and end-
joining occurs (Cesare and Karlseder, 2012). 
In contrast to its role as the main factor in the formation of t-loops, TRF2 participates 
in the unwinding of t-loops in S phase to facilitate efficient telomere replication. The 
homology domain of TRF2 binds the C4C4 motif of RTEL1 helicase during S-phase and 
recruits RTEL1 to the telomeres. This permits the removal of t-loops and other telomeric 
secondary structures such as G-quadruplex structures that might hinder the access of the 
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ribonucleoprotein telomerase (discussed below) or the canonical replication machinery, to 
allow efficient replication of telomere DNA (Sarek et al., 2015). 
Our current knowledge and understanding of TRF1 and TRF2 identifies them as 
anchors through which other shelterin components bind to regulate telomeric length, 
structure and accessibility. The four additional telomere-specific binding proteins are POT1, 
TIN2, TPP1 and Rap1 (de Lange, 2005). POT1 binds to the single-stranded DNA overhang to 
regulate telomere length and inhibit lengthening by telomerase (Loayza and de Lange, 2003; 
Liu et al., 2004b; Baumann and Cech, 2001; Lei et al., 2004); this interaction is postulated to 
be mediated by TRF2 binding, as POT1 defective in TRF2 interaction culminated in telomere 
lengthening (Kendellen et al., 2009). POT1 has also been shown to promote telomerase-
mediated telomere lengthening (Colgin et al., 2003; Armbruster et al., 2004). Although the 
biological explanation for these conflicting results has yet to be resolved, in vitro work with 
human POT1 indicated that the position of human POT1 binding relative to the 3’ end of 
telomeric DNA can determine whether it promotes or inhibits telomerase action at 
telomeric DNA ends (Lei et al., 2005). TIN2 tethers TPP1 and POT1 to the telomeres via TRF1 
and TRF2 (Liu et al., 2004a). Additionally, it promotes TRF2 stability by binding to TRF1 and 
TRF2 simultaneously, stabilising TRF2 and inhibiting ATM activation (Ye et al., 2004a; Cesare 
and Karlseder, 2012). TIN2, TPP1 and POT1 also have biological roles in regulating telomere 
length by affecting the recruitment of telomerase to telomeres; disruption of this function 
can result in short telomere syndromes and diseases such as dyskeratosis congenita 
(discussed later). POT1/TPP1 are negative regulators of the DNA repair pathway homology-
directed repair (HDR) (Takai et al., 2011; Denchi and de Lange, 2007; Wu et al., 2006). The 
loss of TIN2 results in the loss of TPP1 and POT1, exposing single-stranded 3’ ends and 
leading to the activation of the DNA damage protein ATR (Takai et al., 2011). The ability of 
POT1 to repress activation of ATR is mediated by its DNA binding domain, independent of its 
ability to bind other shelterin components (Palm et al., 2009; Denchi and de Lange, 2007). 
Human Rap1 also forms a complex with TRF2 and interacts with telomeres to protect 
them from non-homologous end joining (NHEJ) (Li et al., 2000; Bae and Baumann, 2007; 
Sarthy et al., 2009). Lastly, mouse models have demonstrated that Rap1 is critical for the 
repression of homology directed repair and recombination, and unlike human Rap1, mouse 
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Rap1 is dispensable for TRF2 mediated repression of ATM signalling pathway and NHEJ (Sfeir 
et al., 2010). 
Our initial understanding of the shelterin complex proteins differentiated them from 
other telomeric binding proteins in fulfilling at least two of the following conditions: being 
exclusively abundant only at chromosome ends, being constitutively at telomeres regardless 
of the status of the cell cycle, and having no other known function (de Lange, 2005). 
However, research since then has provided evidence that TRF1 and TRF2 can also bind 
interstitial telomeric, centromeric and pericentromeric satellite DNA sequences (Simonet et 
al., 2011). TRF2 can also behave as a transcriptional regulator by binding to and activating 
promoters to mediate angiogenesis (El Mai et al., 2014). Nonetheless, the vast majority of 
elucidated functions of this group of six proteins involve facilitating the regulation of 
telomere length, as well as the differentiation of telomeres from broken chromosome ends 
that prevents the activation of the DDR. 
1.6 Genomic and telomeric DNA damage responses 
Numerous studies on t-loops and shelterin complexes have provided strong evidence 
for the mechanisms used to differentiate telomeric ends from broken chromosome ends, 
allowing telomeres to exist without activating DDR factors, as discussed in the preceding 
section. However, following a finite number of DNA replication cycles, telomere attrition can 
result in critically short telomeres and activate a DDR, culminating in the exhaustion of 
replicative capacity and the withdrawal of cells from the cell cycle, or apoptosis (Harley et 
al., 1990; d'Adda di Fagagna et al., 2003; von Zglinicki et al., 2005).  
Genomic DNA damage can consist of single-stranded (SSB) or double-stranded 
breaks (DSB). DNA damage and breaks are recognised by the primary sensor MRN complex. 
The MRN complex comprises the Mre11 nuclease, Rad50 helicase and Nibrin (van den Bosch 
et al., 2003; Uziel et al., 2003; Lamarche et al., 2010). Activation of the MRN complex to 
initiate the phosphorylation and activation of histone H2AX and 53BP1 triggers the 
activation of the PIKK family of serine/threonine kinases, including ATM, to bring about DNA 
damage repair, cellular senescence or apoptosis (You et al., 2005; Lee and Paull, 2005; Lee 
and Paull, 2007; Lee et al., 2010). The PIKKs in humans include ATM, ATR, mammalian target 
of rapamycin (mTOR), DNA-dependent protein kinase catalytic subunit (DNA-PKcs), 
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suppressor of morphogenesis in genitalia (SMG1), and the transformation/ transcription 
domain-associated protein (TRRAP) (Lempiainen and Halazonetis, 2009). H2AX and activated 
53BP1 in turn can also be direct substrates of ATM, creating a positive feedback loop that 
accelerates the proliferation of DNA damage signalling (Burma et al., 2001; Jowsey et al., 
2007).  
Although the canonical and best-understood roles of ATM and ATR pathway 
activation are in response to DSB and SSB respectively (Shiloh and Ziv, 2013; Zou and 
Elledge, 2003), there have been instances where the individual activation of ATM and ATR 
are not so clearly defined. ATR kinase activation can compensate for the inactivation of the 
ATM pathway (Takai et al., 2003; Herbig et al., 2004). Additionally, it has been shown that 
under situations of replication fork stalling during S phase, the activation of ATM can be 
mediated by ATR, although the downstream effects of such activation remain to be 
discovered (Stiff et al., 2006). 
Activation of PIKKs activates downstream effectors to facilitate the assembly of DNA 
damage and checkpoint proteins for repair responses (Burma et al., 2001). This results in the 
activation of a signalling cascade starting with the phosphorylation of transducer kinases 
CHK1 and CHK2 (Sanchez et al., 1997; Liu et al., 2000; Matsuoka et al., 1998; Matsuoka et 
al., 2000), which in turn causes phosphorylation in the N-terminal region of the tumour 
suppressor protein p53. N-terminal phosphorylation of p53 disrupts MDM2 binding while 
promoting acetylation and phosphorylation of the C-terminal region to stabilise p53 levels 
(Chehab et al., 1999; Chehab et al., 2000). Increases in p53 levels alone can initiate a G1 cell 
cycle arrest (Kastan et al., 1991), or lead to increases in p21 and p16 levels to synergistically 
inhibit Rb phosphorylation to halt cell cycle progression and induce cellular senescence 
(Sherr and Roberts, 1999). The primary mechanisms involved in the DDR to DSB in 
mammalian cells are homology directed repair (HDR) and non-homologous end joining 
(NHEJ) (Shiloh and Ziv, 2013), both of which can be mediated by the functions of the MRN 
complex and DNA-PKcs (Jiang et al., 2015; Lamarche et al., 2010).  
The ATR signalling pathway primarily responds to DNA SSBs and replication stress 
(Cimprich and Cortez, 2008), is required for the efficient replication of DNA and has roles in 
suppressing replication stress and preventing recombination (Bartek et al., 2007; Fokas et 
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al., 2014). The coating of ssDNA with replication protein A (RPA) and the ATR-interacting 
protein (ATRIP) are important for the signalling and localisation of ATR to sites of DNA 
damage (Zou and Elledge, 2003; Cortez et al., 2001). Activation of ATR activates CHK1 by 
phosphorylating the residues S317 and S345 to culminate in the phosphorylation of 
downstream targets including RPA1, RPA2 and the phosphatase Cdc25A at the replication 
fork (Liu et al., 2000; Cimprich and Cortez, 2008).  
Studies in both primary fibroblasts from Seckel syndrome patients and HeLa cells 
also established the requirement of ATR for efficient telomere replication (Pennarun et al., 
2010). This inherent role of ATR in proper telomere replication is also demonstrated by 
studies performed in murine cells, where ATR is necessary for suppressing telomere fragility 
and preventing recombination, although this function of ATR is dispensable at short 
telomeres (McNees et al., 2010). 
The response to genomic DNA damage is different from that occurring upon 
telomeric DNA damage (d'Adda di Fagagna et al., 2003; Cesare et al., 2013). Telomeric DDR 
in human fibroblasts after telomere shortening displayed markers for DNA double strand 
breaks including 53BP1, MDC1, NBS1, as well as activated CHK1 and CHK2 (d'Adda di 
Fagagna et al., 2003), leading to a G1 checkpoint arrest and replicative senescence (d'Adda 
di Fagagna et al., 2003). However, unlike genomic DNA damage, telomeric DNA damage 
does not contribute to the G2/M checkpoint, instead passing through cell division to induce 
a p53-dependent G1 arrest in the daughter cells (Cesare et al., 2013; d'Adda di Fagagna et 
al., 2003). The response to telomeric DDR due to shortening is also different to the response 
from telomere deprotection, such as that induced by TRF2 depletion (Cesare et al., 2013). 
Partial TRF2 depletion resulted in telomeres that are fusion resistant, and differentially 
activated ATM without leading to phosphorylation of CHK2 (Cesare et al., 2013).       
1.7 Relationship between telomeres, telomerase and cancer 
The critical shortening of telomeres resulting from DNA replication events provides a 
‘mitotic clock’, limiting the proliferative capacity of cells through the induction of a DDR and 
thus conferring protection against tumorigenesis (Cesare et al., 2013; IJpma and Greider, 
2003; Karlseder et al., 1999; Smogorzewska and de Lange, 2002; Takai et al., 2003; van 
Steensel et al., 1998). In contrast, if deregulated cells can activate telomere maintenance 
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mechanisms such as Alternative Lengthening of Telomeres (ALT), a homologous 
recombination-based mechanism (Bryan et al., 1995; Dunham et al., 2000), or telomerase 
enzyme expression, the inherent limit on cellular proliferative capacity can be breached, 
resulting in an important gain of function towards tumorigenesis. This notion is strongly 
supported by the observation that more than 85% of human cancers harbour elevated 
amounts of telomerase activity, while normal somatic cells harbour very low or 
undetectable levels (Kim et al., 1994; Shay and Bacchetti, 1997). Therefore, telomerase 
represents an attractive target to study, in the hopes of developing targeted treatments for 
cancer with fewer side-effects than current treatments. 
1.8 Telomerase 
Telomerase is a ribonucleoprotein that is responsible for catalysing telomere 
elongation through the addition of telomeric 5’-TTAGGG-3’ repeats (Figure 1.5) (Greider and 
Blackburn, 1985; Morin, 1989). This is achieved because telomerase is a reverse 
transcriptase that has the ability to form stable and functional interactions with its RNA 
subunit via conserved motifs within hTERT and hTR (Bryan et al., 2000; Lai et al., 2001; 
Bachand and Autexier, 2001).  
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Figure 1.5: Schematic of the mechanism of processive telomere elongation by 
telomerase. (A) The 3’ end single stranded telomere DNA overhang is recognised by 
telomerase and functions as a primer. (B) Following telomerase recognition and binding, the 
RNA template in telomerase RNA is used during reverse transcription for nucleotide addition 
to the telomere overhang for telomere extension. (C) When telomere extension has reached 
the 5’ boundary of the template, telomerase can translocate along the newly synthesised 
strand for (Di) multiple rounds of nucleotide addition, a process termed ‘repeat addition 
processivity’, or (Dii) dissociation to leave a shorter, but still extended telomere end. 
Telomerase mediated telomere extension involves three main phases: primer 
recognition and binding, telomere elongation, and finally translocation or dissociation 
(Figure 1.5) (Kelleher et al., 2002; Autexier and Lue, 2006; Podlevsky and Chen, 2012). The 3’ 
telomeric single stranded overhang serves as a primer and substrate for telomerase. This 
initial primer recognition and binding of telomerase to the 3’ end of telomeric DNA involves 
a two-step mechanism and protein conformational change (Tomlinson et al., 2015). Upon 
telomerase binding to telomeres, the TEN domain of hTERT has the ability to position the 3’ 
end of the primer towards the active site to catalyse the addition of nucleotides from the 
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short RNA template located within telomerase RNA (Figure 1.5) (Jurczyluk et al., 2011; Wu 
and Collins, 2014; Akiyama et al., 2015). The reverse transcription of the RNA template using 
Watson and Crick base-pairing allows the synthesis of new telomeric sequences (Autexier 
and Lue, 2006; Robart and Collins, 2010). Telomerase is also different from conventional 
reverse transcriptases in that once the 5’ template boundary is reached, it has the ability to 
translocate along the DNA substrate and reposition itself on the telomere substrate to 
continuously catalyse the addition of telomeric repeats, conferring telomerase with a 
unique ability termed ‘repeat addition processivity’ (RAP) (Figure 1.5) (Greider, 1991; 
Jarstfer and Cech, 2002; Wang et al., 2007; Zaug et al., 2008; Qi et al., 2011; Berman et al., 
2011).  
1.9 Composition of the telomerase complex 
Since the discovery of telomerase by Carol Greider and Elizabeth Blackburn in 1985 
(Greider and Blackburn, 1985), early efforts to determine the composition of telomerase led 
to the identification of the RNA component in various species (Greider and Blackburn, 1989; 
Romero and Blackburn, 1991; Feng et al., 1995). The gene encoding the catalytic component 
of telomerase was first discovered in 1996 by a genetic screen in S. cerevisiae and was 
termed the EST2 gene (Lendvay et al., 1996). The Est2 protein was identified as the catalytic 
component of S. cerevisiae telomerase a year later (Lingner et al., 1997b; Counter et al., 
1997) and its human homologue, known as the telomerase reverse transcriptase (hTERT), 
was identified in the same year (Kilian et al., 1997; Meyerson et al., 1997; Nakamura et al., 
1997). It was later discovered that hTERT and hTR are minimally required to reconstitute 
telomerase activity in rabbit reticulocyte lysates (Beattie et al., 1998). However, the 
identification of the minimal functional telomerase complex in humans has been hampered 
by challenges of low telomerase abundance, even in tumorigenic cells (approximately 50 - 
200 molecules per cell) (Cohen et al., 2007; Xi and Cech, 2014), and the transient association 
of telomerase with other proteins for telomerase complex formation, trafficking, 
degradation and telomere recruitment. It was not until 2007 when the differential binding 
affinities of human telomerase with DNA primers terminating in TTA compared to those 
terminating in GGG nucleotides were harnessed to isolate catalytically active telomerase 
(Cohen et al., 2007). Catalytically active telomerase was analysed to reveal a dimeric 
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complex each comprising one molecule of hTR, the protein dyskerin and hTERT (Cohen et 
al., 2007; Sauerwald et al., 2013).  
 
1.9.1 Telomerase RNA  
Telomerase RNA provides a template by which nucleotides (TTAGGG in humans) can 
be added to telomeres during elongation by the reverse transcriptase activity of telomerase. 
This component displays a wide variety of sizes among species, ranging from ~150 
nucleotides in ciliates to larger than 1500 nucleotides in fungi (Chen and Greider, 2004). 
Sequence alignments have revealed a distinct lack of sequence identity between eukaryotic 
groups. In spite of this, phylogenetic comparative analyses have revealed striking similarities 
between the core secondary structures of telomerase RNA between species (Chen and 
Greider, 2004; Lin et al., 2004) (Figure 1.6). Core secondary structures observed across 
ciliate, S. cerevisiae and vertebrate telomerase RNA include the RNA template for nucleotide 
addition to telomeres, a pseudoknot domain, and the adjacent enclosure of the template 
domain through the interaction of long-range base pairs (Chen and Greider, 2004; Lin et al., 
2004). 
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Figure 1.6: Core secondary structure comparisons of ciliate, vertebrate and S. 
cerevisiae telomerase RNA based on phylogenetic analysis. Figure illustrating the 
secondary structures that are conserved between different species. Green areas represent 
conserved TERT binding regions such as the pseudoknot, while blue areas indicate the 
template boundaries, with those in red representing the template region. Structural 
similarities exist between species in the absence of sequence similarities (Chen and Greider, 
2004). 
The vertebrate telomerase RNA is highly conserved across several species and is 
composed of 4 structural domains, namely the pseudoknot domain, the CR4-CR5 domain, 
H/ACA domain and the CR7 domain (Figure 1.6) (Chen et al., 2000).  
The pseudoknot domain consists of a pseudoknot (an RNA secondary structure that 
contains two stem loops in which the first stem’s loop forms part of the second stem) and 
the RNA template, which is necessary for telomere repeat addition (Greider and Blackburn, 
1989). Mutation of the pseudoknot results in the disruption of the secondary structure of 
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hTR, culminating in the failure to reconstitute telomerase activity in vivo (Chen and Greider, 
2005), while mutating the template resulted in the synthesis of altered telomere sequences 
(Autexier et al., 1996). The CR4-CR5 domain lies downstream of the pseudoknot. Helices P5 
and P6 establish a stem-loop structure, while the intervening loop contains the conserved 
sequence element CR4 and CR5 (Chen et al., 2000). This domain is postulated to undergo 
RNA-RNA interactions with the pseudoknot domain, inducing an architectural fold which 
facilitates proper hTERT interaction and telomerase activity (Ueda and Roberts, 2004). An 
RNA-protein interaction involving the P6.1 hairpin of the CR4-CR5 domain and the RNA-
binding domain (RBD) of the hTERT component have been shown to be vital for telomerase 
activity and assembly in vitro and  in vivo (Lai et al., 2001; Chen et al., 2002; Tesmer et al., 
1999; Mitchell and Collins, 2000; Ly et al., 2003; Martin-Rivera and Blasco, 2001).  
The H/ACA domain, in tandem with the CR7 domain, is essential for the in vivo 
accumulation of hTR by enhancing stability of the molecule. The hTR H/ACA domain 
interacts with the protein dyskerin, another component of the active telomerase complex 
(Mitchell et al., 1999; Mitchell and Collins, 2000). This interaction stabilises and permits the 
accumulation of hTR, allowing the formation of the functional telomerase complex. 
Furthermore, mutations in the CR7 and H/ACA domains affected telomerase assembly and 
the amounts of telomerase RNA (Trahan and Dragon, 2009; Theimer et al., 2007). The CR7 
domain of hTR also contains a conserved Cajal body localisation element termed the CAB 
box (Jady et al., 2004). The telomerase Cajal body protein 1 (TCAB1) has been shown to bind 
the CAB box; this interaction is required for the localisation of hTR to Cajal bodies, and 
subsequently to telomeres (Tycowski et al., 2009; Venteicher et al., 2009; Cristofari et al., 
2007).  
It was initially thought that hTERT levels are the limiting factor determining the level 
of telomerase activity. This was a result of the observation that hTR is ubiquitously 
expressed in all human tissues, while elevated levels of hTERT dictate telomerase activity in 
immortalised cells and a variety of epithelial cancer cells (Meyerson et al., 1997; Counter et 
al., 1998; Nakano et al., 1998; Kanaya et al., 1998; Park et al., 1999). However, several 
studies have since challenged this point of view by showing in some cases that the limiting 
factor appears to be the levels of hTR. Mutations in several hTR regions including the 
pseudoknot altered the global structure of hTR, thereby diminishing the catalytic activity of 
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telomerase through haploinsufficiency (Marrone et al., 2004). In support of this observation, 
other studies concluded that hTR levels were limiting telomerase activity in the presence of 
hTERT over-expression in at least some cell types (Cao et al., 2008), and that co-
overexpression of hTR and hTERT appears to have a synergistic effect on telomere 
lengthening in 293T and HT1080 cells compared with individual hTERT or hTR over-
expression (Weinrich et al., 1997; Cristofari and Lingner, 2006). These studies collectively 
indicate that in some circumstances where hTERT is in abundance, hTR levels limit the 
activity of telomerase, which is not surprising considering that hTR forms a vital component 
of the telomerase machinery. 
Mutations in hTR have been linked to autosomal dominant forms of dyskeratosis 
congenita (DC). DC is a bone marrow failure syndrome characterised by a triad of muco-
cutaneous features including abnormal skin pigmentation, nail dystrophy and oral 
leucoplakia (Cole et al., 1930). The cells from autosomal dominant DC patients exhibit a 
lower amount of hTR, which correlates well with lower telomerase activity and telomere 
length compared to normal cells (Cerone et al., 2005; Parry et al., 2011). It was discovered in 
2001 that mutations such as the removal of 74 bases at the 3’ end of hTR, a single point 
mutation C408G, or a double point mutation (GC to AG) at positions 107-108 within hTR are 
responsible for the DC phenotype (Vulliamy et al., 2001). Since then, a plethora of hTR 
mutations within the 5’ untranslated region (UTR), the pseudoknot domain, the CR4-CR5 
and CR7 domains as well as the 3’ UTR have been shown to be responsible for a wide range 
of diseases known as “short telomere syndromes”, such as aplastic anaemia (Marrone et al., 
2007; Xin et al., 2007b; Vulliamy et al., 2011; Vulliamy et al., 2002; Vulliamy et al., 2006; 
Yamaguchi et al., 2003), pulmonary fibrosis (Marrone et al., 2007), Hoyeraal Hreidarrson 
syndrome (Vulliamy et al., 2011), myelodysplastic syndrome (Field et al., 2006; Vulliamy et 
al., 2011; Takeuchi et al., 2008), essential thrombocythemia (Ly et al., 2005) and 
myelodysplasia (Vulliamy et al., 2006; Vulliamy et al., 2002; Marrone et al., 2007). 
Therefore, hTR mutation contributes to the short telomere syndrome phenotypes by 
causing a defect in functional telomerase assembly and activity, resulting in the failure of 
rapidly dividing cells such as stem and bone marrow cells to maintain a population 
necessary for survival.  
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1.9.2 Dyskerin 
Dyskerin was discovered in 1998 as a highly charged nucleolar protein encoded by 
the DKC1 gene (Heiss et al., 1998). This gene has been mapped to position Xq28 on the X 
chromosome (Knight et al., 1996).  Defects in dyskerin caused by mis-sense mutations in the 
DKC1 gene result in a particularly common form of DC known as X-linked DC (Heiss et al., 
1998). The other known forms of DC result from mutations in hTR (Vulliamy et al., 2001), the 
poly(A)-specific ribonuclease PARN (Tummala et al., 2015), the telomerase-associated 
proteins NOP10 (Walne et al., 2007) and NHP2 (Vulliamy et al., 2008), hTERT (Vulliamy et al., 
2005), TCAB1 (Zhong et al., 2011), or telomere-binding proteins such as TIN2 (Savage et al., 
2008; Walne et al., 2008), TPP1 (Kocak et al., 2014), CTC1 (Anderson et al., 2012; Keller et 
al., 2012), and the telomere elongation helicase RTel1 (Ballew et al., 2013; Walne et al., 
2013; Le Guen et al., 2013; Deng et al., 2013). 
Dyskerin is involved in two main processes. Firstly, it facilitates the process of 
pseudo-uridylation of ribosomal RNA molecules for accurate processing and function (Heiss 
et al., 1998; Wang et al., 2002). Secondly, dyskerin is required for the stabilisation of hTR 
and other RNAs of the H/ACA family by binding to the H/ACA RNA motif (Mitchell et al., 
1999), which is vital for the formation of the telomerase complex (Mitchell et al., 1999; 
Wong et al., 2004; Parry et al., 2011). Given the involvement of dyskerin in stabilising hTR, it 
has been shown that breast cancer patients with low dyskerin expression have a better 
prognosis than patients with high dyskerin expression (Montanaro et al., 2006). In addition 
to the function of hTR stabilisation as an important factor in the efficacy of telomerase, 
dyskerin has also been implicated in tumorigenesis via pathways that are independent of its 
telomerase-associated functions (Alawi and Lin, 2010; Bellodi et al., 2013).  
Like other types of DC, X-linked DC results in telomerase dysfunction, culminating in 
the inability to maintain telomere length in rapidly proliferating cells such as those found in 
the bone marrow and skin (Mitchell et al., 1999). Patients with severe DC symptoms such as 
the early onset of immunodeficiency and cerebellar hypoplasia due to mutations in various 
telomerase components such as dyskerin and TERT do not necessarily display shorter 
telomeres than patients who present milder symptoms (Vulliamy et al., 2011). However, the 
onset of DC due to mutations in hTR manifests itself earlier in subsequent generations, 
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which supports the role of defective telomerase-mediated telomere length maintenance in 
contributing to DC phenotypes (Vulliamy et al., 2004).  
To date, the global structure of human dyskerin remains to be elucidated, although 
the structure of the S. cerevisiae homologue has been solved (Li et al., 2011). To fully 
comprehend the complex mechanistic involvement of dyskerin in functional telomerase 
activity as well as telomerase-independent pathways, obtaining the full structure of human 
dyskerin should be endeavoured.  
1.9.3 Human telomerase reverse transcriptase (hTERT) 
The TERT subunit of telomerase represents the catalytic core of the enzyme and was 
first identified in ciliates and S. cerevisiae (Lingner and Cech, 1996; Lingner et al., 1997b). It 
is a reverse transcriptase that is highly conserved across species (Nakamura et al., 1997; 
Lingner et al., 1997b), and catalyses the addition of telomeric nucleotide repeats to the ends 
of telomeres.  
hTERT consists of four domains: the Telomerase Essential N-terminal (TEN) domain, 
the RNA binding domain (RBD), the reverse transcriptase (RT) domain and the C-terminal 
domain (Figure 1.7).  
 
Figure 1.7: Schematic diagram of the hTERT component of the enzyme telomerase. 
Four primary domains of hTERT: the Telomerase Essential N-terminal (TEN) domain, the 
RNA Binding domain (RBD), the Reverse Transcriptase (RT) domain and the C-terminal 
domain. Conserved sequence motifs within each domain that play roles in functionality of the 
enzyme are presented as coloured sections (Jurczyluk et al., 2011).  
The low abundance of hTERT in human cells represents a major hurdle in terms of 
structural studies. Attempts at studying the structure of the human TEN domain have 
involved modelling this conserved domain based on the Tetrahymena TEN domain, the 
structure of which has been elucidated through X-ray crystallography (Jacobs et al., 2006; 
Jurczyluk et al., 2011; Lee et al., 2008; Steczkiewicz et al., 2011). The TEN domain 
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encompasses the first 200 amino acids of TERT, and is a soluble and protease resistant 
structure containing a mixture of α helices and β sheets (Xia et al., 2000; Jacobs et al., 2006; 
Jacobs et al., 2005; O'Connor et al., 2005). This domain of hTERT is vital for tight DNA 
binding (Jurczyluk et al., 2011; Wyatt et al., 2007; Romi et al., 2007; Sealey et al., 2010). This 
binding of the TEN domain to DNA contributes to the overall DNA binding capacity of TERT 
in a cooperative manner with the RBD (Finger and Bryan, 2008). During nucleotide addition, 
the TEN domain is also involved in mediating conformational changes to facilitate the 
positioning of the 3’-end of the primer into the active site and stabilisation of the short 
DNA-RNA hybrid, a role distinct to its function in DNA binding (Jurczyluk et al., 2011; Wu and 
Collins, 2014; Akiyama et al., 2015). 
A region on the surface of the TEN domain is known as the ‘Dissociates Activities of 
Telomerase’ (DAT) motif, which is dispensable for in vitro enzyme catalysis but essential for 
biological activity in vivo; mutant DAT results in telomerase that is deficient in telomere 
elongation (Armbruster et al., 2001).  The wild-type function of hTERT can be partially 
rescued through the fusion of shelterin proteins hTRF2 and hPOT1 with hTERT containing a 
mutated DAT motif. This indicates that the DAT motif of hTERT is implicated in the 
association between telomere ends and telomerase (Armbruster et al., 2004; Armbruster et 
al., 2003). The detailed mechanism of this interaction with the shelterin component TPP1 
has now been elucidated (discussed further below). 
The RBD is an independently folded structure of α helices and β sheets (Rouda and 
Skordalakes, 2007; Mitchell et al., 2010; Harkisheimer et al., 2013; Huang et al., 2014) 
consisting of three conserved motifs: the CP, T and QFP motifs (Nakamura et al., 1997; Xia et 
al., 2000; Bryan et al., 1998). Structural studies of the RBD of Tetrahymena thermophila 
TERT have indicated that the T motif is capable of binding to single-stranded RNA (Rouda 
and Skordalakes, 2007). The structure of the CP motif includes a shallow, wide cavity 
adjacent to the T motif pocket, an observation that is consistent with binding to double 
stranded RNA (Rouda and Skordalakes, 2007). Amino acid mutations within the T and CP 
motifs resulted in decreased levels of telomerase activity (Weinrich et al., 1997; Friedman 
and Cech, 1999; Bryan et al., 2000) caused by a diminished level of RNA binding (Bryan et 
al., 2000; Lai et al., 2001; Bosoy et al., 2003). Thus, both T and CP motifs facilitate the 
formation of a telomerase complex by securing the non-template regions of hTR to hTERT. 
26 
 
Mutational analysis of the QFP motif reported a reduction in hTR association with hTERT, 
indicating that the QFP motif mostly likely facilitates the interaction between hTERT and hTR 
by inducing a conformational fold in the RBD (Moriarty et al., 2002; Bosoy et al., 2003).  
The RT domain represents the catalytic domain of telomerase and consists of seven 
conserved motifs across species, namely, motifs 1, 2, and A to E (Nakamura et al., 1997; 
Lingner et al., 1997b). The only elucidated crystal structure for the RT domain so far is that 
of a TERT protein from the beetle Tribolium castaneum (Gillis et al., 2008). These motifs are 
all vital for the functioning of the complex as a reverse transcriptase and essential for the 
synthesis of DNA in vitro and in vivo. Mutational analysis in the A, B’ and C motifs by 
substituting aspartic acid and glutamine resides with alanine residues prevented telomerase 
activity, resulting in shortened telomeres and cellular senescence (Lingner et al., 1997b). 
Supporting this observation that these motifs serve vital roles in telomerase activity, 
deletion of motifs B’, C, D and E in S. pombe haploid cells led to progressively shortened 
telomeres, which ultimately induced senescence (Nakamura et al., 1997). Motifs A and C 
contain one and two aspartic acid residues respectively that are conserved within the HIV-1 
reverse transcriptase; in that enzyme, they play a role coordinating the active site 
magnesium ion (Kohlstaedt et al., 1992). These three aspartic acid residues make up the 
‘catalytic triad’ that is directly involved in nucleotide addition (Lingner et al., 1997b; 
Nakamura et al., 1997). Motif E has been called the ‘primer grip’, since mutations in this 
motif affected DNA binding (Wyatt et al., 2007). An insertion between motifs A and B’ in the 
RT domain of TERT relative to that of HIV-1 RT has been termed the ‘insertion in fingers’ 
domain (IFD), and is important for the stabilisation of interactions between RNA and DNA, 
and thus telomerase processivity (Lue et al., 2003; Gillis et al., 2008).  
The C-terminal domain represents the least evolutionarily conserved domain of TERT 
(Friedman and Cech, 1999; Peng et al., 2001; Lai et al., 2001). As such, it was hypothesised 
that this domain does not contribute substantially to the overall function of telomerase. 
This concept was challenged, however, by the observation that the addition of a 
hemagglutinin (HA) epitope tag to the C-terminal end of hTERT resulted in the reduction of 
telomere length and induction of cellular senescence or apoptosis in primary and 
immortalised transformed human cells (Counter et al., 1998; Ouellette et al., 1999). Since 
then, 14-3-3 and CRM1 binding motifs were mapped within the hTERT C-terminal domain, 
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indicating that the interaction of hTERT with 14-3-3 and CRM1 proteins facilitates 
telomerase accumulation in the nucleus, thus providing evidence for the functional 
relevance of this domain (Seimiya et al., 2000).  
Mutational analysis of specific amino acid residues gave further credence to the 
notion that the C-terminal domain is indeed essential for telomerase function. Deletion and 
mutation analysis identified amino acid residues 963 to 1117 to be vital for telomerase 
repeat addition processivity, while several other residues were deduced to be important for 
nucleotide addition (Huard et al., 2003) as well as oligomerisation of hTERT (Arai et al., 
2002). Discovery of a region of the C-terminal domain that ‘dissociates activities of 
telomerase’ (C-DAT) further identified important amino acid residues, such as 1127-1129, 
that are not involved in nuclear localisation or protein multimerisation, but mutation of 
which manifests in defects in telomere synthesis in vivo following assembly of catalytically 
active telomerase (Banik et al., 2002). Taken together, it can be concluded that the C-
terminal domain has specialised roles in proper telomerase functioning, assembly and 
maintenance of cellular proliferation.  
1.10 Regulation of telomerase activity 
Based on the high occurrence of telomerase over-expression in cancer cells, as well 
as the involvement of telomerase in promoting cellular immortality and tumorigenesis, it 
could be erroneously concluded that the expression of telomerase is detrimental to the 
survival of the organism. On the contrary, telomerase is essential for survival, with roles in 
the maintenance of a stem cell pool to regenerate a wide array of cell lineages throughout 
the lifetime of the organism (Hiyama and Hiyama, 2007; Shay and Wright, 2010). In addition, 
aplastic anemia (Yamaguchi et al., 2005) and similar conditions such as dyskeratosis 
congenita, which leads to bone-marrow failure, tissue degeneration and a diminished life 
expectancy, have been linked to dysfunctional or low levels of telomerase expression, as 
discussed above. 
Therefore, the delicate balance between expression and sequestration of telomerase 
and its activity is crucial for the viability of the organism. This requires precise mechanisms 
of telomerase regulation, which can be broadly categorised into transcriptional, post-
transcriptional and post-translational regulation. 
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1.10.1 Transcriptional regulation 
One of the pioneering observations about telomerase regulation involves the 
positive correlation between the levels of hTERT mRNA and telomerase activity (Meyerson 
et al., 1997; Nakamura et al., 1997; Kilian et al., 1997). The hTERT gene in human diploid 
cells consists of a single copy on chromosome band 5p15.33 (Bryce et al., 2000). The core 
hTERT promoter region spans 200 to 300 base pairs. It does not contain any TATA or CAAT 
boxes but is highly G-C rich with a large CpG island before the ATG transcriptional start site 
(Horikawa et al., 1999; Takakura et al., 1999). In addition, the promoter region contains two 
E boxes located at -34 and -242 nucleotides upstream of the ATG site (Cong et al., 1999; 
Horikawa et al., 1999; Takakura et al., 1999), several GC boxes, and other potential binding 
sites of transcription factors such as c-Myc, Sp1 and AP-2, indicating that transcriptional 
control may be an important regulatory factor in hTERT expression (Cong et al., 1999; Wick 
et al., 1999). 
Studies have since classified transcriptional regulators of hTERT into those that 
activate transcription and those that repress it. Transcriptional activators include c-Myc, 
Sp1, Human Papillomavirus Virus (HPV) 16 E6, the E26 Transformation-Specific (Ets) 
transcription factor family and hormones such as estrogen and progesterone. 
The onco-protein c-Myc promotes cellular proliferation by forming a heterodimer 
with the Max protein (Evan et al., 1992). Through mobility shift assays and chromatin 
immunoprecipitation (ChIP), the Myc/Max heterodimer was observed to bind directly to the 
two E-boxes in the hTERT promoter (Wu et al., 1999). This binding leads to an increase in 
hTERT expression and telomerase activity in normal human mammary epithelial cells and 
diploid fibroblasts (Wang et al., 1998; Greenberg et al., 1999). The Sp1 transcriptional 
activator binds GC-motifs found between two E-boxes within the hTERT promoter region to 
work synergistically with c-Myc and induce hTERT promoter activity (Cong et al., 1999; Kyo 
et al., 2000). Sp1 proteins have also been demonstrated to initiate transcription of non-
TATA promoters such as the hTERT promoter by interacting with the TATA-box binding 
protein (TBP) and TBP-associated proteins (Emili et al., 1994; Pugh and Tjian, 1991). 
However, in spite of the observations implicating Sp1 in hTERT promoter activity, the 
pathways involved in Sp1-mediated hTERT transcription remain to be elucidated. 
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The HPV16 E6 protein has been shown to induce telomerase activity in a cell type-
specific manner (Klingelhutz et al., 1996) by upregulating hTERT transcription through a 
mechanism that does not involve the degradation of p53 or the induction of c-Myc (Gewin 
and Galloway, 2001; Oh et al., 2001; Veldman et al., 2001). The exact mechanism leading to 
elevated levels of hTERT transcription by HPV 16 E6 remains elusive. Another transcription 
factor family, the Ets transcription factors, in particular Ets1 and Ets2, were found to be 
elevated in human breast cancer tissues compared to normal breast epithelial cells (Sapi et 
al., 1998; Myers et al., 2005). Mutation and protein-DNA binding analyses of putative Ets 
binding elements in the hTERT promoter suggest a direct interaction between Ets1/2 and 
the promoter (Xiao et al., 2003; Maida et al., 2002). Unexpectedly, over-expression of Ets1 
and 2 in the human myeloid erythroleukemia K562 cell line can result in either an increase 
or decrease in the regulation of telomerase activity, depending on the binding sites in the 
promoter of hTERT (Xiao et al., 2003). 
Steroid hormones such as estrogen also appear to induce hTERT mRNA expression 
leading to enhanced telomerase activity. Two estrogen response elements situated at -950 
bp and -2754 bp upstream of hTERT ATG were identified in the promoter region, with 
studies supporting the biological functions of these elements as part of the estrogen-
induced hTERT expression pathways in hormone-sensitive tissues such as human ovary 
epithelium and the MCF-7 breast cancer cell line (Kyo et al., 1999; Misiti et al., 2000). To 
further support this notion of estrogen-mediated activation of the hTERT promoter, 
tamoxifen (a nonsteroid anti-estrogen drug) was used successfully to reduce telomerase 
activity in breast and colon cancer cell lines, opening up potential avenues for drug 
intervention (Aldous et al., 1999; Nakayama et al., 2000).  
In addition to positive regulators of hTERT mRNA expression, a group of negative 
transcriptional regulators have also been identified. These include Mad1, p53, pRB, E2F, 
Wilms’ tumour 1 tumour suppressor and the myeloid cell-specific zinc finger protein 2. 
The transcription factor Mad1 was demonstrated to be involved in regulating hTERT 
transcription (Gunes et al., 2000). It has been shown that while cells are proliferating, c-Myc 
protein dimerizes with the ubiquitously expressed Max protein to occupy the E-box motifs 
of the hTERT promoter of human promyelocytic leukemia cells. Under conditions in which 
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the cells are differentiated, Mad1 protein expression is induced. Following dimerisation with 
Max protein, it binds competitively to the E-box motifs, thereby antagonising the activation 
of hTERT gene transcription by the c-Myc/Max heterodimer (Xu et al., 2001). Deletion 
analysis indicated that binding to the E-boxes is essential for the Mad-1 mediated repression 
of hTERT expression, suggesting that a direct interaction between either Mad-1 or c-Myc 
and the Max protein at the hTERT promoter regulates hTERT mRNA expression (Gunes et al., 
2000; Oh et al., 2000). 
Another transcriptional regulator of hTERT is the p53 tumour suppressor protein. 
Over-expression of p53 represses the transcription of the hTERT gene in an Sp1-dependent 
manner (Kanaya et al., 2000; Xu et al., 2000). Current evidence suggests that p53 binds to 
Sp1 protein, preventing Sp1 from binding to the promoter of hTERT to initiate c-Myc 
dependent hTERT expression (Xu et al., 2000). Several studies have further implicated the 
over-expression of retinoblastoma tumour suppressor protein (pRB), p21 and E2F in 
regulating hTERT transcriptional activity in head and neck squamous cell carcinoma (SCCHN) 
cell lines, although the detailed regulatory pathways remain to be determined (Crowe and 
Nguyen, 2001; Henderson et al., 2000). E2F-1 binds to two binding sites located at -174 and 
-98 bp relative to the transcriptional start site, resulting in a four-fold decrease in hTERT 
mRNA and resultant telomerase activity in human SCCHN cells (Crowe et al., 2001). 
Paradoxically, the over-expression of E2F isoforms in hTERT-negative non-transformed cell 
lines induced the activation of hTERT. This activation has been linked to the direct 
interaction with a non-canonical E2F binding site located between -58 and -88 of the hTERT 
promoter (Won et al., 2002). Alternatively, this observation could indicate that the E2F-
mediated regulation of hTERT may be a complex interaction with other transcription factors. 
In support of this view, it has been shown that E2F recruits pRB to the hTERT promoter to 
induce pRB-mediated repression (Crowe et al., 2001; Nguyen and Crowe, 1999). Although 
the precise mechanism of pRB in regulating hTERT expression is currently unknown, several 
hypotheses regarding its mode of action have been proposed. These include facilitating the 
accessibility of chromosomes to other transcriptional factors by altering higher order 
chromatin structure in an SWI/SNF nucleosome-remodelling manner. This could be achieved 
through pRB binding to histone deacetylases (HDAC) 1, 2 and 3, potentially reversing the 
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histone acetylation of hTERT promoters to repress transcription (Brehm et al., 1998; Luo et 
al., 1998; Magnaghi-Jaulin et al., 1998; Chen and Wang, 2000; Dahiya et al., 2000). 
Both Wilms’ tumour 1 (WT1) tumour suppressor and myeloid cell-specific zinc finger 
protein 2 (MZF-2) inhibit hTERT transcription by binding directly to their respective binding 
sites in the promoter region (Oh et al., 1999; Fujimoto et al., 2000). The binding of WT1 
appears to be cell type-specific, with cells expressing endogenous levels of WT1, such as 293 
kidney cells, showing a downregulation of hTERT transcription following WT1 over-
expression. Cells that do not express endogenous WT1 such as HeLa cells do not display any 
hTERT transcriptional regulation by WT1 (Oh et al., 1999). MZF-2 has a number of binding 
sites within the hTERT promoter region between -594 to -764 upstream of the ATG start site 
(Fujimoto et al., 2000). Having been shown to interact directly with the promoter region via 
mobility shift assays, over-expression of MZF-2 correlates with a suppression of hTERT 
promoter activity in vitro (Fujimoto et al., 2000). However, our knowledge regarding the in 
vivo relevance of MZF-2 remains poor.  
In recent years, an exciting and novel mechanism of hTERT regulation has been 
identified. Non-coding mutations within the hTERT promoter are found in a subset of 
cancers, such as those of the central nervous system, bladder, thyroid, melanomas (Vinagre 
et al., 2013; Horn et al., 2013; Huang et al., 2013), carcinomas (Griewank et al., 2013), 
glioblastomas (Bell et al., 2015), sarcomas (Griewank et al., 2014), urothelial cancer (Borah 
et al., 2015), gliomas (Labussiere et al., 2014; Killela et al., 2013) as well as ovarian and 
breast cancers (Bojesen et al., 2013). These mutations can result in an increase in hTERT 
transcription and mRNA abundance (Chiba et al., 2015; Borah et al., 2015; Horn et al., 2013; 
Huang et al., 2013; Fredriksson et al., 2014; Labussiere et al., 2014), hTERT protein (Borah et 
al., 2015; Griewank et al., 2013), and telomerase activity, resulting in longer telomeres or 
maintenance of telomere lengths (Borah et al., 2015; Griewank et al., 2013), as well as 
association with a poorer cancer prognosis (Griewank et al., 2014).  The most common 
mutations in the hTERT promoter have been found to generate binding motifs for the E-
twenty-six (Ets) transcription factors, or the ternary complex factors (TCF) Elk1 and Elk4, 
which are subfamilies of Ets transcription factors (Huang et al., 2013; Horn et al., 2013). 
Increasing the binding of these transcription factors increases hTERT transcription activity 
(Huang et al., 2013; Horn et al., 2013), which can enhance telomerase activity and promote 
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tumorigenic activity. Mutations within the hTERT promoter have also been shown to display 
the methylation marks of transcriptionally active chromatin, leading to the specific 
recruitment of the multimeric GA-binding protein (GABP) transcription factors to the 
mutant allele, which cooperates with Ets to activate hTERT transcription (Bell et al., 2015; 
Stern et al., 2015).  
1.10.2 Post-transcriptional regulation 
Over the past two decades, emerging evidence suggests that in addition to 
transcriptional regulation, hTERT can be regulated post-transcriptionally and post-
translationally. Regulators of hTERT post-transcriptional regulation include the cytosolic 
protein NFX1-123, autocrine human growth hormone (hGH) and poly(C)-binding proteins 
(αCP1 and αCP2), as well as hTERT mRNA alternative splicing. 
The post-transcriptional regulation of hTERT by NFX1-123, hGH and αCP1/2 centres 
around the stabilisation of hTERT mRNA. This facilitates the accumulation of the mRNA 
transcript, facilitating translation to result in a higher level of hTERT expression and 
telomerase activity. In keratinocytes co-expressing HPV-16 E6 and NFX1-123, the PAM2 
motif and R3H domain of NFX1-123 are both critical for the interaction with and eventual 
stabilisation of hTERT mRNA (Katzenellenbogen et al., 2007). Similarly, autocrine hGH 
secretion in human mammary carcinoma cells up-regulates αCP1 and αCP2 expression. 
These proteins bind to the 3’-UTR cis-regulatory elements of the hTERT mRNA between 
nucleotide positions 120-360 bp resulting in its stabilisation (Emerald et al., 2007). Although 
the precise mechanism of αCP1 and αCP2 stabilisation of hTERT mRNA remains to be 
examined, this interaction may protect the ribonuclease-sensitive sites from recognition by 
sequence-specific endoribonucleases, preventing mRNA cleavage (Wang and Kiledjian, 
2000).  
The cloning of the TERT gene revealed multiple pre-mRNA variants (Kilian et al., 
1997). Currently, splicing of hTERT pre-mRNA has been reported to yield 22 mRNA splice 
variants (Kilian et al., 1997; Bojesen et al., 2013; Hrdlickova et al., 2012). The most well 
studied of these variants reside within the RT domain of hTERT and consist of four insertion 
sites designated sites 1-4 and two deletion sites termed α and β sites (Kilian et al., 1997). 
Insertions 3 and 4 result in the premature termination of hTERT mRNA after the RT motifs, 
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while the β- deletion and insertions 1 and 2 cause premature translation terminations, and 
the α- deletion results in removal of 36 bp within motif A of the RT domain that eliminates 
telomerase activity (Kilian et al., 1997). The introduction of hTERT deletion variants α- into 
normal human fibroblasts and a range of cancer cell lines resulted in a dominant negative 
phenotype, causing inhibition of telomerase activity in telomerase positive cells, resulting in 
telomere shortening to induce either a senescent like state or apoptosis (Yi et al., 2000; 
Colgin et al., 2000). The physiological relevance of alternate hTERT splicing is observed in 
early human foetal development, where the α- splice variant was noted in the liver and early 
kidney tissues while the β- splice variant was observed in the fetal heart, kidney and liver 
and the α-β- forms of hTERT were found to be liver-exclusive (Ulaner et al., 2001).  
Additionally, hTERT transcript containing the β- deletion variant has been found to 
be the most abundant hTERT transcript in thyroid tumours, breast cancer, lung carcinoma 
and melanoma cell lines (Listerman et al., 2013; Wang et al., 2008; Zaffaroni et al., 2002; Liu 
et al., 2012; Lincz et al., 2008). hTERT containing this β- deletion can confer a growth 
advantage to cancer cells, which renders the cells resistant to cisplatin-induced apoptosis 
(Listerman et al., 2013). Furthermore, the β- deletion transcript variant of hTERT is relatively 
unresponsive to the nonsense-mediated decay (NMD), and also found to be associated with 
polyribosomes, an indication that most of the β- deletion transcripts are translated 
(Listerman et al., 2013). 
The distinct distributions of alternatively spliced hTERT suggest that these variants 
are involved in vital telomerase control during physiological development, providing 
another avenue of regulation to enable fine-tuning of the level of telomerase activity. These 
studies presented convincing evidence to support post-transcriptional regulation as another 
form of hTERT control.  
1.10.3 Post-translational regulation- Phosphorylation 
Phosphorylation emerged as a form of post-translational regulation of hTERT 
following a study postulating that PKC can be an effector of hTERT phosphorylation and 
telomerase activity (Li et al., 1998). However, the PKC isoform involved in hTERT regulation 
appears to be cell-type specific, with PKCα postulated as being responsible in human breast 
cancer cells while PKCζ controls telomerase activity in human lymphocytes and 
34 
 
nasopharyngeal cancer cells (Yu et al., 2001; Sheng et al., 2003). In both human 
nasopharyngeal cancer cells and lymphocytes, PKC involvement was elucidated by using 
inhibitors and stimulators of this kinase, followed by examining the corresponding effect on 
hTERT mRNA levels and telomerase activity (Yu et al., 2001; Sheng et al., 2003), although no 
direct evidence for hTERT phosphorylation by PKC was provided. The effects on hTERT and 
telomerase activity could be indirect, via phosphorylation of other unknown intermediates. 
Perhaps a more direct involvement of PKC in the post-translational regulation of 
hTERT was examined in OEC-M1 cells, where it was determined that bisindolylmaleimide I 
(BIS) decreased PKC activity and telomerase activity but not core telomerase gene 
expression. Immunoprecipitation (IP) experiments and autoradiography data indicated that 
hTERT is the target for PKC phosphorylation, although the exact residues were not 
identified. This study also implicated a wide range of PKC isoforms in regulating hTERT 
phosphorylation in OEC-M1 cells, further strengthening the view that PKC involvement 
appears to be cell-type specific (Chang et al., 2006). 
Another kinase pathway that has been implicated in hTERT phosphorylation is the 
Akt kinase pathway. This was first investigated in a human melanoma cell line (SK-MEL 28) 
using a fluorescein-labelled hTERT peptide containing an Akt phosphorylation recognition 
sequence. This peptide was monitored for phosphorylation in vitro after treatment with 
Wortmannin, an Akt kinase pathway inhibitor, as well as okadaic acid, an Akt kinase 
pathway activator. The peptide phosphorylation state at S824 correlated well with changes 
in the Akt kinase activity as well as telomerase activity, suggesting that human telomerase 
may be regulated by Akt kinase phosphorylation (Kang et al., 1999). Later studies further 
implicated the role of Akt in hTERT phosphorylation and cellular localisation. 
Phosphorylation of hTERT at another site, S227, resulted in the nuclear localisation of hTERT 
in multiple cell lines by increasing the affinity of hTERT for importin-α protein. The specificity 
of Akt in mediating phosphorylation of hTERT at this site was further verified with an IP and 
detection with an anti-phospho Akt substrate antibody (Jeong et al., 2015; Chung et al., 
2012). One way in which Akt maintains hTERT phosphorylation involves the protein 
assembly of an HSP90/Akt and hTERT complex, maintaining telomerase activity and 
inhibiting apoptosis in an endothelial cellular context (Haendeler et al., 2003b).  
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In keeping with the notion that Akt kinase pathway is involved in hTERT regulation, 
further characterisation in Caov-3 and MCF-7 cells revealed that 17β-Estradiol (E2) 
phosphorylates Akt in an estrogen (ER), Src and PI3K dependent manner, revealing an 
expanded kinase cascade in Akt-mediated hTERT phosphorylation (Kimura et al., 2004). In 
addition, E2 induces the association of 14-3-3 proteins with phosphorylated hTERT, 
mediated by ER through Akt/PI3K, culminating in nuclear accumulation of hTERT (Kimura et 
al., 2004). The association with 14-3-3 proteins as a post-translational control mechanism is 
supported by a study employing the yeast 2-hybrid system that located a segment of hTERT 
C-terminal domain that binds 14-3-3 proteins. This interaction requires the phosphorylation 
of the target protein, and results in hTERT nuclear localisation, while dephosphorylation 
abolishes 14-3-3 interaction leading to the cytoplasmic localisation of hTERT (Seimiya et al., 
2000).   
Another study to identify a direct phosphorylation site showed that the presence of 
reactive oxygen species in cells initiated the phosphorylation of Y707 within hTERT by the 
Src kinase family, resulting in the cytoplasmic translocation of hTERT from the nucleus to 
decrease telomerase activity (Haendeler et al., 2003a). This observation was confirmed with 
the Src kinase inhibitor PPI, as well as site directed mutagenesis of Y707 (Haendeler et al., 
2003a). Subsequent studies expanded this observation and found that phosphorylation by 
Src kinase is also balanced by Shp-2 tyrosine phosphatase, which negatively regulates hTERT 
phosphorylation at Y707 to retain hTERT nuclear localisation (Jakob et al., 2008). More 
recently, evidence of hTERT phosphorylation by Src kinase was also observed on 
mitochondrial hTERT in HEK 293 cells, potentially implicating phosphorylation of 
mitochondrial hTERT in oxidative stress response and cellular survival (Buchner et al., 2010).  
Although several residues have been identified to be subtrates for Akt and Src kinase 
phosphorylation, how phosphorylation affects telomerase-specific activity and regulation 
have not been characterised. Continuing efforts into locating phosphorylation sites could 
yield invaluable insight into the mechanistic principle behind how phosphorylation of hTERT 
affects telomerase activity, potentially providing new avenues for highly specific therapeutic 
interventions. 
1.10.4 Post-translational regulation- Assembly and transport of telomerase complex 
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Since the catalytically active telomerase enzyme complex is composed of multiple 
subunits that are required to be assembled for telomerase activity, the process of 
component assembly dictates the levels of catalytically active telomerase available for S 
phase telomere extension (Tomlinson et al., 2008). In S. cerevisiae, telomerase components 
include the regulatory subunits Est1 and Est3 (Lundblad and Szostak, 1989; Morris and 
Lundblad, 1997; Hughes et al., 2000; Livengood et al., 2002), which are dispensable for the 
in vitro catalytic activity of telomerase (Cohn and Blackburn, 1995; Lingner et al., 1997a), the 
catalytic subunit Est2 (Lingner et al., 1997b; Counter et al., 1997), and TLC1 telomerase RNA 
(Singer and Gottschling, 1994). Telomerase assembly during S phase in S. cerevisiae involves 
the interaction of Est3 with the pre-assembled Est1-TLC1-Est2 complex through Est3 binding 
sites on Est1 and Est2, as well as a ‘toggle switch’ on the surface of Est3 (Tucey and 
Lundblad, 2014).  
In humans, the process of telomerase assembly involves the assembly of hTR and 
hTERT by chaperone proteins p23 and Hsp90 (Holt et al., 1999; Forsythe et al., 2001). 
Additionally, hTERT affinity purification has identified two other factors required for 
telomerase assembly, the ATPases reptin and pontin (Venteicher et al., 2008). These factors 
associate directly with hTERT and dyskerin, with association peaking in S phase, and deletion 
of both reptin and pontin diminishes telomerase accumulation (Venteicher et al., 2008). 
Once assembled, hTR accumulates in Cajal bodies (Zhu et al., 2004; Jady et al., 2004), which 
are spherical nucleolar accessory bodies containing coiled threads of the marker protein 
coilin (Morris, 2008). The association of telomerase with Cajal bodies is mediated by the 
presence of the CAB box in hTR (Cristofari et al., 2007). hTR with a defective CAB box can 
form catalytically active telomerase, but is defective in Cajal body accumulation and 
telomere lengthening (Cristofari et al., 2007). Later, it was discovered that the telomerase 
Cajal body protein 1 (TCAB1) can bind to hTR via the CAB box and, together with Cajal 
bodies, shuttle telomerase to telomeres (Cristofari et al., 2007; Venteicher and Artandi, 
2009; Tycowski et al., 2009). TCAB1 also has a Cajal body independent role in directly 
mediating the process of telomerase recruitment to telomeres (Stern et al., 2012). The 
process of hTR localisation to Cajal bodies and telomeres in human cells requires hTERT and 
peaks during S phase, in line with the observation that telomerase extends telomeres at S 
phase of the cell cycle (Tomlinson et al., 2006; Tomlinson et al., 2008; Jady et al., 2006).  
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Interestingly, there have also been studies in coilin knockout HeLa cells and 
telomerase overexpressing HEK293T cells suggesting that telomerase in such contexts can 
still function at telomere ends in the absence of coilin, in a Cajal body independent manner 
(Chen et al., 2015; Stern et al., 2012). It is possible that Cajal body localisation serves to 
concentrate telomerase components, a process which is redundant when telomerase is 
present at high enough levels.  
Although our collective understanding of telomerase assembly is limited by our 
ability to detect transient interactions between multiple factors that may be dispensable for 
the final catalytic activity, continued investigations into these transient factors will greatly 
increase our conceptual knowledge of telomerase biogenesis and possibly provide new 
avenues for future telomerase-based cancer therapeutics. 
1.10.5 Post-translational regulation- Recruitment of telomerase to telomeres 
To enable telomerase-mediated telomere repeat addition, direct establishment of 
interactions between the enzyme and its DNA substrate is required. Telomerase recruitment 
to the telomere is mediated by interactions with telomere specific binding proteins. Some of 
these proteins bind to the single stranded overhangs of telomere ends and positively 
regulate telomerase interactions, enabling telomere extension to occur. 
Cdc13 is a single-stranded telomere binding protein in S. cerevisiae; it binds 
telomeres with high affinity and selectivity through multiple OB-fold domains (Bourns et al., 
1998; Lin and Zakian, 1996; Nugent et al., 1996; Theobald and Wuttke, 2004; Mitton-Fry and 
Wuttke, 2002). Pull down assays, yeast two hybrid experiments and electrophoretic mobility 
shift assays (EMSA) demonstrated the direct interaction between Cdc13 and Est1, an S. 
cerevisiae telomerase accessory factor (Wu and Zakian, 2011; Nugent et al., 1996; Qi and 
Zakian, 2000). This interaction between Cdc13 and Est1 is mediated by phosphorylation of 
Cdc13 by Cdk1, and is essential for Est1 presence at telomere ends and telomere elongation 
(Wu and Zakian, 2011; Li et al., 2009; Evans and Lundblad, 1999; Pennock et al., 2001). 
Tethering of Cdc13 to a double stranded DNA break resulted in the formation of telomere 
repeats and allowed the direct visualisation of Cdc13-regulated telomerase recruitment, 
confirming that Cdc13 mediates telomerase recruitment (Evans and Lundblad, 1999; 
Pennock et al., 2001; Bianchi et al., 2004). 
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In S. pombe, immunoprecipitation experiments pulled down the single-stranded 
binding protein Tpz1 (a human TPP1 homolog) with telomerase activity, providing the first 
clues that Tpz1 plays a role in telomerase recruitment (Miyoshi et al., 2008). The C-terminus 
of Tpz1 regulates binding with Ccq1, another component of the S. pombe Pot1 complex 
(Miyoshi et al., 2008), and this Tpz1-Ccq1 interaction is required for telomere elongation. 
Subsequent studies using ChIP and real-time quantitative PCR directly demonstrated that 
the complex of Ccq1 and Tpz1 is essential for telomerase recruitment to telomeres (Harland 
et al., 2014; Tomita and Cooper, 2008). Further characterisation of Ccq1 revealed the 
necessity for the threonine 93 residue to be phosphorylated for telomerase recruitment to 
be regulated (Moser et al., 2011; Harland et al., 2014). Mutational analysis of Ccq1 to 
abolish threonine 93 phosphorylation disrupted Tpz1 complex binding, culminating in 
reduced telomerase recruitment, as visualised directly with a Trt1 ChIP (Moser et al., 2015).  
The single-stranded DNA binding proteins involved in mediating the interaction 
between telomerase and telomeres in humans are the heterodimer POT1-TPP1 (Baumann 
and Cech, 2001; Houghtaling et al., 2004; Liu et al., 2004b; Ye et al., 2004b). Like Tpz1 in S. 
pombe, the human homolog TPP1 is a shelterin component that, when pulled down with 
tandem affinity purification, was found to associate with ~20% of telomerase activity, 
indicating that it may be involved in telomerase recruitment (Xin et al., 2007a). The first 
direct evidence of TPP1 involvement in telomerase recruitment came from studies using 
immunofluorescence/ fluorescent in situ hybridisation (IF/ FISH) and ChIP to measure the 
association of hTR and hTERT with telomeres. TIN2-tethered TPP1 is directly involved in 
modulating telomerase recruitment to telomeres (Abreu et al., 2010); the OB-fold of TPP1 
was identified as being essential for this association (Abreu et al., 2010; Zhong et al., 2012). 
Further investigation into TPP1 revealed a group of 7 amino acids, termed the ‘TEL patch’, 
which resides on the surface of the OB fold and is necessary and sufficient for telomerase 
recruitment (Nandakumar et al., 2012; Sexton et al., 2012; Dalby et al., 2015). Tethering of 
the TPP1 OB fold to non-telomeric sites is sufficient to recruit telomerase to a heterologous 
chromatin locus, via the residues D166, E168 and K170 (Zhong et al., 2012). A naturally 
occurring mutations in the TEL patch of TPP1 found in patients (deletion of K170) abolished 
telomerase recruitment and processivity, resulting in short telomeres and manifestion of 
the short telomere syndromes aplastic amaemia and Hoyeraal-Hreidarsson (HH) syndrome, 
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a more severe form of dyskeratosis congenita (Guo et al., 2014; Kocak et al., 2014). Amino 
acids within the TEN domain of hTERT mediate interactions with the TEL patch on TPP1 
(Schmidt et al., 2014). Mutations within the TEN domain at K78 and R132 resulted in the 
failure of telomerase to interact with TPP1 and POT1, affecting telomerase localisation to 
the telomeres and telomere maintenance, further reaffirming the positive regulatory role of 
TPP1 and POT1 in mediating telomerase interactions with telomeres (Stern et al., 2012; 
Schmidt et al., 2014).  
Separable from the role of TPP1 in regulating telomerase recruitment, TPP1 can also 
stimulate telomerase processivity and regulate the telomere length homeostasis set-point 
(Zaug et al., 2010; Nandakumar et al., 2012; Sexton et al., 2014; Dalby et al., 2015). The 
binding of POT1-TPP1 to DNA primer substrates stimulated an increase in telomerase 
activity and processivity (Zaug et al., 2010; Sexton et al., 2014; Wang et al., 2007). The 
mechanism behind these observations involves POT1-TPP1 stabilising the associations 
between telomerase and telomeric DNA to decrease the rate of primer dissociation, while 
the TEL patch of TPP1 also facilitates translocation efficiency (Latrick and Cech, 2010; Dalby 
et al., 2015). Furthermore, TPP1 has a role in providing a regulatory telomere length 
feedback to telomerase in order to regulate the homeostasis set point (Sexton et al., 2014). 
Telomerase-mediated telomere elongation has been found to occur preferentially at 
short telomeres across multiple species. The elongation of telomeres by telomerase occurs 
preferentially on shorter telomeres in S. cerevisiae (Teixeira et al., 2004; Sabourin et al., 
2007; Marcand et al., 1999; Chang et al., 2007; Bianchi and Shore, 2007a), mouse models 
(Hemann et al., 2001) and human cells (Britt-Compton et al., 2009; Ouellette et al., 2000; 
Steinert et al., 2000). An unexpected result showed that in addition to the preferential 
elongation of shorter S. cerevisiae telomeres, there was also an increase in the processivity 
of telomerase activity at short telomeres (Chang et al., 2007). Live cell imaging in S. 
cerevisiae revealed that a subset of telomerase RNA molecules cluster during S phase and 
associate with a small number of telomeres to mediate lengthening, and that this process 
requires the MRX complex (the S. cerevisiae homolog of the MRN complex), Tel1 (the ATM 
homolog), Rif1 and Rif2 (the S. cerevisiae Rap1p binding partners) as well as Cdc13 (Gallardo 
et al., 2011). This preferential recruitment of S. cerevisiae telomerase to short telomeres is 
also directed by TERRA, a telomeric repeat containing RNA (Cusanelli et al., 2013). Short 
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telomeres increase the transcription and nuclear accumulation of TERRA and enhance 
TERRA association with telomerase components. Live cell imaging and microscopy directly 
demonstrated the recruitment of telomerase to the short telomeres from which the TERRA 
has been transcribed (Cusanelli et al., 2013). 
Although numerous studies above have demonstrated that telomerase elongation 
occurs preferentially at short telomeres, in human cells this may only be the case under 
conditions of changing telomere lengths. Under telomere length maintenance conditions, 
70% to 100% of telomere ends in HeLa and H1299 cells were observed to be extended at 
every S phase, indicating that human telomerase can act at every telomere at every cell 
cycle under some conditions (Zhao et al., 2009).  
Conversely, telomerase is negatively regulated by long telomeres. This negative 
regulation of telomere elongation is mediated by double-stranded telomeric binding 
proteins. Rap1 is the double stranded telomeric binding protein in S. cerevisiae (Conrad et 
al., 1990). Demonstration of the negative regulation of Rap1 was performed by targeting 
Rap1 to specific telomeres using hybrid proteins; this binding of Rap1 to specific targeted 
telomeres shortened those telomere repeats, thus increasing overall telomere length 
heterogeneity (Marcand et al., 1997a). The negative regulatory effects of Rap1 are partially 
mediated by the proteins Rif1 and Rif2. Rap1 recruits both of these proteins via its C-
terminal domain (Gilson et al., 1993; Hardy et al., 1992; Wotton and Shore, 1997). A 
decrease in telomere length during replication results in the loss of Rif1 and Rif2 telomeric 
binding, due to reduced Rap1 abundance at the telomere. These decreases in protein 
binding result in eventual telomere elongation, providing a “protein counting” model for 
telomere repeat binding and elongation (Marcand et al., 1997a; Levy and Blackburn, 2004). 
Like the yeast counterpart, human Rap1 is also a negative regulator of telomere length and 
distribution; increasing the abundance of human Rap1 resulted in diminishing telomere 
length and telomere heterogeneity (Li and de Lange, 2003). 
In S. pombe, the double stranded telomere binding protein involved in negative 
telomere regulation is the protein Taz1. First discovered in 1997, it shares homology with 
the Myb proto-oncogene DNA binding domain found in human shelterin components TRF1 
and TRF2 (Cooper et al., 1997). Depletion of Taz1 resulted in telomerase-dependent 
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telomere elongation (Cooper et al., 1997; Nakamura et al., 1998). Direct evidence for Taz1 
negatively mediating telomerase recruitment was later demonstrated using IF with tagged 
Trt (S. pombe telomerase reverse transcriptase subunit) and Trt ChIP to show that deletion 
of Taz1 resulted in stalled replication forks and a deregulation of telomerase recruitment 
outside S phase, culminating in telomere elongation (Dehe et al., 2012). Taz1 also interacts 
with Rap1 (Chikashige and Hiraoka, 2001) and Rif1 (Kanoh and Ishikawa, 2001), and the 
interaction between Rap1 and Taz1 is essential for regulating telomere length (Chikashige 
and Hiraoka, 2001). 
TRF1 and TRF2 are the double stranded telomere binding proteins in humans (Bilaud 
et al., 1997; Broccoli et al., 1997; Chong et al., 1995). As previously described, over-
expression of either TRF1 or TRF2 results in telomere shortening (Smogorzewska et al., 
2000; van Steensel and de Lange, 1997), although TRF2 over-expression specifically 
accelerates this process and reduces the senescence threshold by protecting short 
telomeres (Karlseder et al., 2002). Phosphorylation of TRF1 at S367 has also been shown to 
result in telomere dissociation of TRF1, culminating in telomerase-mediated telomere 
lengthening (McKerlie et al., 2012). These studies demonstrate how TRF1 and TRF2 mediate 
aspects of telomere length dynamics in a telomerase-dependent and independent manner 
respectively. 
DNA damage pathways are also involved in telomere length regulation. Tel1 is 
required for telomere repeat addition in S. cerevisiae (Chang et al., 2007), and the absence 
of Tel1, or the introduction of a Tel1 mutant lacking kinase activity, resulted in short 
telomeres (Lustig and Petes, 1986; Ritchie et al., 1999). Tel1, together with telomerase 
subunits Est1 and Est2, is highly enriched at short telomeres from early S to G2 phase 
(Sabourin et al., 2007; Arneric and Lingner, 2007; Bianchi and Shore, 2007b; Hector et al., 
2007). As discussed above, the cell cycle dependent clustering of telomerase in S. cerevisiae 
occurs preferentially on short telomeres, and this recruitment and clustering requires the 
MRX complex and Tel1 (Gallardo et al., 2011; Tsukamoto et al., 2001). The involvement of 
the MRX complex and Tel1 implicates the involvement of S. cerevisiae DNA damage 
response proteins in short telomere recognition, and there is direct evidence that this 
ultimately mediates telomerase recruitment (Gallardo et al., 2011; Cusanelli et al., 2013).  
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Although it has been suggested that the downstream phosphorylation target of Tel1 
in mediating Est1 interaction, telomerase recruitment and hence regulating telomere length 
is Cdc13 (Tseng et al., 2006), three results from the Lundblad lab contradict this notion (Gao 
et al., 2010). Firstly, Cdc13 and Est1 were found to interact in a strain lacking Tel1. Secondly, 
the pattern of Cdc13 phosphatase-sensitive isoforms were unchanged following the loss of 
Tel1. Finally, there were no significant changes in telomere length between controls and a 
strain expressing a Cdc13 variant that has all Tel1 phosphorylation sites eliminated (Gao et 
al., 2010). The downstream substrate of Tel1 remains to be identified, but the authors 
suggest that the lack of Tel1 results in a longer G-overhang (a consequence of chromosomal 
end resection), which provides an optimal substrate for telomerase-mediated elongation 
(Gao et al., 2010). 
It has been shown in S. pombe that Tel1 and Rad3 (the ATR homolog) are recruited 
to telomeres in S/G2 phase, demonstrating that these DNA damage proteins also have roles 
in telomere maintenance in S. pombe (Moser et al., 2009). ChIP analyses have directly 
shown that the deletion of Tel1 and Rad3 reduced telomerase recruitment and decreased 
the telomeric association of Ccq1 and Tpz1 (Moser et al., 2009). Furthermore, the Tel1 and 
Rad3-mediated phosphorylation of downstream substrate Ccq1 at T93 is essential for Est1 
(S. pombe telomerase regulatory subunit) binding, and for the recruitment of telomerase 
(Moser et al., 2011; Yamazaki et al., 2012). Thus, both studies have indicated the 
requirement for Tel1 and Rad3 for telomere length maintenance and telomerase 
recruitment.  
Conversely, murine studies suggested that the Tel1 homologue ATM and the Rad3 
homologue ATR are dispensable for telomerase-mediated lengthening of short telomeres 
(Feldser et al., 2006; McNees et al., 2010). These results contradict those from yeast models, 
leaving it unclear as to whether ATM and ATR are required for human telomerase 
recruitment. 
The first clue for the involvement of DNA damage proteins in telomere maintenance 
in humans came from the autosomal recessive disease Ataxia Telangiectasia, in which 
patients present with a multitude of symptoms such as premature aging, chromosomal 
instability, immunodeficiency, ionising radiation sensitivity, cell cycle abnormalities, 
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increased cancer predisposition and short telomeres. These symptoms may partially relate 
to deficiencies in telomere length maintenance and can be attributed to a single defective 
gene, the Ataxia telangiectasia mutated (ATM) gene (Savitsky et al., 1995; Painter and 
Young, 1980; Metcalfe et al., 1996), suggesting that PIKKs may play a biological role in 
regulating telomerase-mediated telomere lengthening.  
Co-immunoprecipitation and in vitro binding assay experiments identified the 
shelterin protein TRF1 as a substrate for ATM phosphorylation following DNA double strand 
breaks (Kishi et al., 2001). Since then, multiple ATM phosphorylation sites have been 
discovered on TRF1 (Kishi et al., 2001; Wu et al., 2007; McKerlie et al., 2012). The residue of 
most relevance to telomere length maintenance appears to be S367 of TRF1, since only 
phosphorylation on S367 resulted in changes in telomere length (McKerlie et al., 2012). 
Phosphorylation of TRF1 at S367 releases it from the telomeres and marks TRF1 for 
proteosomal localisation and subsequent degradation. At the same time, telomeres were 
observed to lengthen (McKerlie et al., 2012).  
The involvement of Rad3 in telomerase regulation in S. pombe suggests an 
involvement of the DNA damage signalling resulting from single stranded DNA, or from 
stalled DNA replication (Yamazaki et al., 2012; Moser et al., 2011). Additionally, it has been 
demonstrated in mouse and human cells that telomeres provide a poor template for DNA 
replication, frequently resulting in stalled replication forks (Sfeir et al., 2009; Ohki and 
Ishikawa, 2004; Fouche et al., 2006; Ivessa et al., 2002). A potential link between replication 
fork stalling and telomerase recruitment has been shown in S. pombe, where Taz1 is 
required for the efficient passage of replication forks through telomeric DNA (Miller et al., 
2006), and deletion of Taz1 also deregulated telomerase recruitment, resulting in telomere 
lengthening (Dehe et al., 2012). This evidence suggests, at least in S. pombe, that stalled 
replication forks may be a signal that is required for the propagation of a DNA damage 
response to mediate telomerase recruitment at the telomere. Whether stalled replication 
fork occurrence following ATM-dependent dissociation of TRF1 mediates a signal for human 
telomerase recruitment, or whether ATR is involved in this signalling cascade, are topics for 
investigation in this thesis. 
1.11 Project aims 
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This project has three main aims, all centred on the role of phosphorylation in 
mediating various stages of telomerase regulation. 
The first aim (chapter 3) was to investigate novel phosphorylation sites within hTERT, 
to test the hypothesis that they regulate different aspects of telomerase activity. Our 
current knowledge of hTERT phosphorylation is limited to the Akt and Src kinase pathways 
in regulating telomerase activity and mediating the cellular localisation of hTERT as well as 
cellular apoptotic response (Haendeler et al., 2003a; Kang et al., 1999). The mechanistic 
understanding of phosphorylation as a form of regulation in mediating telomerase assembly 
or recruitment to telomeres is rudimentary. For this aim, we chose to analyse several 
phosphorylation sites in hTERT that had been identified by phospho-enrichment and mass 
spectrometry, in house at CMRI (Dr Scott Cohen) or in a published phospho-proteomic 
screen (Tao et al., 2005). Using the cell biology techniques established in the Bryan 
laboratory, the possibility that these novel sites may regulate various aspects of telomerase 
was investigated. 
The second aim (chapter 4) was to investigate the role of ATM and ATR in telomere 
length regulation and telomerase recruitment in human cell lines. Studies performed in S. 
cerevisiae and S. pombe demonstrated the requirement for the activity of the DNA damage 
proteins Tel1 (ATM) and Rad3 (ATR) in regulating telomerase and telomere length (Sabourin 
et al., 2007; Hector et al., 2007; Arneric and Lingner, 2007; Moser et al., 2011; Yamazaki et 
al., 2012). It is unknown whether the role of ATM and ATR pathways in regulating 
telomerase recruitment is conserved in mammals, since these kinases were reported to be 
dispensable for the elongation of the shortest mouse telomeres (Feldser et al., 2006; 
McNees et al., 2010). In addition, immortalized cell lines derived from human patients 
harbouring ATM mutations were able to maintain their short telomeres with telomerase 
(Sprung et al., 1997). Using hTR/telomere FISH to directly visualise the cellular localisation of 
endogenous telomerase (Stern et al., 2012), investigations were carried out to elucidate the 
role of ATM and ATR in regulating human telomerase recruitment, with particular focus 
given to the ATM-TRF1 kinase pathway and how the localisation of TRF1 affects the 
localisation of telomerase to telomeres.  
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To examine if there are any other aspects of telomerase regulation in which ATM 
and ATR may have a regulatory role, the third aim of this project (chapter 5) was to 
investigate the possibility that ATM and ATR can mediate telomerase assembly, 
independent of their effects on recruitment and TRF1 pathways.  
Together, this PhD project provided new information on the roles of DNA damage 
responses and phosphorylation in mediating human telomerase recruitment to telomeres 
and telomerase regulation. It is hoped that providing a deeper understanding of telomerase 
regulation by the process of phosphorylation can assist in identifying future targets for 
interfering with telomerase action, with the ultimate aim of producing highly specific 
chemotherapeutics. 
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Chapter 2 
Materials & Methods  
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2. Materials and Methods 
2.1 Site-directed mutagenesis 
Wild-type hTERT, hTR and dyskerin expression plasmids pApex-3P-hTERT and pApex-
3-dyskerin- U3–hTR have been described (Tomlinson et al., 2015). A plasmid encoding WT 
TRF1 was constructed by subcloning the TRF1 open reading frame from pCMV-GFP.hTRF1 (a 
gift from T. de Lange) into a pcDNA3.1/myc-HisB plasmid by In-Fusion® cloning (Clontech 
Laboratories, Inc.) according to the manufacturer's protocol. 
The mutation of specific residues in hTERT and TRF1 to alanine and aspartic acid was 
performed using the Stratagene® QuikChange® II XL Site-Directed Mutagenesis kit. 
Mutagenic primer design follows the manufacturer’s recommendations of between 25 and 
45 bases in length and a melting temperature (Tm) of > 78˚C. The minimum GC content is 
40% and the primer terminates in one or more C or G bases. The primers used in this project 
are listed below with the mutations in red: 
Table 2.1: Primers used for site directed mutagenesis 
Protein Primer name Primer sequence (5’-3’) 
hTERT S206A forward GATGCGAACGGGCCTGGAACCATGCCGTCAGGGAGG 
hTERT S206A reverse CCTCCCTGACGGCATGGTTCCAGGCCCGTTCGCATC 
hTERT S206D forward GGATGCGAACGGGCCTGGAACCATGACGTCAGGGAGGC 
hTERT S206D reverse GCCTCCCTGACGTCATGGTTCCAGGCCCGTTCGCATCC 
hTERT S523A forward GCTTGGCTGCGCAGGGCCCCAGGGGTTGGC 
hTERT S523A reverse GCCAACCCCTGGGGCCCTGCGCAGCCAAGC 
hTERT S523D forward CGCTTGGCTGCGCAGGGACCCAGGGGTTGGC 
hTERT S523D reverse GCCAACCCCTGGGTCCCTGCGCAGCCAAGCG 
hTERT T1113A forward GGGACGACGCTGGCTGCCCTGGAGG 
hTERT T1113A reverse CCTCCAGGGCAGCCAGCGTCGTCCC 
hTERT T1113D forward  GGGGACGACGCTGGATGCCCTGGAGGCC 
hTERT T1113D reverse GGCCTCCAGGGCATCCAGCGTCGTCCCC 
hTERT S1125A forward CCCGGCACTGCCCGCAGACTTCAAGACC 
hTERT S1125A reverse GGTCTTGAAGTCTGCGGGCAGTGCCGGG 
hTERT S1125D forward  CCAACCCGGCACTGCCCGATGACTTCAAGACCATCCT 
hTERT S1125D reverse AGGATGGTCTTGAAGTCATCGGGCAGTGCCGGGTTGG 
TRF1 TRF1S367A forward GCAGAATACCTGTTTCAAAGGCTCAGCCGGTAACTCCTG 
TRF1 TRF1S367A reverse CAGGAGTTACCGGCTGAGCCTTTGAAACAGGTATTCTGC 
TRF1 TRF1S367D forward GCAGAATACCTGTTTCAAAGGATCAGCCGGTAACTCCTG 
TRF1 TRF1S367D reverse CAGGAGTTACCGGCTGATCCTTTGAAACAGGTATTCTGC 
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 Site-directed mutagenesis reactions were prepared as per manufacturer’s protocol. 
 The conditions for site-directed mutagenesis polymerase chain reaction (PCR) were 
modified from manufacturer’s protocol. The modified parameters are as follows: 
Segment Cycles Temperature Time 
1 1 95˚C 1 minute 
2 18 95˚C 50 seconds 
68˚C 50 seconds 
68˚C 30 minutes 
3 1 68˚C 7 minutes 
4  4˚C Hold 
 
 Following site-directed mutagenesis, 10 U of Dpn1 was added to the PCR products 
and incubated at 37˚C to digest parental DNA. The entire PCR reaction was ethanol 
precipitated in 115 mM sodium acetate pH 4.6. The supernatant was aspirated and the DNA 
pellet was air dried before resuspension with 10 mM Tris-Cl pH 7.5. 
2.2 Competent cell transformation 
Depending on the plasmid, larger plasmids (≥10kb) were transformed with XL10- 
Gold® ultra competent cells (Stratagene®, catalog # 200315) while smaller plasmids (≤10kb) 
were transformed with JM109 competent cells (Promega, catalog # L2005). Competent cell 
transformation reactions were performed according to manufacturers’ protocols. 
2.3 Plasmid preparation and sequencing reactions 
All plasmid preps were performed using QIAGEN® Plasmid Mini, Maxi and Giga kits 
following the manufacturer’s protocols 
 Sequencing was performed by making up a sequencing reaction consisting of 67 
ng/mL of plasmid and 0.8 µM of sequencing primer. The reactions were sent to the 
Australian Genome Research Facility (AGRF) at the Westmead Millennium Institute for 
sequence verification by Sanger sequencing. 
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2.4 Cell culture  
2.4.1 Maintaining 293T/ HeLa cells 
 HEK 293T cells (from Dr. T. Adams, CSIRO), HeLa cells (American Type Culture 
Collection), HeLa204 cells (Takai et al., 2010), and TRF1 stably transfected HeLa cells 
(McKerlie et al., 2012) were maintained in T225 flasks containing Gibco® Dulbecco’s 
Modified Eagle Medium (DMEM) medium (Catalog # 11965-092) supplemented with 10% 
fetal bovine serum (FBS) (Gibco® Life Technologies™ catalog # 10437028). The cells were 
incubated in a humidified incubator at 37°C with 5% CO2.  
2.4.2 Transient transfection of 293T for the production of human telomerase 
 293T cells were plated into a T225 flask containing 54 mL of DMEM + 10% FBS for 24 
h at 37˚C at a density of 1.5 × 107 cells/flask. Room temperature Roche XtremeGENE9 DNA 
transfection reagent (180 µL) was added into 6 mL of FBS-free DMEM, incubated for five 
min at room temperature before the addition of 60 µg of DNA (6 µg of pApex-3P-hTERT 
plasmid and 54 µg of pApex-3-dyskerin-U3-hTR plasmid) and incubated for another 30 min 
at room temperature. The solution was then added drop-wise into the medium. The cells 
were incubated at 37˚C for 6 h and at 32˚C for 66 h before harvesting. 
2.4.3 Transient transfection of 293T for chromatin immunoprecipitation (ChIP) 
 293T cells (3 × 106 cells) were plated onto a 15 cm tissue culture plate and incubated 
overnight at 37˚C before plasmid transfections with Roche XtremeGENE9 DNA transfection 
reagent (pApex-3P-hTERT- plasmid (1 µg), pApex-3-dyskerin-U3-hTR plasmid (11.5 µg), or 
empty pApex-3P plasmid (12.5 µg)). The cells were harvested for ChIP after 48 h of 
incubation at 37˚C. 
2.4.4 Transient transfection of 293T for myc-TRF1 over-expression 
 293T cells (2 × 105 cells) were plated onto 6 cm tissue culture plates and incubated at 
37˚C for 24 h before protein over-expression. Cells were then transfected using Roche 
XtremeGENE9 DNA transfection reagent and 2.5 µg of WT TRF1 or 1.0 µg of S367A/D TRF1 
expression plasmid to ensure even protein expression levels, in DMEM for 72 h. 
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2.4.5 siRNA silencing transfection of 293T  
 293T cells (2 × 105 cells) were plated onto 6 cm tissue culture plates and incubated at 
37˚C for 24 h before siRNA transfection. For each siRNA transfection, 90 pmol of siRNA 
(Table 2.2) was added to 150 µL of room temperature Opti-MEM (Invitrogen), while in a 
separate tube 5.5 µL of Lipofectamine® RNAiMax was added to 150 µL of room temperature 
Opti-MEM (Invitrogen). The contents of both tubes were mixed, left to stand at room 
temperature for 30 min and added drop-wise to cells with constant swirling of the tissue 
culture dish. If over-expression of exogenous proteins was to be performed, transfection 
with 3.5 µg of plasmid DNA using 7.5 µL of XtremeGENE 9 in 200 µL of serum -free DMEM 
was carried out 24 h after siRNA transfection, and the cells were harvested 72 h after siRNA 
transfection. 
Table 2.2: siRNA used in this study 
siRNA Company Catalogue 
number 
Sequence (5’- 3’) 
Hs_ATM_5 Flexi Tube QIAGEN SI00299299 5’-AAGGCTATTCAGTGTGCGAGA-3’ 
ATM stealth siRNA Invitrogen HSS181473  
TRF1 siRNA QIAGEN (custom) 1027423 5'-AAGAATATTTGGTGATCCAAA-3' 
Hs_TERF1_10 GeneSolution  QIAGEN SI04906062 5’-TTGCCAGTTGAGAACGATATA-3’ 
Hs_ATR 11 Flexi Tube QIAGEN SI02660231 5’-AAGGACATGTGCATTACCTTA-3’ 
Hs_ATR 12 Flexi Tube QIAGEN SI02664347 5’-CAGGCACTAATTGTTCTTCAA-3’ 
All Stars Negative control QIAGEN 1027281  
 
2.4.6 Thymidine-aphidicolin double cell synchronisation of 293T 
 At 32 h after the addition of siRNA or plasmid, 293T cells were synchronised with 2 
mM thymidine (Sigma-Aldrich) for 15 h. The cells were released for 9 h before medium 
containing 0.5 µg/mL aphidicolin (Sigma-Aldrich) was added to the cells for 16 h. The cells 
were released into S phase by replacing the aphidicolin with fresh medium. Cell 
synchronisations were verified by analysis of DNA content by flow cytometry on a FACSDiva 
(Becton Dickinson). 
2.4.7 Double thymidine cell synchronisation of HeLa 
 HeLa cells grown in DMEM (+ 10% FBS) were initially synchronised with medium 
containing 2 mM thymidine for 18 h, releasing into thymidine-free DMEM (+ 10% FCS) for 9 
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h before a second round of thymidine block for a further 15 h, to obtain HeLa cells 
synchronised at the G1/S boundary. 
2.4.8 Ku55933 ATM kinase inhibitor and VE-822 ATR kinase inhibitor treatment 
 Following the thymidine-aphidicolin cell synchronisation of 293T in the previous 
section, fresh media containing 10% FBS and 1.5 µM of KU55933 (Merck Millipore), 500 nM 
of VE-822 (Selleckchem) or DMSO was added to the cells for 3 h, until the cells were at mid S 
phase.  
2.4.9 VyBrant cell staining and sorting 
Cells were harvested and resuspended in Hank's balanced salt solution (Life 
Technologies) at a concentration of 1 × 106 cells/mL. The cells were stained with VyBrant 
DyeCycle Violet (Life Technologies) at a concentration of 5 µM at 37°C for 30 min before cell 
sorting using a BD FACSAriaIII Cell Sorter (BD Bioscience, US). Confirmation of cell cycle 
phases was performed using the FACSDiva (Becton Dickinson). 
2.4.10 Flow cytometry for cell cycle analysis 
Cells were fixed by resuspending 2 × 106 cells in 500 µL of phosphate buffered saline 
(PBS) (MP Biomedicals, LLC) containing 0.1% (w/v) EDTA (pH 7.0) and 80% v/v ethanol. The 
cells were then left to incubate overnight at -20˚C before flow cytometry. 
Ethanol fixed cells were centrifuged at 1000 × g for 5 min, the supernatant was 
aspirated and the cells were washed with 5 mL of PBS before another round of 
centrifugation at 1000 x g for 5 min. The cells were resuspended in PBS, 40 µg/mL of 
propidium iodide (Sigma Aldrich) and 50 µg/mL of RNase A (Sigma Aldrich) and incubated at 
room temperature for 30min and at 4°C overnight. After 10 min incubation at room 
temperature, FACS analysis was performed with a BD FACS Canto™ Flow Cytometer the 
following day. 
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2.5 Induction of DNA damage  
2.5.1 Gamma (γ) irradiation 
Gamma irradiation was performed using the Gammacell® 1000 Elite irradiator (Best 
Theratronics) with a 137Caesium source. The irradiated cells were returned to incubate at 
37°C for an hour before harvesting for downstream analysis. 
2.5.2 Ultraviolet (UV) treatment 
UV treatment was performed using the Vilber Lourmat VL-6C on the bench top for 
the required duration. Treated cells were incubated at 37°C for an hour before harvesting 
for downstream analysis. 
2.6 Cell lysis and immunoblot 
Cell pellets were resuspended in 4 × LDS buffer (106 mM Tris-HCl, 141 mM Tris-Base, 
2% LDS (Novagen), 40% w/v glycerol, 0.075% SERVA blue G50 (SERVA Electrophoresis), 
0.025% phenol red) containing Benzonase® nuclease (Novagen) (0.5 U/µL) and β-
mercaptoethanol (2% v/v) to give a final cell concentration of 104 cells/µL. The lysate was 
incubated at room temperature for 30 min for complete chromatin digestion, then heated 
to 68°C for 10 min before directly loading onto a Novex NuPAGE® 4-12% Bis-Tris gel (for low 
molecular weight proteins) or 3-8% Tris-Acetate gel (for high molecular weight proteins).  
Bis-Tris gels were run with MES buffer (Novagen) at 200 V for 50 min while Tris-
Acetate gels were run with Tris Acetate buffer (Novagen) at 150 V for 3.5 h. Protein transfer 
was performed in Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% v/v methanol) 
using Whatman® Protran® nitrocellulose transfer membrane and the Bio-Rad Ready Gel Cell 
blot module at 100 V for 60 min at 4°C.  
After protein transfer, the membrane was stained with Ponceau-S staining solution 
(0.1% w/v in 5% acetic acid) before blocking in TBS-T (15 mM Tris-HCl, 4.6 mM Tris-base, 
137 mM NaCl, and 0.1% Tween-20) containing 5% skim milk at room temperature for one 
hour. The appropriate antibody (Table 2.3) was then diluted in 5% skim milk in TBS-T and 
incubated with the membrane overnight at 4°C.  
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The membrane was then washed 5 × 5 minutes in TBS-T with rocking, before 
incubating the membrane in diluted secondary antibody in 5% skim milk/ 1X TBS-T at room 
temperature for one hour prior to another series of 5 × 5 minutes washes in TBS-T. 
Detection was performed with Amersham™ ECL™ Western Blotting Detection kit or 
Amersham™ ECL™ Prime Western Blotting Detection kit according to the manufacturer’s 
directions. Western blot imaging was performed with the Fujifilm Las-4000 Luminescent 
image analyser. 
Table 2.3: Antibodies used in this study 
Antibody Company Cat. no Species Application Dilution 
 (hTERT) Santa Cruz sc-7215 Goat Western blots 1:1000 
HTCS2 
(hTERT) 
In house - Sheep Immunoprecipitation 20 µg/mL 
p-ATM 
(S1981) 
Abcam AB81292 Rabbit Western blots 1:1000 
ATM  Abcam AB32420 Rabbit Western blots 1:2000 
TRF1 Titia de Lange 
lab 
- Rabbit Western blots 1:2000 
    Immunofluorescence 1:2000 
ATR Cell Signaling 2790 Rabbit Western blots 1:1000 
p-CHK1 (S345) Cell Signaling 23485 Rabbit Western blots 1:1000 
CHK1 Cell Signaling 23605 Mouse Western blots 1:1000 
p-CHK2 (T68) Cell Signaling 2661 Rabbit Western blots 1:1000 
CHK2 Merck 
Millipore 
05-649 Mouse Western blots 1:1000 
p-RPA (S4/S8) Bethyl Labs A300-245 Rabbit Western blots 1:1000 
S33 RPA Bethyl Labs A300-246A Rabbit Western blots 1:1000 
RPA Abcam AB2175 Mouse Western blots 1:1000 
γH2AX BioLegend 613404 Mouse Western blots 1:2000 
    Immunofluorescence 1:1000 
9B11 Myc-tag  Cell Signaling 2276 Mouse Immunoprecipitation 20µL per 
5,000,000 
cells 
    Western blots 1:5000 
Vinculin Sigma-Aldrich V9131 Mouse Western blots 1:10 000 
Actin Sigma-Aldrich A2103 Rabbit Western blots 1:10 000 
 
The secondary antibodies from Dako (goat anti-rabbit, catalog #P044801-2; goat 
anti-mouse, catalog #P044701-2) were diluted 1:2000 in 5% skim milk in TBS-T.  
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2.7 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
RNA extraction was performed using the RNeasy Mini Kit (Qiagen) according to 
manufacturer's protocol and quantitated with a NanoDrop (ThermoFisher ND-1000 
spectrophotometer). DNA was removed from RNA sample (1 µg per sample) by digestion 
with 1 U of DNase (Amp grade; Sigma-Aldrich) at room temperature for 15 min, before the 
addition of EDTA to 2.5 mM and heat inactivation of DNase at 65°C for 10 min.  
cDNA synthesis was performed using the ‘Superscript III First-Strand Synthesis 
System for RT-PCR’ (Life Technologies) according to manufacturer’s protocol.  
2.7.1 Quantitative PCR (qPCR) 
qPCR was performed in triplicate on each cDNA with corresponding GAPDH controls, 
using the Roche real-time PCR LightCycler® 96 system with 45 cycles of 95 °C for 15 s and 60 
°C for 60 s, in Applied Biosystems SYBR green mix, with 0.5 µM forward and reverse primers 
(TRF1 forward: 5'-CGAGCTAGAAAAAGACAGGC, TRF1 reverse: 5'-AGTTTTAGTTTCTTCATGGT, 
GAPDH forward: 5'-ACCCACTCCTCCACCTTTG, GAPDH reverse: 5'-CTCTTGTGCTCTTGCTGGG).  
Analysis was carried out using the ΔΔCt method with the Roche LightCycler® 96 system 
software. 
2.8 Radioactive probe labelling 
The probe reaction was prepared using DNA oligonucleotide (2 µM), T4 kinase 
buffer, 15 U T4 kinase, and 2.5 µM [α-32P]ATP (6000 Ci/mmol, 150 µCi/µL) in a reaction 
volume of 20 µL. The reaction was incubated at 37˚C for 2 h before removal of 
unincorporated nucleotides with a ‘mini Quick Spin oligo column’ (Roche) by centrifugation 
at 1000 × g for 4 min.  
2.9 Immunoprecipitation (IP) of telomerase 
Clarified cell lysate was mixed with 10 µg of anti-hTERT antibody (HTCS2) and rotated 
at 4˚C for one hour. Blocked protein G beads (40 µL of 50% v/v suspension; see below) were 
added and incubated with constant rotation at 4˚C for a further hour.  
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The protein G beads were collected by vacuum in a micro-spin column and washed in 
5 mL of ice-cold Telomerase Buffer (20 mM HEPES-KOH pH 7.9, 300 mM KCl, 2 mM MgCl2, 
10% v/v glycerol, 0.1% v/v Triton X-100). Beads were resuspended in Telomerase Buffer 
supplemented with 1 mM antigenic peptide solution (peptide sequence: 
ARPAEEATSLEGALSGTRH; available from Abbexa Ltd., Cambridge, UK) followed by rotation 
at room temperature for one hour before eluting telomerase in a fresh 1.5 mL Eppendorf 
Protein Lo-bind tube by centrifugation at 1,000 x g for 10 s. 
2.10 Preparation for blocking protein G beads 
Roche Applied Science Protein G-Agarose beads (2 mL) were mixed with 10 mL of 
Telomerase buffer containing 0.5 mg/mL bovine serum albumin (BSA). After 30 min room 
temperature incubation with constant rotation, the beads were pelleted by centrifugation 
at 1,000 x g at room temperature for 5 min before aspirating the supernatant. This washing 
procedure was repeated with another equal volume of blocking solution. The beads were 
washed with a final 20 mL of Telomerase Buffer (without BSA) for 1 min, before 
resuspension in a final volume of 4 mL. 
2.11 Chromatin Immunoprecipitation (ChIP) 
hTERT ChIP experiments were performed as described (Stern et al., 2012). Harvested 
293T cells (5 × 106 to 1 × 107 cells) were resuspended with 1 mL of ice cold lysis buffer (5 
mM HEPES pH 8.0, 85 mM KCl, 0.4% Igepal CA-630, 1 mM phenylmethanesulfonyl fluoride 
(PMSF) and 1× complete protease inhibitor (CPI) (Roche)) and incubated on ice for 10 min. 
Centrifugation at 5000 x g for 15 min at 4˚C was performed to pellet the nuclei, which were 
resuspended in 1 mL of cell lysis buffer without Igepal CA-630 (see above) at room 
temperature. 1% formaldehyde (Merck Millipore, catalog # 1039992500) was added for 
cross-linking, and nuclei were incubated at room temperature for 10 min. Glycine (112.5 
mM) was added to quench crosslinking and incubated at room temperature for 5 min. 
Nuclei were pelleted at 5000 x g for 15 s at 4˚C, the supernatant was removed and the tube 
was kept on ice from this point onwards. The nuclei were lysed by adding 50 µL of nuclei 
lysis buffer (per 5 × 106 cells) (50 mM Tris-Cl, pH 8.1, 1 mM EDTA, 1% sodium dodecyl 
sulphate (SDS), 1 mM PMSF and 1× complete protease inhibitor (CPI)) and incubation on ice 
for 10 min. Ice cold Telomerase Buffer containing 1 mM EDTA (see above; 750 µL per 50 µL 
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of nuclei lysis buffer used) was added to each sample before sonication. Sonication was 
performed with a Branson 450 probe tip sonicator with parameters: 1 × 20 seconds at duty 
cycle 10, output 3; repeated at output 4 and 5 for 40 s each. The samples were centrifuged 
at 16 000 x g for 10 min at 4˚C and the supernatant containing chromatin was transferred to 
a new Eppendorf Protein Lo-bind tube; an aliquot of 50 µL was kept aside for total 
chromatin quantitation, while the remaining solution was snap frozen in liquid nitrogen and 
stored at -80˚C until immunoprecipitation.  
Each chromatin sample (‘input’) was mixed with 100 µL elution buffer (50 mM 
NaHCO3, 1% SDS) and 100 µg proteinase K for 3 h at 45˚C. The samples were purified using 
the QIAGEN PCR purification kit and eluted with 75 µL of filter sterilised TE buffer pH 8.0 (10 
mM Tris, 1 mM EDTA).  
To the immunoprecipitation (IP) reaction, a volume of 112.5 µL chromatin solution 
was added to 225 µL of ice cold IP buffer [20 mM HEPES-KOH pH7.9, 150 mM KCl, 1.0% 
Triton X-100 (v/v) and 1.5 mM EDTA], antibody (20 µg of HTCS2 antibody for TERT), 1 mM 
PMSF and 1× CPI. The samples were incubated for 1 h at 4˚C with constant rotation, before 
the addition of 60 µL pre-blocked Roche protein G agarose beads (see above) and rotation 
overnight at 4˚C. 
The following day, samples were centrifuged for 30 s at 12,000 x g at 4˚C. The 
supernatant was aspirated, and the beads were washed with 1 mL each of room 
temperature Telomerase Buffer and TE buffer. The beads were incubated with 100 µL of 
elution buffer and 100 µg of proteinase K at 45˚C for 3 h before purifying the DNA samples 
using a QIAGEN QIAquick PCR purification kit, followed by elution of the DNA in 140 µL TE 
buffer pH 8.0. Dilutions were set up for standard curves using the ‘input’ samples (0.5%, 1% 
and 2% covers the range pulled down by HTCS2, while 5%, 10% and 20% covers the range 
pulled down by TRF1 or myc-tag antibodies).  
To the inputs and 70 µL of eluted samples, 490 µL of 0.46 M NaOH was added before 
heating the samples to 95˚C for 5 min, cooling on ice and dot blotting onto a GE Healthcare 
Life Sciences Amersham™ Hybond™-XL membrane that was prewet with 1× SSC (0.15 M 
NaCl, 15 mM tri-sodium citrate dihydrate). The inputs and samples were washed through 
with 500 µL of TE buffer. The membrane was air dried, crosslinked three times in a 
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Stratagene® Stratalinker® UV crosslinker before pre-hybridising in 30mL of Church and 
Gilbert hybridisation buffer (1% BSA Fraction V grade, 1 mM EDTA pH 7.5, 500 mM NaHPO4 
pH 7.2, 7% SDS) at 55˚C. 107 cpm of Probe 1 (5’-CCCTAACCCTAACCCTAA-3’) labelled with T4 
polynucleotide kinase and γ-32P-ATP was incubated with the membrane overnight at 55˚C. 
The membrane was washed for 3 × 10 min in 0.1× SSC/0.1% SDS, sealed in a plastic sleeve 
and exposed to a phosphoscreen, which was imaged using a GE Healthcare Life Sciences 
Typhoon 8600 Variable Mode Imager before quantitating the IP and input samples with the 
‘Array Analysis’ on the ImageQuant program.  
2.12 hTR dot blot 
Harvested cells were lysed with telomerase buffer (+ 1 mM DTT and 1 mM PMSF) at 
a cell concentration of 104 cells/µL (cells over-expressing telomerase) or 105 cells/µL (cells 
with endogenous telomerase). Lysates were rotated at 4˚C for 1 h before centrifugation at 
16,200 × g at 4˚C for 20 min. Lysate (10 µL) was mixed with 90 µL of formamide loading 
buffer (90% deionised formamide, 0.1% bromophenol blue, 0.1% xylene cyanol, 1× TBE 
(Amresco)), heated to 70˚C for 10 min and cooled to 4˚C for 5 min before applying the 
samples onto a GE Healthcare Life Sciences Amersham™ Hybond™-XL membrane. The 
membrane was air dried for 30 min, crosslinked in a Stratagene® Stratalinker® UV 
crosslinker, pre-hybridised in 30 mL of Church and Gilbert hybridisation buffer (see above) 
at 55˚C, and then incubated with 106 cpm of radioactive Telo4 probe (5’-CGG TGG AAG GCG 
GCA GGC CGA GGC-3’) labelled with T4 polynucleotide kinase and γ-32P-ATP, overnight at 
55˚C. The membrane was washed for 3 × 10 min in 0.1× SSC/0.1% SDS and imaged with 
phosphorimaging using a GE Healthcare Life Sciences Typhoon 8600 Variable Mode Imager 
before quantitating the levels of hTR abundance using the ImageQuant program. 
2.13 Direct telomerase activity assay (solid phase) for telomerase assays in chapter 3 
Before performing the solid phase direct telomerase activity assay, Pierce 
NeutrAvidin Plus beads (Thermo Fisher) were prepared for (TTAGGG)3 immobilisation by 
suspending 2 mL of beads in 10 mL of Telomerase Buffer. Per 20 µL of beads, 100 pmol of 
Bio-L-18GGG [5’-BIOTIN-CTAGACCTGTCATCA(TTAGGG)3] (10,000 pmol DNA) was added and 
the suspension rotated overnight at room temperature. The beads were washed once with 
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10 mL of Telomerase Buffer the next day and suspended in Telomerase Buffer as 50% (v/v) 
slurry before storing at 4°C. 
Direct telomerase activity assays were performed as described (Cohen and Reddel, 
2008). Immunopurified telomerase was added to a micro-spin column containing 40 µL of 
50% v/v suspended (TTAGGG)3-modified beads (see above) (Cohen and Reddel, 2008) and 
rotated at room temperature for one hour before addition of 50 µL of assay buffer (20 mM 
HEPES-KOH pH7.9, 300 mM KCl, 2 mM MgCl2, 5 mM DTT, 0.1% Triton X-100, 1 mM 
spermidine, 1 mM dTTP, 1 mM dATP, 10 µM dGTP and 100 µCi α-32P-dGTP (198 Ci/mmol)) 
and incubation for 2 h at 37°C. The assay solution was separated from the beads by a 10 s, 
5000 x g centrifugation. The beads were washed once with 5 mL 1M NaCl solution followed 
by 5 mL TE buffer pH 8.0. Excess buffer was removed by centrifugation and the beads were 
resuspended in 20 µL of formamide-TBE elution solution (90% deionised formamide, 0.1% 
bromophenol blue, 0.1% xylene cyanol, 1× TBE, 0.5 mM biotin). Telomerase extension 
products were eluted by incubating the bead suspension at 90°C for 10 min and 
centrifugation for 10 s at 1000 × g followed by running 3 µL of each sample on a Bio-Rad 
Sequi-Gen GT large format sequencing gel at 85 W for 2 h.  
Calculation of telomerase processivity was performed as described (Latrick and Cech, 
2010). Briefly, total telomerase bands for each reaction were quantitated, normalised for 
incorporated radiolabelled guanine nucleotides before summation to give the total lane 
count (TLC), which was then normalised to the loading control. For each telomerase 
extension band n, the fraction left behind (FLB) was calculated by dividing the sum of counts 
for repeats (1-n) by TLC. A graph was drawn, plotting ln(1-FLB) against repeat number, and 
fit to a linear regression equation with slope m; (-0.693/m) was defined as the processivity 
value. 
2.14 Direct telomerase activity assay (solution phase) for telomerase assays in chapter 5 
The solution phase direct telomerase activity assay was performed as described 
(Tomlinson et al., 2015). A 20 µL telomerase extension reaction was prepared to give a final 
reaction concentration of 20 mM HEPES-KOH pH 7.9, 2 mM MgCl2, 5 mM DTT, 1 mM 
spermidine, 0.1% Triton X-100, 0.5 mM dTTP, 0.5 mM dATP, 4.8 µM dGTP, 5 µM α-32P-dGTP 
(198 Ci/mmol) and 1 µM of Bio-L-18GGG (5’-Biotin-CTAGACCTGTCATCA(TTAGGG)3). 
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Telomerase enzyme suspended in Telomerase Buffer was added last, and the reaction was 
allowed to proceed for 60 min at 37°C. The reaction was terminated with 5 µL of STOP 
solution (250 mM EDTA, 1000 cpm 32P-Bio-Tet3) (Bio-Tet3: 5’-GGGGTTGGGGTT-Biotin-3’). 
Dynabead M280 beads (20 µL, washed in B&W buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 
2 M NaCl)) were added to each telomerase reaction in a total of 100 µL B&W buffer, and 
allowed to mix with constant rotation at room temperature for 10 min. The beads were 
washed twice with 200 µL 2× B&W buffer followed by one wash of 200 µL TE buffer pH 8.0.  
The beads were resuspended in 10 µL of elution mix (2 mM biotin formamide-TBE) 
before incubating at 95°C for 5 min to release the telomerase extension products. The 
elution mix was transferred into a fresh Eppendorf tube and electrophoresed on a 
sequencing gel as above.  
2.15 Immunofluorescence (IF) 
Cells were harvested and resuspended in 500 µL of hypotonic solution (0.2% KCl, 
0.2% tri-sodium citrate) before cytocentrifuging (Thermo Shandon Cytospin 4) the cells for 
10 min at 2000 rpm with medium acceleration onto slides (Grale HDS Colourfrost). The 
slides were fixed in PBS (10 mM Na2HPO4, 1.8 mM KH2PO4, 0.137 M NaCl, 2.7 mM KCl) 
containing 2% paraformaldehyde at room temperature for 10 min before rinsing twice with 
MilliQ water. The cells were subsequently permeabilised in KCM (120 mM KCl, 20 mM NaCl, 
10 mM Tris pH 7.5, 0.1% Triton® X-100, 0.1% sodium azide) at room temperature for 10 min 
before rinsing once with PBS. The slides were placed in a humidity chamber and overlaid 
with 200 µL ABDIL (20 mM Tris pH 7.5, 2% BSA, 0.2% cold fish gelatine (Sigma), 150 mM 
NaCl, 0.1% Triton® X-100, 0.1% sodium azide) and 100 µg/mL RNaseA before covering with 
Parafilm for a 30 min incubation at room temperature. The slides were then overlaid with 
200 µL ABDIL containing the appropriate primary antibody dilution (see Table 2.3) before 
being covered with Parafilm and incubated at 37°C for one hour.  
The slides were washed with PBS + 0.1% Tween-20 for 4 × 5min at room 
temperature, overlaid with ABDIL containing secondary antibody and incubated at room 
temperature for 30 min. The slides were washed 3 × 5 min in PBS-T and 2 × 5 min in PBS at 
room temperature. At the final wash, DAPI was added at a final concentration of 50 ng/mL. 
The slides were rinsed twice with MilliQ water and dehydrated with a graded ethanol series 
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consisting of 70% ethanol for 3 min, 90% ethanol for 2 min and 100% ethanol for 2 min. The 
slides were air-dried and mounted with one drop of ProLong® Gold (Life Technologies) and 
cured overnight at room temperature away from any light source before imaging.  
2.16 Fluorescent in situ hybridisation (FISH) 
FISH was performed as described (Stern et al., 2012). 293T cells (4 × 104) or HeLa 
cells (3 × 104) were resuspended in 500 µL of PBS and cytospun onto slides at 800 rpm for 5 
min using a Shandon cytospin 4 (Thermo). Cells were fixed in PBS containing 2% 
paraformaldehyde at room temperature for 10 min, before incubation in PBS containing 
0.5% IGEPAL CA-630 for 10 min, rinsing twice with MilliQ water, and incubation in methanol 
and acetone solution (1:1) for 10 min. 
If performing simultaneous IF, the cells were air dried and blocked with PBG (PBS pH 
7.0, 1% cold water fish gelatin, 0.5% (w/v) BSA fraction V) for 2 h at room temperature. 
Primary antibody was diluted (see Table 2.3) in PBG and overlaid onto the cells before 
incubation at room temperature for 3 h, or overnight at 4°C. The cells were washed for 3 × 
5min with PBG and incubated with secondary antibody diluted in PBG for 60 min at room 
temperature. Another series of 3 × 5min washes in PBG was performed before rinsing the 
cells once in MilliQ water. The cells were re-fixed in 4% formaldehyde in PBS, rinsed twice 
with MilliQ water, and taken through FISH as described below. 
 
Probe 
Name 
Sequence (5'-3')  Complementary 
to hTR 
sequence (nt)  
Telomere TexasRed-CCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTA 
ACCCTAACCCTAA 
 
hTR 1  AF488-GCTGACATTTTTTGTTTGCTCTAGAATGAACGGAAGGCGGCAGGCCGAGGCTT  
 
128-183  
(pseudoknot/  
template domain)  
hTR 2  AF488-TCCAGGCGGGGTTCGGGGGTGGGCAGGCGACCCGCCGCAGGTCCCCGGGAGGGGCGAA  
 
195-252  
hTR 3  AF488-CGCGGCTGACAGAGCCCAACTCTTCGCGGTGGCAGTGGGTGCCTCCGGAGAAGCCCCGG  
 
266-324  
(CR4/CR5 domain)  
hTR 4  AF488-CTCCGTTCCTCTTCCTGCGGCCTGAAAGGCCTGAACCTCGCCCTCGCCCCCGAGAG  
 
328-383  
(H domain)  
hTR 5  AF488-ATGTGTGAGCCGAGTCCTGGGTGCACGTCCCACAGCTCAGGGAATCGCGCCGCGCGC  393-449  
(CR7 and ACA 
domain)  
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After methanol/acetone fixation or IF, the cells were dehydrated in a gradient of 70% 
ethanol, 90% ethanol and 100% ethanol for 2 min each at room temperature. The cells were 
probed with 30 µL of RNA FISH hybridisation buffer [10% dextran sulphate, 2 mM vanadyl-
ribonucleoside complex (NED S1402S), 0.02% RNase-fee BSA (New England Biolabs), 30 µg E. 
coli tRNA (Roche 10109541001), 2× SSC, 50% deionised formamide] containing a mixture of 
five Alexa Fluor 488-labeled anti-hTR oligonucleotides (Sigma) and a Texas Red-labeled 
telomere probe (Sigma) (Table 2.4). Probes were diluted, heated to 90˚C for 2 min and 
cooled for 3 min on ice before mixing with the RNA FISH hybridisation buffer. 
 Table 2.4: Probes used for hTR and telomere FISH 
Coverslips (Menzel Glaser #1) were placed on the slides, which were heated to 80˚C 
for 3 min in a Hybaid Omnislide in situ PCR machine and incubated overnight at 37˚C in a 
humidified chamber. 
The slides were washed twice in pre-warmed 2× SSC pH7.2, 50% formamide and 
0.1% SDS at 37˚C for 30 min with constant shaking. The slides were then washed in 4× SSC 
pH 7.2 and 0.1% Tween®-20 for three times at 42˚C with shaking in the dark. Finally, the 
slides were rinsed twice with MilliQ water before air-drying and cured with 1 drop of 
ProLong® Gold (Life Technologies) for 24 h in the dark at room temperature. 
2.17 Microscope imaging 
2.17.1 Manual image acquisition with Carl Zeiss® Axio Imager M1 for hTR, myc-TRF1 and 
telomere co-localisation 
All interphase cell imaging was performed on the Carl Zeiss® Axio Imager M1. A total 
of 13 z-stacks were taken for each image with an interval of 0.28 µm. The exposure duration 
for TexasRed was 1500.00 ms, FITC was 3200.00 ms and Cy5 700.00 ms. Co-localising myc-
TRF1 or hTR and telomere foci were manually counted in 100-150 cells per treatment, and 
data were analysed by Student t test for pairwise comparison. 
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Table 2.5: Filter sets used for microscope imaging 
Filter sets for Zeiss Axio Imager 
 Product number Excitation Beam Splitter Emission 
DAPI 488049-9901-000 G 365 FT 395 BP 445/50 
FITC 000000-1114-459 BP 475/40 FT 500 BP 530/50 
TexasRed 000000-1114-462 BP 560/40 FT 585 BP 630/75 
Cy5 488050-9901-000 BP 640/30 FT 660 BP 690/50 
 
Table 2.6: Objectives used for Zeiss Axio Imager 
Objectives for Zeiss Axio Imager 
Objective EX ‘Plan-Neofluar’ 2.5x/0.075 
Objective EX ‘Plan-Neofluar’ 10x/0.3 
Objective ‘Plan-Apochromat’ 63x/1.40 Oil (DIC) 
 
2.17.2 Automated quantification of 3D co-localisation between TRF1 and telomeres 
Immunofluorescence with anti-TRF1 antibody (Figure 4.10) had sufficiently low 
background that quantitation of co-localising foci was able to be automated using Metafer4 
software (Metasystems, GmbH, Altlussheim, Germany) on a Zeiss Axioplan 2 microscope 
(Germany), with a 63× NA (1.4 Plan-Apochromat) oil objective, and appropriate filter cubes. 
DAPI stained nuclei were identified and background subtraction, image sharpening and 
TopHat transformation applied to the TRF1 immunofluorescence and telomere PNA FISH 
channels. TRF1 immunofluorescence and telomere FISH foci were defined as foci of > 0.1 
µm2, > 25% intensity over background, separated by a minimum distance of 0.5 µm. Co-
localisations were events where the centre of a TRF1 and a telomere PNA FISH focus were ≤ 
0.3 µm apart in three dimensions. Co-localising TRF1 and telomere foci were counted in 200 
- 300 cells per treatment, and data were analysed by Student t test for pairwise comparison.
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Chapter 3 
Phosphorylation of hTERT in 
regulating telomerase 
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3. Results: Phosphorylation of hTERT in regulating telomerase 
Abstract 
Phosphorylation is an important post-translational modification in regulating protein 
– protein interactions, protein structure, stability and activity (Nishi et al., 2011; Johnson 
and Barford, 1993). Here, I analysed potential functional roles for four hTERT 
phosphorylation sites (S206, S523, S1125 and T1113), that had been identified through 
phospho-enrichment and mass spectrometry (Scott Cohen, unpublished) and quantitative 
phosphoproteome analysis (Tao et al., 2005). These phosphorylation sites were mutated to 
mimic a phosphorylated (aspartic acid) or a non-phosphorylated (alanine) amino acid. The 
experiments described in this chapter examined various aspects of telomerase regulation 
and activity, and found that mutation of these phosphorylation sites did not have any 
substantial impact on the levels of telomerase activity under saturating primer 
concentrations, the ability of hTR and hTERT to assemble into a functional telomerase 
complex, or the recruitment of telomerase to telomeres . However, there was a slight 
improvement in the primer binding ability of telomerase when the hTERT serine residue 
1125 was mutated to either aspartic acid or alanine. Collectively, these results suggest that 
phosphorylation of hTERT does not impact on the properties of telomerase measured in this 
chapter, but effects on other functional aspects of telomerase or hTERT cannot be excluded. 
3.1 Introduction 
Catalytically active telomerase consists of a dimer of the telomerase reverse 
transcriptase (hTERT), telomerase RNA (hTR) and the protein dyskerin (Cohen et al., 2007; 
Sauerwald et al., 2013). Since telomerase expression can have negative consequences, such 
as in cancer cells, there are numerous studies on regulatory factors that control telomerase 
function (Cong et al., 2002; Cifuentes-Rojas and Shippen, 2012; Collins, 2006; Bianchi and 
Shore, 2008; Stern and Bryan, 2008). Gene transcription, protein translation, post-
transcriptional and post-translational modifications, complex assembly, the process of 
complex maturation and transport to the telomeres, as well as telomere accessibility, are all 
factors that determine the levels of telomerase-mediated telomere lengthening.  
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This section of the project focuses on phosphorylation of hTERT as a mechanism of 
telomerase regulation, and aims to characterise newly-identified phosphorylation sites. 
Phosphorylation is a well known form of post-translational modification that involves the 
addition of a phosphate group to a specific group of amino acid residues, such as serine, 
threonine and tyrosine. The addition of a negatively charged phosphate group can regulate 
protein function by inducing conformational change, altering protein-protein interactions 
and changing the accessibility of protein active sites (Nishi et al., 2011; Johnson and Barford, 
1993).  
Several lines of evidence have suggested that the catalytic subunit of telomerase 
(hTERT) can be regulated by phosphorylation, beginning from the discovery that the kinase 
PKC can phosphorylate hTERT in various cancer cell types, to the understanding that AKT 
phosphorylation of hTERT influences its nuclear localisation and increases telomerase 
activity (Chang et al., 2006; Sheng et al., 2003; Li et al., 1998; Kimura et al., 2004; Kang et al., 
1999). These studies suggest that phosphorylation plays a major role in hTERT regulation 
and telomerase activity.  
Because phosphorylation events on components of telomerase can directly regulate 
telomerase and its activity, it is pertinent to understand the functional significance of such 
phosphorylation events. In addition, it is also important to comprehensively map potential 
phosphorylation sites to uncover other novel ways in which phosphorylation can alter hTERT 
and resultant telomerase activity levels. Telomerase studies, however, have been hampered 
by the low cellular abundance of telomerase, even in telomerase positive cancer cells 
(Cohen et al., 2007). This presents difficulties in generating large amounts of catalytically 
active telomerase for phospho-enrichment and mass spectrometry to identify new hTERT 
phosphorylation sites.  
The Bryan laboratory is in a unique position in having a HEK293T cell-based system 
to generate large amounts of catalytically active telomerase for the identification of novel 
hTERT phosphorylation sites (Jurczyluk et al., 2011; Tomlinson et al., 2015). Telomerase 
enzyme was immunopurified from 293T cells by Dr. Scott Cohen, and telomerase peptides 
were obtained by tryptic digestion. These peptides were subjected to phospho-enrichment 
and titanium dioxide column purification, before a mass spectrometry analysis for 
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phosphorylated residues. Two potential phosphorylation sites on hTERT (S206 and S523) 
were identified by this method (see Appendix). Additionally, a published tandem 
phosphoproteome analysis and mass spectrometry study reported two other hTERT 
phosphorylation sites that have not yet been functionally characterised: T1113 and S1125 
(Tao et al., 2005).  
Examining these potential phosphorylation sites for consensus kinase sequences 
showed that the residues S206, T1113 and S1125 fit the sequence for casein kinase I and II 
(Fig. 3.9 and 3.10). The only known link between casein kinase I and II and telomere 
maintenance is in phosphorylating TRF1 to mediate telomeric binding (Kim et al., 2008). 
Other potential telomere maintenance roles of casein kinase have yet to be examined 
(discussed further in section 3.3).  The sequence surrounding S206 and S523 revealed a fit 
with the PKC consensus sequence (Fig. 3.9). PKC is a kinase with a large amount of 
documented evidence for a role in regulating telomerase activation and activity, assembly 
and hTERT transcription in human cancer cells (Li et al., 1998; Chang et al., 2006; Sheng et 
al., 2003) (elaborated further in the discussion to this chapter). 
These phosphorylation sites are also located in or near some of the functional 
domains of hTERT. The hTERT subunit of telomerase contains four domains: the telomerase 
essential N-terminal (TEN) domain, the RNA binding domain (RBD), reverse transcriptase 
(RT) domain and the C-terminal domain (Figure 1.6). The TEN domain consists of the first 
200 amino acids of hTERT, which have roles in mediating DNA affinity, positioning the 3’ end 
of the telomeric primer in the active site during nucleotide addition as well as telomerase 
recruitment to the telomere (Jacobs et al., 2006; Stern et al., 2012; O'Connor et al., 2005; 
Jurczyluk et al., 2011). Since S206 resides just downstream of the TEN domain, it is possible 
that phosphorylation on this residue mediates primer binding, and we hypothesised that 
changes in phosphorylation states of S206 could affect telomerase activity, recruitment to 
the telomere and/or primer binding.  
The RBD facilitates interactions between hTERT and hTR and consists of three 
conserved motifs (Figure 1.6); these motifs play a vital role in hTR interaction and are highly 
conserved among species (Friedman and Cech, 1999; Bryan et al., 2000; Armbruster et al., 
2001; O'Connor et al., 2005). Mutation of key amino acids within the RBD results in 
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decreased RNA binding, culminating in reduced telomerase activity (Moriarty et al., 2002; 
Bosoy et al., 2003; Lai et al., 2001; Bryan et al., 2000). This interaction is achieved by 
securing the non-template regions of hTR to hTERT, facilitated by a nucleic acid binding 
pocket on the surface of the RBD (Rouda and Skordalakes, 2007; Moriarty et al., 2002; 
Bosoy et al., 2003). As S523 is within the RBD domain, we hypothesised that 
phosphorylation at this site may regulate hTERT association with hTR, which will affect 
telomerase assembly and activity, resulting in reduced levels of hTR recovered by an hTERT 
immunopurification, as well as reduced telomerase activity due to diminished abundance of 
catalytically active telomerase. 
T1113 and S1125 are residues located within the C-terminal domain of hTERT. The 
sequences within the C-terminal region are highly divergent among species and exhibit poor 
evolutionary conservation (Friedman and Cech, 1999; Peng et al., 2001). Nonetheless, 
modifications to the C-terminal domain, such as the addition of an HA or FLAG epitope tag, 
have induced telomere shortening, cellular senescence and apoptosis in primary and 
immortalised transformed human cells (Counter et al., 1998; Ouellette et al., 1999; Kim et 
al., 2003). Furthermore, mutational analysis identified residues from 963 to 1117 as being 
involved in telomerase processivity (Huard et al., 2003) and hTERT oligomerisation (Arai et 
al., 2002). The extreme C-terminus of hTERT also contains a region that may be involved in 
DNA binding, described as the C terminal ‘dissociates activities of telomerase’ or ‘C-DAT’ 
domain (Banik et al., 2002; Moriarty et al., 2005). Telomerase with a deletion of residues 
from 1123 to 1132 catalysed repeat addition less efficiently than WT telomerase (Moriarty 
et al., 2005), and residues 1127-1129 are important for telomere synthesis in vivo (Banik et 
al., 2002). Because the putative phosphorylation sites of T1113 and S1125 reside ~10 amino 
acid residues upstream and within the C-DAT domain respectively, we hypothesised that 
phosphorylation on these residues may impact upon telomerase activity, recruitment and 
primer binding abilities. 
The aim of this chapter is to investigate if phosphorylation on any of these residues 
can lead to changes in telomerase activity and recruitment to the telomere, mediate 
assembly between hTERT and hTR, or affect the primer binding ability of telomerase. 
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3.2 Results 
3.2.1- Telomerase containing non-phosphorylated and phospho-mimetic hTERT had 
similar levels of telomerase activity 
Site-directed mutagenesis was performed on WT hTERT pApex-3P-hTERT (Tomlinson 
et al., 2015) to obtain the desired phospho-mimetic (aspartic acid) and non-phosphorylated 
(alanine) mutants. Amino acid changes with the least amount of base pair mismatches were 
introduced, and PCR conditions were optimised by altering DMSO concentrations as well as 
melting and annealing temperatures. The entire hTERT coding region was verified by 
sequencing to ensure that only the desired mutations were introduced. Western blots were 
performed to verify that the stabilities of the panel of mutant hTERTs were similar to those 
of WT hTERT (Figure 3.1). 
To test the effects of phosphorylation on the catalytic activity of telomerase, 
telomerase containing mutations in hTERT (S206A or D, S523A or D, T1113A or D, S1125A or 
D and double mutations S206A/S523A, S206D/S523D, T1113A/S1125A and T1113D/S1125D) 
were immunopurified from 293T cells using an hTERT specific antibody (Cohen and Reddel, 
2008), and the amounts of assembled telomerase were quantified with an hTR dot blot 
(Figures 3.2A and 3.3A). Equal amounts of telomerase molecules were then used for direct 
telomerase activity assays (Cohen and Reddel, 2008) to measure the catalytic activities of 
mutant telomerase (Figures 3.2B and 3.3B). There was no significant difference in the levels 
of telomerase activity between WT and telomerase containing mutations in residues 206, 
523, 1113 and 1125 (Figures 3.2C and 3.3C). These results imply that under conditions 
where telomerase is associated with a primer in vitro (Cohen and Reddel, 2008), 
phosphorylation at residues S206, S523, S1125 and T1113 has no significant biological effect 
on the catalytic activity of telomerase. 
Primer KM (the primer concentration at which half-maximal enzyme activity is 
observed) has previously been measured to be 0.5 nM for WT telomerase (Tomlinson et al., 
2015). Previous direct telomerase activity assays used saturating levels of telomeric primer 
DNA (Figures 3.2 and 3.3); to ensure that this does not mask differences in activity from 
telomerase containing WT and mutant hTERT, a telomerase assay using a much lower 
concentration of DNA primer was performed (Figure 3.4A). Quantitation of the resulting 
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telomerase extension products revealed a ~3-4 fold increase in telomerase activities of both 
S1125A and S1125D mutants compared to WT (Figure 3.4B).  
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Figure 3.1: Immunoblots of WT hTERT compared to a panel of indicated mutant 
hTERT 
Immunoblots of 293T cells over-expressing the indicated WT or various hTERT mutants, 
using the respective antibodies, with actin as a control.  
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Figure 3.2: Measurement of telomerase activity with hTERT containing S206 and 
S523 mutants 
A: A dot blot probed for levels of hTR after hTERT IP in 293T cells over-expressing hTR and 
hTERT containing S206A/D, S523A/D or double mutants (S206A/S523A and 
S206D/S523D). Top row: in vitro-transcribed hTR standard.  
B: A sequencing gel showing the telomeric extension products from telomerase containing 
WT, S206A/D, S523A/D or double mutant hTERT from a direct telomerase activity assay. 
C: Quantitation of the mean (+ SD) relative telomerase activity from Figure 3.2B, normalised 
to WT enzyme; n = 2. 
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Figure 3.3: Measurement of telomerase activity with hTERT containing T1113 and 
S1125 mutants 
A: A dot blot probed for levels of hTR after hTERT IP in 293T cells over-expressing hTR and 
hTERT containing T1113A/D, S1125A/D or double mutants (T1113A/S1125A and 
T1113D/S1125D). Top row: in vitro-transcribed hTR standard. 
B: A sequencing gel showing the telomeric extension products of telomerase containing WT, 
T1113A/D, S1125A/D or double mutant hTERT from a direct telomerase activity assay.  
C: Quantitation of the mean (+ SD) relative telomerase activity from Figure 3.3B, normalised 
to WT enzyme; n = 2. 
  
73 
 
 
Figure 3.4: Direct telomerase activity assay at lower primer concentration, using 
WT telomerase and telomerase with mutations in hTERT at S1125 
A: A direct telomerase activity assay using 0.5 nM telomeric substrate primer and 
telomerase containing mutations in hTERT as indicated. LC represents an 18 nt loading 
control. 
B: Quantification of the mean (+ SD) levels of telomerase activity from Figure 3.4A, 
normalised to WT; *p < 0.05, n = 3. 
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3.2.2- A slight decrease in primer KM of mutant telomerase compared to WT telomerase, 
with no change in telomerase processivity between WT, S1125A and S1125D hTERT 
mutants 
A full titration of primer concentrations was used to determine KM for WT, S1125A 
and S1125D hTERT mutants (Figure 3.5A). Quantitation of three independent experiments 
revealed a KM of 1.0 + 0.1, 0.6 + 0.1 and 0.5 + 0.1 for telomerase containing WT, S1125A and 
S1125D hTERT, respectively (Figure 3.5B). From these calculations, a subtle two fold 
decrease in KM was observed between the two mutants and WT hTERT (Figure 3.5B). 
Telomerase ‘processivity’ was also calculated, i.e. the number of repeats initiating from a 
single telomeric primer-binding event before telomerase dissociation. We calculated the 
processivity value based on the proportion of molecules of each telomerase product that 
continue to be extended, as described (Latrick and Cech, 2010; see Materials and Methods). 
Telomerase processivity measurements indicated that, although there was some variability 
between experiments, there were no consistent differences in processivity between 
telomerase containing WT or S1125A/D hTERT (Figure 3.5C). 
3.2.3- WT and mutant telomerase have similar levels of telomerase recruitment to the 
telomere 
A chromatin immunoprecipitation (ChIP) assay allows the quantification of 
chromatin that is bound to a protein of interest. Over-expression of telomerase enables the 
use of an hTERT-specific antibody (Cohen and Reddel, 2008) to immunopurify sonicated 
chromatin and quantify the levels of telomeric chromatin that is bound to hTERT relative to 
the total amount of telomeric chromatin; this enables the levels of telomerase present at 
the telomere to be determined (Stern et al., 2012). 
  A first set of hTERT ChIP analyses was performed for hTERT with non-phosphorylated 
or phospho-mimetic mutations of S206, S523 or both (S206A/S523A and S206D/S523D) 
(Figure 3.6). Agarose gel analysis of the sonicated chromatin samples indicated even 
sonication across all samples (Figure 3.6A), while an hTR dot blot confirmed even over-
expression of the limiting telomerase component hTR (Figure 3.6B). ChIP results using a dot 
blot to quantitate chromatin recovery following hTERT IP (Figure 3.6C) showed a ~2.8 fold 
enrichment of WT telomerase bound to chromatin compared to empty vector controls. The 
signal from empty vector controls likely represents background from the hTERT antibody (J. 
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Stern, unpublished data). There were no significant differences in the telomere recruitment 
abilities of WT or mutant telomerase containing non-phosphorylated or phospho-mimetic 
mutations in the residues of 206, 523 or both (Figure 3.6D). 
A second set of ChIP analyses was performed for hTERT containing mutations at 
T1113, S1125 or both (T1113A/S1125A and T1113D/S1125D) (Figure 3.7). A second negative 
control was included, consisting of hTERT with a R132D mutation (‘DAT’), which is defective 
in recruitment to the telomere while retaining WT telomerase activity (Stern et al., 2012). 
Agarose gel analysis of sonicated samples confirmed equal levels of sonication (Figure 3.7A), 
while the hTR dot blot confirmed the even over-expression of the limiting telomerase 
component hTR (Figure 3.7B). Following ChIP dot blot (Figure 3.7C), there was a ~2.6 fold 
enrichment of chromatin immunoprecipitated by hTERT antibody in the WT telomerase 
sample compared to empty vector and DAT mutant controls (Figure 3.7D). The lack of 
difference in telomerase recruitment between WT and mutations in residues T1113 and 
S1125 indicates that phosphorylation on these residues does not affect the levels of 
telomerase recruitment (Figure 3.7).  
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Figure 3.5: Primer titration of telomerase activity with telomerase containing 
mutations in hTERT at S1125 
A: A sequencing gel analysis of telomerase extension products from telomerase assays with 
a titration of primer concentrations for telomerase containing WT, S1125A and S1125D 
hTERT mutations. 
B: A plot of relative (+ SD) telomerase activity against BiohTel1 concentrations to determine 
KM for telomerase containing WT (black), S1125A (blue) and S1125D (red) hTERT; n = 3. 
C: A plot of mean processivity (+ SD) against BiohTel1 concentrations to determine the 
processivity for telomerase containing WT (black), S1125A (blue) and S1125D (red) hTERT; 
n = 3.  
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Figure 3.6: ChIP analysis to measure telomere localisation of telomerase containing 
mutations in S206 and S523 of hTERT 
A: A 1% agarose gel showing sonicated chromatin from 293T cells over-expressing hTR and 
WT hTERT, an empty vector control (E), a non-transfected control (NT), and hTERT 
containing S206 and S523 mutations. 
B: A dot blot probed for the levels of hTR to verify equal levels of telomerase over-
expression. Top row: in vitro-transcribed hTR standard. 
C: An hTERT ChIP dot blot probed with a telomere specific probe, with titrations of total 
chromatin (inputs) and the hTERT immunoprecipated chromatin in the ‘IP’ rows. 
D: Quantification of the mean (+ SD) of chromatin immunoprecipitated using an hTERT 
specific antibody from figure 3.6C, normalized to WT enzyme; n = 3. 
The signal from empty vector controls likely represents background from the hTERT 
antibody (J. Stern, unpublished data). 
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Figure 3.7: ChIP analysis to measure telomere localisation of telomerase containing 
mutations in T1113 and S1125 of hTERT 
A: A 1% agarose gel analysis showing sonicated chromatin from 293T cells over-expressing 
hTR and WT hTERT, an empty vector control (E), a non-transfected control (U), and hTERT 
containing T1113 and S1125 mutations. 
B: A dot blot probed for the levels of hTR to verify equal levels of telomerase over-
expression of hTR plasmids. Top row: in vitro-transcribed hTR standard. 
C: An hTERT ChIP dot blot probed with a telomere specific probe, with titrations of total 
chromatin (inputs) and the hTERT immunoprecipated chromatin in the ‘IP’ rows. 
D: Quantification of the mean (+ SD) of chromatin immunoprecipitated using a hTERT 
specific antibody from Figure 3.7C, normalized to WT enzyme. A DAT mutant containing 
amino acid change R132D was included as a control; n > 2. 
The signal from empty vector controls likely represents background from the hTERT 
antibody (J. Stern, unpublished data).  
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3.2.4- Telomerase assembly levels were unchanged with hTERT containing non-
phosphorylated or phospho-mimetic mutations 
Another manner in which phosphorylation could regulate telomerase is through the 
ability of hTERT, hTR and dyskerin to assemble into a functional telomerase complex. 
Because telomerase RNA is the limiting factor in determining the amounts of assembled 
telomerase complex in the 293T over-expression system (S. Cohen, unpublished data), 
measurement of the pre-IP levels of hTR and levels of hTR after hTERT IP can reveal any 
defects in telomerase assembly caused by the phosphorylation of residues 206, 523, 1113 or 
1125. To this end, 105 cell equivalents of input cell lysates and 5 × 106 cell equivalents of IP 
samples were used on each dot blot to measure the total levels of hTR over-expression and 
the amount of hTR that forms a functional telomerase complex with hTERT following hTERT 
IP (Figures 3.8A and C).  
Measurement of the hTR intensities in dot blots containing non-phosphorylated or 
phospho-mimetic mutations of serine 206, 523 or both (Figure 3.8A) revealed some 
statistically significant increases in the ability of hTERT to form a functional telomerase 
complex with hTR in the S206A, S206D and S523D mutants compared to the WT controls 
(Figure 3.8B). However, these differences appear minor, and do not seem to be regulated by 
phosphorylation since the increases occur in both the non-phosphorylated and phospho-
mimetic mutants. 
This assay was repeated with hTERT containing T1113, S1125 or double mutations. 
The measurements of hTR intensities for these blots (Figure 3.8C) indicate a very slight but 
not statistically significant increase in telomerase assembly for the T1113D, S1125 and 
double mutants. The lack of any differences in telomerase assembly between non 
phosphorylated and phospho-mimetic mutations again suggests that there is no biologically 
significant effect of phosphorylation on these residues in regulating telomerase assembly 
(Figure 3.8D). 
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Figure 3.8: Measurement of telomerase assembly levels between WT and mutant 
telomerase 
A: A dot blot probing for hTR in 293T cells over-expressing hTR and the indicated hTERT 
mutants. 105 cell equivalents of inputs and 5 × 106 cell equivalents of IP samples were 
analysed on the dot blot. Top row: in vitro-transcribed hTR standard. 
B: Quantitation of Figure 3.8A showing the mean (+ SD) assembly capabilities of telomerase 
containing mutant hTERT (S206, S523 and double mutants), normalised to WT; *p < 0.05, 
**p< 0.01, n = 5.  
C: An hTR dot blot identical to figure 3.8A, with the exception that hTERT containing T1113 
and S1125 mutations were examined. 
D: Quantitation of Figure 3.8C showing the mean (+ SD) assembly capabilities of telomerase 
containing mutant hTERT (T1113, S1125 and double mutants), normalised to WT; n = 2. 
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3.3- Discussion 
This chapter aims to characterise novel hTERT phosphorylation sites, and to test the 
hypothesis that phosphorylation at these sites is involved in regulating telomerase. Two of 
these sites, S206 and S523, were identified by Dr. Scott Cohen through phospho-enrichment 
followed by mass spectrometry analysis, while phosphorylation at T1113 and S1125 was 
demonstrated by tandem quantitative phosphoproteome analysis and mass spectrometry 
(Tao et al., 2005). S206 lies just downstream of the TEN domain, S523 is located within the 
RBD, and T1113 and S1125 are both close to the C-terminal DAT domain. The location of 
these phosphorylation sites raises the possibility that these residues have important roles in 
regulating functional telomerase complex formation, DNA binding and telomerase activity. 
Using a range of biochemical assays developed in the Bryan Laboratory, the properties of 
telomerase activity (Figures 3. 2 - 3.4), primer KM and telomerase processivity (Figure 3.5), 
recruitment to the telomere (Figures 3.6 – 3.7), and enzyme complex assembly (Figure 3.8) 
were examined with largely biologically insignificant results.  
There may be several caveats in experimental execution that could explain why 
distinct phenotypes were not observed. Firstly, these experiments involve the over-
expression of telomerase, which is necessary for the examination of telomerase recruitment 
to telomeres using an hTERT ChIP assay; as such, changes in telomerase recruitment could 
have been masked by high levels of telomerase over-expression in 293T cells, which were 
~25 times over the endogenous levels of telomerase (Figures 3.6B and 3.7B). High levels of 
exogenously expressed telomerase resulted in telomerase recruitment to telomeres that is 
independent of coilin and Cajal bodies, whereas both of these are indispensable for 
endogenous levels of telomerase recruitment (Stern et al., 2012), further supporting the 
notion that protein over-expression can alter native biological processes. To circumvent 
potential issues with protein over-expression, hTERT mutations should be introduced by 
CRISPR knock in or TALEN-based genome editing, allowing investigation of recruitment at 
endogenous telomerase levels using an hTR/ telomere FISH assay. 
Secondly, since telomerase is highly regulated in its timing and spatial localisation to 
telomeres (Tomlinson et al., 2006; Marcand et al., 2000; Dehe et al., 2012; Hemann et al., 
2001; Teixeira et al., 2004; Sabourin et al., 2007; Marcand et al., 1997a), it seems reasonable 
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to suggest that if phosphorylation is involved in the regulation of telomerase, it might work 
synergistically across multiple sites. This synergistic effect from phosphorylation has been 
observed when the downstream target of protein kinase A and C, phospholemman (PLM), 
was investigated for its calcium channel stimulating effects (Guo et al., 2015); simultaneous 
phosphorylation across four different sites further enhanced the effects seen when only two 
of the sites were phosphorylated. To test this possibility, different permutations of 
mutations between the other potential hTERT phosphorylation sites (further discussed in 
Chapter 6) should be examined for any combinations that could provide a phenotype in 
different aspects of telomerase regulation. A phenotype resulting from a combination of 
phosphorylation at different sites may provide better fine-tuning in regulating telomerase.  
Thirdly, interpretation of the results on telomerase assembly relies on the 
assumption that these phosphorylation mutations regulate telomerase directly, while it is 
entirely plausible that such phosphorylation events on hTERT affect interaction with other 
intermediates in regulating telomerase assembly. The levels of telomerase over-expression 
may overcome the biological effects of hTERT phosphorylation in regulating its interaction 
with intermediates that would have otherwise mediated telomerase assembly at the 
endogenous level. 
Another possible experimental caveat may be that the introduction of phospho-
mimetic amino acids such as aspartic acid does not always accurately mimic 
phosphorylation of a serine or threonine in vivo. Aspartic acid carries a single negative 
charge compared to a double negative charge for phosphate groups, whilst also lacking the 
methyl side chain of phospho-threonine.  A study on AKT phosphorylation sites in relation to 
oncogenicity found that aspartic mutations can be poor and unsuitable substitutions for 
native phospho-threonine, resulting in poor recapitulation of phosphorylated Akt in vivo 
(Hart and Vogt, 2011). Therefore, such substitutions to mimic phosphorylation states in 
hTERT might not be sufficiently or genuinely realistic to elicit a biological change and exhibit 
a phenotype. 
Although some enhancements to telomerase assembly capabilities were observed in 
telomerase containing hTERT with mutations in S206A, S206D and S523D, these increases 
are unlikely to be due to regulation by phosphorylation, since both phospho-mimetic and 
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non-phosphorylated residues displayed a slight increase in assembly capabilities (Figure 
3.8B). Also, if phosphorylation did regulate assembly, a more pronounced phenotype would 
be expected; despite statistical significance, the effect was subtle and there was large 
variability in hTERT and hTR associations between experiments (Figure 3.8B). Nevertheless, 
an effect of phosphorylation in mediating telomerase assembly on these sites cannot be 
discounted entirely. As mentioned below, the levels of over-expression may have influenced 
assembly rates or bypassed biological requirements associated with endogenous levels of 
telomerase (Stern et al., 2012). A better investigation of telomerase assembly capabilities 
could be performed with a hTR dot blot probing for endogenous expression of phospho-
mimetic or non-phosphorylated telomerase components. 
The only convincing phenotype observed in this study was the propensity of 
telomerase containing hTERT with a mutation at S1125 to exhibit a slight increase in 
telomeric primer binding without a change in telomerase processivity (Figures 3.5A, B and 
C). Interestingly, both phospho-mimic and non-phosphorylated mutants resulted in an 
increase in DNA binding ability, arguing against the idea that the phenotype observed is due 
to phosphorylation events. Instead, S1125 is most likely a residue that plays a role in primer 
binding. Indeed, S1125 is only two amino acids upstream of S1127, which is part of the C-
DAT domain, which has been reported to have a role in DNA binding (Moriarty et al., 2005). 
It is conceivable that mutating the serine residue to aspartic acid and alanine disrupts the 
local charge or hydrophobicity to bring about some form of protein conformational 
disruption leading to an increase in DNA binding.  
The measurement of KM might also be masking potential defects or increases in DNA 
binding, since it is not a direct read-out of binding affinity. A direct read out can be obtained 
with a primer pull-down assay that directly measures primer affinity. This assay was 
originally developed in the Bryan Laboratory for Tetrahymena telomerase (Finger and Bryan, 
2008), and later adapted for use in human cells (Tomlinson et al., 2015). 
It is also possible that these phosphorylation sites have a telomerase activity-
independent effect, since hTERT has been known to have non-canonical functions such as 
protective roles in the mictochondria (Li and Tergaonkar, 2014; Haendeler et al., 2009). To 
investigate this possibility, it would be ideal to introduce mutant hTERT and express it within 
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the cells at a physiologically relevant level using either CRISPR or TALEN gene editing. These 
cells could then be measured for any changes in reactive oxygen species (ROS) levels using 
specific dyes, or changes in hTERT cellular localisation with IF (Indran et al., 2011; Ahmed et 
al., 2008).  
Investigation of the phosphorylation sites for consensus kinase sequences using the 
online PhosphoMotif Finder from Human Protein Reference Database revealed that with 
the exception of S523, all the other sites form a consensus sequence for casein kinase I and 
II (Figures 3.9 and 3.10). Casein kinase II is an important kinase involved in cellular survival 
and conferring resistance to apoptosis (Litchfield and Luscher, 1993), and has been 
demonstrated to mediate phosphorylation of TRF1 as well as affecting its telomere binding 
(Kim et al., 2008). Elevated levels of casein kinase II have also been observed in solid human 
tumours, suggesting that these sites may have roles in mediating cancer progression, but 
the mechanism for this has not been elucidated (Munstermann et al., 1990).  
PKC phosphorylation consensus motifs were also identified surrounding the residues 
of S206 and S523. PKC has been linked to increases in telomerase activation and activity, 
assembly and hTERT transcription in human cancer cells (Li et al., 1998; Chang et al., 2006; 
Sheng et al., 2003). Possibly this function of PKC in hTERT phosphorylation is cell type 
specific, or as described above, the level of protein over-expression is masking any 
phenotypes. Experiments investigating telomerase regulation could be performed in other 
cell types to rule out cell-type specific regulation. Additionally, the levels of PKC activity 
could be modulated with activators such as ingenol mebutate (Kedei et al., 2004) or 
inhibitors like ruboxistaurin (Tang et al., 2008; Mochly-Rosen et al., 2012) to examine 
changes in the phosphorylation states of S206 and S523 by mass spectrometry. If the 
phosphorylation states of S206 or S523 change, it would implicate these residues as a target 
for PKC phosphorylation, and the levels of telomerase activity, assembly and primer binding 
can be examined in cells with inhibited PKC, or activated PKC, to overcome the possibility 
that introducing phospho-mutations does not accurately recapitulate actual 
phosphorylation in vivo. 
To further our understanding of how phosphorylation as a form of regulation can 
affect telomere length and various aspects of telomerase action, it is important to 
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understand in future studies why these sites have been identified as hTERT phosphorylation 
sites, and whether they have any roles in regulating telomerase and telomere length, or 
non-canonical functions of hTERT. 
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Figure 3.9: Identification of potential kinase motifs surrounding S206 and S523 of hTERT 
PhosphoMotif Finder results from the Human Protein Reference Database displaying the identification of phosphorylation motifs and the 
potential kinases that can phosphorylate the residues of S206 and S523 on hTERT. 
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Figure 3.10: Identification of potential kinase motifs surrounding T1113 and S1125 of hTERT 
PhosphoMotif Finder results from the Human Protein Reference Database displaying the identification of phosphorylation motifs and the 
potential kinases that can phosphorylate the residues of T1113 and S1125 on hTERT. 
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Chapter 4 
ATM and ATR in mediating 
telomerase recruitment 
Chapters 4 and 5 were published in the journal Cell Reports: 
Tong AS, Stern JL, Sfeir A, Kartawinata M, de Lange T, Zhu XD, Bryan TM. ATM and ATR 
Signaling Regulate the Recruitment of Human Telomerase to Telomeres, Cell Reports (2015), 
http://www.cell.com/cell-reports/references/S2211-1247(15)01211-5. 
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4. Results: ATM and ATR in mediating telomerase recruitment 
Abstract 
The yeast homologues of the ATM and ATR DNA damage response kinases play key 
roles in telomerase-mediated telomere maintenance, but the role of ATM/ATR in the 
mammalian telomerase pathway has been less clear. This chapter demonstrates the 
requirement for ATM and ATR in the localisation of telomerase to telomeres in immortal 
human cells. Stalled replication forks increased telomerase recruitment in an ATR-
dependent manner. Furthermore, increased telomerase recruitment was observed upon 
phosphorylation of the shelterin component TRF1 at an ATM/ATR target site (S367). This 
phosphorylation leads to loss of TRF1 from telomeres and may therefore increase 
replication fork stalling. These data establish that human telomerase recruitment and 
telomere elongation are modulated by DNA damage-transducing kinases. 
4.1 Introduction 
The differentiation of telomeres from broken chromosome ends is conferred by a 
family of six telomere-specific binding proteins collectively termed ‘shelterin’ (de Lange, 
2005). This complex consists of the double stranded binding proteins TRF1 and TRF2, the 
single stranded binding proteins POT1 and TPP1, the bridging protein TIN2 which links these 
two groups of proteins, and Rap1 (reviewed in Palm and de Lange, 2008). TRF1 protects the 
telomere and negatively regulates telomerase-mediated telomere lengthening (van Steensel 
and de Lange, 1997; Smogorzewska et al., 2000; Ancelin et al., 2002; Karlseder et al., 2002). 
TRF1 also facilitates the progression of the replication machinery; deletion of TRF1 increases 
replication fork stalling, leading to ATR kinase activation and a “fragile telomere” phenotype 
(Sfeir et al., 2009; Martinez et al., 2009). A potential model to explain the mechanism by 
which TRF1 prevents the formation stalled replication forks may be that the TRF1-mediated 
repression of the ATR response requires recruitment of the shelterin components TIN2 and 
the TPP1/POT1 heterodimer to exclude RPA loading and accumulation onto the lagging 
telomeric DNA template (Zimmermann et al., 2014). TRF1 also interacts with the BLM 
helicase, possibly to facilitate the removal of any secondary structures formed by the G-rich 
sequences of the lagging telomeric DNA strand and allow the uninterrupted progression of 
the replication machinery (Zimmermann et al., 2014). 
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Telomerase action at the telomere is highly regulated; it preferentially elongates the 
shortest telomeres, and recruitment of the enzyme complex to the telomere occurs in mid-S 
phase of the cell cycle (Bianchi and Shore, 2007b; Britt-Compton et al., 2009; Teixeira et al., 
2004; Hemann et al., 2001; Tomlinson et al., 2006; Jady et al., 2006). In both budding and 
fission yeasts, the preference of telomerase to extend the shortest telomeres requires the 
activity of Tel1, the yeast homolog of human ATM (Sabourin et al., 2007; Hector et al., 2007; 
Arneric and Lingner, 2007). ATM and ATR are kinases within the phosphatidylinositol-3 
kinase-related kinase (PIKK) family, which regulate cellular responses to DNA damage, 
mRNA decay and nutrient-dependent signalling (Lovejoy and Cortez, 2009). Activation of 
these DNA damage pathways is dampened at telomeres; in mammalian cells, TRF2 
represses activation of ATM while POT1 represses ATR (Karlseder et al., 2004; Celli and de 
Lange, 2005; Denchi and de Lange, 2007; Guo et al., 2007; Okamoto et al., 2013). 
Nevertheless, there is a large amount of evidence that their yeast homologues play a 
positive role in facilitating telomere extension by telomerase (Moser et al., 2009; Moser et 
al., 2011; Yamazaki et al., 2012; Churikov et al., 2013).  
It is not known whether the role of the ATM and ATR pathways in recruiting 
telomerase is conserved in mammals. Although ATM deficiency or ATR mutations can 
induce telomere shortening or instability in human and mouse cells (Metcalfe et al., 1996; 
Smilenov et al., 1997; Wong et al., 2003; Wu et al., 2007; Pennarun et al., 2010), these 
kinases were reported to be dispensable for elongation of the shortest telomeres in mouse 
models (Feldser et al., 2006; McNees et al., 2010). Also, immortalised cell lines from human 
patients with ATM mutations are able to maintain their telomeres with telomerase, albeit at 
short lengths (Sprung et al., 1997). Nonetheless, there is evidence that TRF1-mediated 
telomere length regulation in human cells involves ATM. Inhibition of human ATM resulted 
in increased TRF1 at the telomere, and phosphorylation of TRF1 on serine 367, an ATM/ATR 
target site, reduced the interaction of TRF1 with telomeres and abrogated its ability to 
inhibit telomere lengthening (McKerlie et al., 2012; Wu et al., 2007).  
In this chapter, I demonstrate that both ATM and ATR are required for the 
recruitment of human telomerase to telomeres. 
4.2 Results 
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4.2.1- ATM and ATR are both required for the presence of human telomerase at telomeres 
I used fluorescence in situ hybridisation (FISH) to detect human telomerase RNA 
(hTR) in combination with a probe for telomeres to visualise the presence of endogenous 
telomerase at telomeres in HEK 293T cells (Stern et al., 2012) (Figure 4.1A). Depletion of 
ATM and ATR using siRNA resulted in reduction of levels of each protein by ~95% and ~80% 
respectively (Figure 4.1B), without causing significant perturbations in progression of the 
cells through the cell cycle (Figure 4.1C). Depletion of either kinase resulted in a significant 
decrease in telomerase recruitment to telomeres in asynchronously-growing cells (Figure 
4.1A and D). The roles of both ATM and ATR in telomerase recruitment were confirmed with 
a second siRNA against each protein (Figure 4.1E). 
The involvement of the kinase activities of both ATM and ATR were demonstrated by 
using the kinase inhibitors KU-55933 and VE-822 (Figure 4.2A - C), at concentrations 
sufficient to inhibit ATM autophosphorylation at S1981 and ATR phosphorylation of Chk1 at 
S345, respectively (Figure 4.2D), without inhibiting related kinases (1.5 µM for KU-55933 
and 0.5 µM for VE-822, Hickson et al., 2004; Fokas et al., 2014). 
Telomerase recruitment across the cell cycle was examined by synchronising cells at 
the G1/S boundary with overnight thymidine and aphidicolin treatments, followed by 
release from the cell cycle block and harvest at hourly intervals (Figure 4.1C). Telomerase 
presence at the telomere peaks in mid-S phase (Figure 4.3), as previously described 
(Tomlinson et al., 2006; Jady et al., 2006). Depletion of ATM abolished recruitment of 
telomerase to the telomere across all phases of the cell cycle (Figure 4.3A and B). Since this 
synchronisation procedure is likely to cause DNA damage, I confirmed these observations by 
sorting ATM- and ATR-depleted cells by flow-activated cell sorting (FACS) into different cell 
cycle phases based on DNA content (Figure 4.1C). Despite reduced numbers of hTR-
telomere foci in control cells across the cell cycle (discussed further below), lack of either 
kinase again resulted in a large decrease in telomerase recruitment, particularly in S phase 
(Figure 4.3C and D). Reduction of hTR-telomere co-localisations across the cell cycle after 
ATM depletion was also demonstrated in a second human cell line, HeLa (Figure 4.4). These 
results provide direct evidence that telomere shortening in telomerase-positive human cells 
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defective in ATM and ATR activity is at least partially the result of diminished recruitment of 
telomerase to telomeres. 
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Figure 4.1: ATM and ATR are both required for the presence of human telomerase 
at telomeres 
A: Representative images of hTR/telomere FISH in 293T cells treated with the indicated 
siRNAs. Cells were synchronised to mid-S phase of the cell cycle and probed with hTR 
probes (green) or a telomere probe (red). Co-localisations are indicated by white arrows in 
the merge row. Scale bar = 10 µm. 
B: Immunoblot of 293T cells with either ATM (top panel) or ATR (bottom panel) siRNA-
mediated knockdown, using the respective antibodies, with vinculin as a control. 
C: Cell cycle analysis by flow cytometry of propidium iodide-stained 293T cells treated with 
control siRNA, ATM siRNA or ATR siRNA. 
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D: Average co-localisations between telomerase and telomeres in unsynchronised 293T 
cells treated with control siRNA (gray), ATM siRNA (red) (*p = 0.012) or ATR siRNA (purple) 
(**p = 0.0095). 
E: Quantitation of decrease in telomerase recruitment in S-phase synchronised 293T cells 
following treatment with two independent ATM and ATR siRNAs; **p < 0.01. Cells were 
synchronised with a thymidine/aphidicolin block (ATM) or sorted into cell cycle phases by 
FACS based on DNA content (ATR). 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 4.2: Kinase activity of ATM and ATR are both required for the presence of 
human telomerase at telomeres 
A: Representative images of hTR/telomere FISH in 293T cells treated with the indicated 
kinase inhibitors. Cells were synchronised to mid-S phase of the cell cycle and probed with 
hTR probes (green) or a telomere probe (red). Co-localisations are indicated by white arrows 
in the merge row. Scale bar = 10 µm. 
B: Cell cycle analysis by flow cytometry of propidium iodide-stained 293T cells treated with 
DMSO, 1.5 µM ATM inhibitor KU-55933 or 500 nM ATR inhibitor VE-822. 
C: Average telomerase co-localisation with telomeres in S-phase synchronised 293T cells 
after treatment with DMSO vehicle (gray), 1.5 µM KU-55933 (light yellow) or 500 nM VE-822 
(dark yellow); *p < 0.05. 
D: Immunoblots for 293T cells treated with DMSO control, 1.5 µM ATM inhibitor KU-55933 
or 500 nM ATR inhibitor VE-822 in the presence or absence of 2 Gy γ-irradiation or 2 mW of 
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ultraviolet treatment, respectively, probed with the indicated antibodies to observe activation 
of ATM or ATR and their substrates Chk2 or Chk1; actin and vinculin were probed as 
controls. 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 4.3: Depletion of ATM or ATR depletes recruitment of human telomerase to 
telomeres across the cell cycle 
A: hTR/telomere FISH in 293T cells treated with control or ATM siRNA and synchronised 
with thymidine/aphidicolin. White arrows indicate hTR signals co-localising with telomeric 
signals, scale bar = 10 µm. 
B: Telomerase co-localisation with telomeres in 293T cells at the indicated number of hours 
after release from a thymidine/aphidicolin block, treated with control (gray) or ATM (red) 
siRNA. 
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C: Telomerase co-localisation with telomeres in 293T cells treated with control (gray) or ATM 
(red) siRNA. Cells were stained with the DNA dye VyBrant DyeCycle Violet and isolated into 
cell cycle phases with FACS. Enrichment of cells in the indicated phases was confirmed by 
flow cytometry of sorted cells (Figure 4.1C). 
D: Telomerase co-localisation with telomeres in 293T cells treated with control (gray) or ATR 
(purple) siRNA and sorted by FACS as in Figure 4.3C.  
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 4.4: ATM is required for the presence of human telomerase at telomeres in 
HeLa cells 
A: hTR/telomere FISH in HeLa cells treated with control or ATM siRNA and synchronised 
with a double thymidine block. White arrows indicate hTR signals co-localising with telomeric 
signals, scale bar = 10 µm. 
B: Immunoblot of HeLa cells treated with control or ATM siRNA and probed for ATM 
knockdown, with actin as a control. 
C: Quantitation of average (± SD) co-localisations between hTR and telomeric signals in 
asynchronous HeLa cells following control (black) or ATM (red) siRNA treatment. 
D: Average telomerase recruitment over the cell cycle (± SD) in HeLa cells treated with 
control (black) or ATM (red) siRNA. Cells were sorted by FACS into the indicated cell cycle 
phases. 
In all panels, data is presented as the mean of three independent experiments ± SD.  
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4.2.2- ATM effect on telomerase recruitment is partially mediated by TRF1 
It is known that TRF1 is a substrate of ATM and/or other PIKK kinases, and such 
phosphorylation events lead to changes in TRF1 localisation and telomere length (Kishi et 
al., 2001; Wu et al., 2007; McKerlie et al., 2012). To investigate whether these changes in 
telomere length are due to changes in the presence of telomerase at telomeres, I knocked 
down TRF1 by ~70-80% with two independent siRNAs (Figure 4.5A - C) and examined hTR-
telomere co-localisation. Knockdown of TRF1 resulted in large increases in telomerase 
recruitment in asynchronous cells or in cells synchronised to G2/M (Figure 4.5D - F). Analysis 
of telomerase recruitment over the cell cycle revealed a deregulation of recruitment, 
particularly in G2/M phase, in both thymidine/aphidicolin synchronised and FACS sorted 
293T and HeLa cells (Figure 4.6). TRF1 knockdown also resulted in increased hTR/telomere 
co-localisations in G1 phase in FACS-sorted cells (Figure 4.6C and E), demonstrating that 
TRF1 is involved in the signalling pathway that restricts telomerase presence at the telomere 
to S phase. 
To confirm that ATM and TRF1 function in the same pathway, a double knockdown 
of ATM and TRF1 was performed (Figure 4.7A and B). Western blot analysis of cells depleted 
for ATM only, TRF1 only and double ATM/TRF1 knockdown indicated that the double 
knockdown of two proteins did not affect the depletion levels of each individual protein 
(Figure 4.7A). If ATM involvement in telomerase recruitment is mediated by the 
phosphorylation and removal from the telomere of TRF1 (Wu et al., 2007), we predict that 
depletion of TRF1 will render telomerase insensitive to the absence of ATM. Simultaneous 
knockdown of ATM and TRF1 significantly elevated the levels of telomerase recruitment in S 
and G2/M phases compared to depletion of ATM alone (p = 0.0018 and p = 0.0097, 
respectively) (Figures 4.7C and D). A full recovery of recruitment was not observed in S 
phase cells; this may be partially due to residual TRF1 remaining after knockdown, but also 
indicates that other TRF1-independent ATM substrates may be involved in telomerase 
recruitment (discussed further in chapter 5). 
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Figure 4.5: TRF1 depletion leads to elevated levels of human telomerase 
recruitment to the telomeres 
A: Immunoblot of 293T cells treated with control or two different TRF1 siRNAs. All lanes are 
from the same immunoblot, which was cropped to remove intervening irrelevant lanes. Actin 
was probed as a control. 
B: Quantitation of TRF1 mRNA levels using qRT-PCR after TRF1 knockdown in 293T cells. 
C: Cell cycle analysis by flow cytometry of propidium iodide-stained 293T cells treated with 
TRF1 or control siRNA. 
D: hTR/telomere FISH in thymidine/aphidicolin synchronised 293T cells treated with TRF1 
siRNA, and harvested at G2/M phase; scale bar = 10 µm. 
E: Average recruitment of telomerase to telomeres in asynchronous 293T cells treated with 
control (gray) or TRF1 (blue) siRNA; **p = 0.0011. 
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F: Average co-localisation of telomerase with telomeres in 293T cells synchronised to G2/M 
of the cell cycle by release from a thymidine/aphidicolin block; cells were treated with control 
(gray) or two different TRF1 siRNAs (blue); *p < 0.05. 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 4.6: TRF1 is required for the cell cycle regulation of human telomerase 
recruitment 
A: hTR/telomere FISH in HeLa cells treated with control or TRF1 siRNA and synchronised 
with a double thymidine block. White arrows indicate hTR signals co-localising with telomeric 
signals; scale bar = 10 µm. 
B: Telomerase co-localisation with telomeres in thymidine/aphidicolin synchronised 293T 
cells, treated with control (gray) or TRF1 (blue) siRNA. The values along the x-axis represent 
the number of hours since release of cells from G1/S boundary. The control data are the 
same as those in Figure 4.3B since these experiments were performed simultaneously. 
C: Telomerase co-localisation with telomeres in 293T cells, treated with control (gray) or 
TRF1 (blue) siRNA; cells were stained with the DNA dye VyBrant DyeCycle Violet and 
isolated into the cell cycle phases with FACS. The control data are the same as those in 
Figure 4.3C since these experiments were performed simultaneously. 
D: Quantitation of average co-localisation between hTR and telomeric signals in 
asynchronous HeLa cells following control (black) or TRF1 (blue) siRNA treatment; *p = 
0.0103. 
E: Average telomerase recruitment over the cell cycle in HeLa cells treated with control 
(black) or TRF1 (blue) siRNA. Cells were sorted by FACS into the indicated cell cycle 
phases. 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 4.7: ATM effect on telomerase recruitment is partially mediated by TRF1 
A: Immunoblots for ATM and TRF1 in 293T cells treated with control, ATM only, TRF1 only 
or double ATM/TRF1 siRNA, with vinculin probed as a control. 
B: Cell cycle analysis by flow cytometry of propidium iodide-stained 293T cells treated as in 
Figure 4.7A. 
C: FISH for hTR (green) and telomeres (red) in 293T cells treated with control or combined 
ATM and TRF1 siRNAs. Cells were either asynchronous, or synchronised with thymidine 
and aphidicolin and harvested 3 – 4 h (S phase) or 7 h (G2/M) after release from the G1/S 
boundary. Co-localisations are indicated by the white arrows in the merge row. Scale bar = 
10 µm. 
D: Quantitation of Figure 4.7C; average telomerase-telomere co-localisations after control 
(gray), ATM only (red), TRF1 only (blue) and ATM/TRF1 (green) siRNAs, in asynchronous, 
S phase or G2/M phase cell populations; n = 4; **p < 0.01. 
 
Data is presented as the mean of three independent experiments except where indicated 
otherwise, ± SD. 
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4.2.3- Phosphorylation of TRF1 at serine 367 controls TRF1 and telomerase localisation to 
telomeres 
It has been demonstrated that phosphorylation of serine 367 of TRF1 results in 
localisation of TRF1 to proteasome centres for degradation, resulting in telomere elongation 
(McKerlie et al., 2012). To demonstrate that such elongation events are due to changes in 
telomerase localisation to telomeres, I transiently expressed in 293T cells similar levels of 
myc-tagged wild-type (WT) TRF1, or TRF1 containing mutations at S367 that either abolish 
(S367A) or mimic (S367D) phosphorylation at this residue, and confirmed even levels of 
overexpression (Figure 4.8A and B), and no perturbation of the cell cycle (Figure 4.8C). 
Exogenous TRF1 was expressed at levels 10- to 15-fold greater than endogenous TRF1 
(Figure 4.8A); this level of over-expression was sufficient for replacement of endogenous 
TRF1 with myc-tagged exogenous TRF1 at ~25% of telomeres (Figures 4.9A and B, 4.10A and 
B). S367D TRF1 demonstrated lower telomere association across all phases of the cell cycle 
than WT or S367A TRF1 (Figure 4.9A and B), consistent with its inability to bind telomeric 
DNA in vitro (McKerlie et al., 2012). Levels of endogenous TRF1 were not reduced by siRNA 
in this experiment, since we expected S367D TRF1 to behave in a dominant-negative 
manner to sequester endogenous TRF1 from the telomere, as has been observed for other 
DNA binding-defective TRF1 mutants (van Steensel and de Lange, 1997); this was confirmed 
using immunofluorescence with an antibody against TRF1 (Figure 4.10). This observation 
coincided with an elevated level of telomerase recruitment in the presence of S367D TRF1 in 
G1 and G2/M phases (Figure 4.9A and C). Deregulation of telomerase recruitment in G1 and 
G2/M phases upon both TRF1 knockdown and S367D TRF1 expression was confirmed in a 
HeLa cell line stably expressing an shRNA against TRF1, together with shRNA-resistant 
S367D TRF1 (McKerlie et al., 2012, Figure 4.9D).  
Conversely, there was an ~50% decrease in telomerase recruitment at S phase in the 
presence of phosphodeficient S367A TRF1 compared to WT TRF1, in both 293T and HeLa 
cells (Figure 4.9C and D). These data suggest that phosphorylation of TRF1 at serine 367 
results in dissociation of a portion of TRF1 from telomeres during S phase, and that this is 
necessary for full telomerase recruitment. This is supported by the slight increase in levels 
of endogenous TRF1 at telomeres in G2/M relative to S phase (Figure 4.10). However, 
depletion of TRF1 levels at the telomere using siRNA, shRNA or expression of the dominant 
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negative S367D TRF1 did not lead to substantially increased telomerase at the telomere 
during S phase (Figures 4.6B, C and E, 4.7C and D, 4.9C and D, 4.10B), suggesting that 
removal of TRF1 is necessary but not sufficient for full telomerase recruitment in S phase. 
Together, these data show that the major function of TRF1 is in the displacement of 
telomerase from the telomere outside S phase, for which removal of the phosphate group at 
S367 appears to be necessary. 
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Figure 4.8: Verification of over-expressed myc-tagged TRF1 
A: Immunoblot of over-expressed myc-tagged WT TRF1, empty vector, myc-S367A TRF1 or 
myc-S367D TRF1, probed with an anti-TRF1 antibody, and with vinculin probed as a control. 
B: Relative total TRF1 mRNA abundance measured by qRT-PCR in 293T cells over-
expressing WT, S367A, and S367D myc-tagged TRF1. 
C: Profile of Vybrant DyeCycle Violet-stained 293T cells as seen in the cell sorter, illustrating 
the gating used to isolate cells in G1, mid-S and G2/M phases of the cell cycle. 
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Figure 4.9: Phosphorylation of TRF1 at serine 367 controls TRF1 and telomerase 
localisation to telomeres 
A: Immunofluorescence with an anti-myc antibody (purple) and hTR/telomere FISH (green 
and red respectively) in asynchronous 293T cells over-expressing myc-tagged WT, S367A 
or S367D TRF1. Co-localisations between hTR and telomeres are indicated by white arrows. 
Scale bar = 10 µm. 
B: Quantitation of average co-localisation of over-expressed myc-tagged TRF1 with 
telomeres across cell cycle stages in FACS sorted 293T cells; *p < 0.05, **p < 0.01, ***p < 
0.005. 
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C: Quantitation of average co-localisation of hTR and telomeres across cell cycle stages in 
FACS sorted 293T cells over-expressing myc-tagged WT TRF1, myc-S367A TRF1, or myc-
S367D TRF1; *p < 0.05, **p < 0.01, ***p < 0.005. 
D: Average telomerase recruitment over the cell cycle (± SD) in HeLa cells stably over-
expressing vector control (black), shRNA against TRF1 (grey), WT TRF1 (blue), S367A 
TRF1 (green) and S367D TRF1 (pink). The latter 3 cell lines expressed both TRF1 shRNA 
and an shRNA-resistant TRF1 construct. Cells were synchronised by a double thymidine 
block into the indicated cell cycle phases; *p < 0.05, **p < 0.01, n = 3 - 4. 
 
Data is presented as the mean of three independent experiments except where indicated 
otherwise, ± SD. 
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Figure 4.10: Phosphomimetic mutation of TRF1 at serine 367 sequesters 
endogenous TRF1 from telomeres 
A: Immunofluorescence with an anti-TRF1 antibody (red) and telomere FISH (green) in 293T 
cells transfected with empty vector and sorted into S or G2/M phase based on DNA content. 
Scale bar = 10 µm. 
B: Quantitation of total TRF1 at telomeres in S and G2/M phase sorted 293T cells over-
expressing myc-tagged WT TRF1, empty vector, or myc-S367D TRF1; *p < 0.05. 
 
Data is presented as the mean of three independent experiments ± SD. 
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4.2.4- Stalled replication forks trigger telomerase recruitment 
The mechanism of telomerase regulation at the telomere by TRF1 may involve the 
known role of TRF1 in facilitating replication of telomeric DNA (Sfeir et al., 2009). Repetitive 
telomere repeats represent challenging templates for the canonical DNA replication 
machinery, often resulting in stalled replication forks and recruitment of single-stranded 
DNA binding protein RPA and activation of ATR (Ohki and Ishikawa, 2004; Sfeir et al., 2009; 
Fouche et al., 2006; Ivessa et al., 2002); in mammalian cells, this phenotype is exacerbated 
by depletion of TRF1 (Sfeir et al., 2009; Martinez et al., 2009). The observation that 
treatment of cells with aphidicolin and thymidine results in an apparent increase in numbers 
of hTR-telomere foci (Figures 4.3B and C) suggests that DNA damage directly regulates 
telomerase recruitment. To directly examine whether this effect can be attributed to stalled 
replication forks, I subjected asynchronous 293T cells to a much shorter period of 
aphidicolin treatment. Telomerase recruitment increased ~2-fold after 30 min treatment 
with 0.5 µg/mL aphidicolin compared to controls (Figure 4.11A and B), despite no significant 
change in cell cycle profile (Figure 4.11C), and this increase was dependent upon ATR 
(Figures 4.11B). Phosphorylation of the ATR target protein Chk1 demonstrated that a 30 min 
treatment with aphidicolin was sufficient to cause replication problems and activate the ATR 
pathway (Figure 4.12A). To ensure that this aphidicolin treatment did not result in damage 
signalling from DNA double strand breaks (DSBs) arising from collapsed replication forks, I 
examined activation of the ATM-Chk2 DSB response pathway (Figure 4.12A). Aphidicolin 
treatment caused a moderate activation of ATM and Chk2 phosphorylation (Figure 4.12A, 
lane 2, and Figure 4.12B), but this was abolished by knockdown of ATR (Figure 4.12A, lane 5, 
and Figure 4.12B), indicating that it results from the direct activation of ATM by ATR that is 
known to occur upon replication fork stalling (Stiff et al., 2006), rather than from DSB 
formation. In addition, induction of DSBs by γ-irradiation triggered robust ATR-independent 
ATM activation (Figure 4.12A, lanes 3 and 6) that did not result in increased telomerase 
recruitment to telomeres (Figures 4.11A and 4.11B). Together our data demonstrate that an 
increase in stalled replication forks and the resulting ATR signalling result in an increase in 
telomerase presence at the telomere. This is consistent with the telomere lengthening 
previously observed in telomerase-positive human cells after long-term treatment with 
aphidicolin (Sfeir et al., 2009).  
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Figure 4.11: Stalled replication forks trigger telomerase recruitment 
A: FISH for hTR (green) and telomeres (red) in asynchronous 293T cells treated with control 
(3 top panels) or ATR (3 bottom panels) siRNA. DNA damage was induced by either 30 min 
of aphidicolin treatment to induce stalled replication forks or 2 Gy γ-irradiation to induce 
double strand breaks. Co-localisations between hTR and telomeres are indicated by the 
white arrows. Scale bar = 10 µm. 
B: Quantitation of telomerase localisation to telomeres in cells from Figure 4.11A; *p < 0.05. 
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C: Cell cycle analysis by flow cytometry of propidium iodide-stained 293T cells treated with 
control or ATR siRNA and the indicated treatments, to ensure that the induction of DNA 
damage did not alter the cell cycle profile. 
 
Data is presented as the mean of three independent experiments ± SD. 
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Figure 4.12: Aphidicolin treatment (30min) did not induce DNA double strand breaks 
A: Immunoblot of cells treated as in Figure 4.11, probed for ATR, pS1981 ATM, ATM, pT68 
Chk2, Chk2, pS345 Chk1, Chk1 and vinculin as a control. 
B: Quantitation of ATM activation (pS1981 ATM levels) from blot in Figure 4.12A; *p = 0.028. 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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4.3- Discussion 
In this chapter I have demonstrated that ATM and ATR are both necessary for full 
telomerase recruitment to telomeres in human cell lines. This provides an explanation, at 
least in part, for the long-standing observation of short telomeres in the ATM-deficient cells 
of ataxia telangiectasia (AT) patients (Metcalfe et al., 1996; Smilenov et al., 1997), and the 
telomere shortening observed upon inhibition of ATM in telomerase-positive immortal 
human cell lines (Wu et al., 2007). Consistently, while AT patient cells can become 
immortalised by activation of telomerase, most of these cell lines harbour very short 
telomeres (Sprung et al., 1997).  
Data from this chapter show that TRF1 is involved in the signalling pathway 
restricting telomerase access to the telomere to S phase; loss of TRF1 results in an increase 
in telomerase at the telomere in both G1 and G2/M phases. Evidence from this and previous 
studies suggests that phosphorylation of TRF1 at serine 367 results in partial TRF1 
dissociation from telomeres and its degradation; removal of this phosphate is necessary for 
correct cell cycle control of telomerase presence at the telomere. Constitutive expression of 
a phosphomimetic of S367 TRF1 also leads to inappropriate retention of telomerase at the 
telomere outside S phase, leading to a telomere length increase (Wu et al., 2007; McKerlie 
et al., 2012 and this study, Figures 4.8 – 4.10). The mechanism for this regulatory function of 
TRF1 may include its known role in facilitating telomere replication; TRF1 dissociation from 
telomeres induces replication fork stalling that activates ATR (Sfeir et al., 2009), and I 
provided evidence that replication fork stalling leads to an ATR-dependent increase in 
telomerase recruitment (Figures 4.11 and 4.12). The control of telomere replication and 
telomerase presence at the telomere by human TRF1 (Figure 4.13) appears analogous to the 
situation in Schizosaccharomyces pombe, in which deletion of the double-stranded 
telomeric binding protein Taz1 results in stalled telomeric replication forks (Miller et al., 
2006), and leads to deregulation of the cell cycle control of telomerase at the telomere 
(Dehe et al., 2012; Chang et al., 2013). It is possible that in the absence of TRF1, aberrant 
products of stalled replication forks may persist into the subsequent G2/M and G1 phases, 
forming substrates for telomerase, as has been postulated in the case of Taz1 in S. pombe 
(Dehe et al., 2012). While it has previously been hypothesised that it is the tendency of the 
replication machinery to stall in repetitive DNA that forms the signal for telomerase 
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recruitment specifically in S phase (Rog and Cooper, 2008; Verdun and Karlseder, 2006; Wu 
et al., 2007; Stern and Bryan, 2008; Dehe et al., 2012; Chang et al., 2013), we provide here 
the first direct evidence for this concept. 
The downstream targets of ATR involved in mediating human telomerase 
recruitment have not yet been identified. Under stalled fork conditions, activated ATR is 
able to phosphorylate and activate ATM (Figures 4.12A and B, Stiff et al., 2006); whether 
this phosphorylation of ATM participates in a positive feedback loop in removing TRF1 to 
accelerate ATR-mediated telomere length regulation remains to be investigated.  
Data from this chapter support a role for ATM and ATR in mediating the recruitment 
of human telomerase to telomeres (Figure 4.13). One pathway involved implicates ATM in 
mediating phosphorylation of TRF1 and its removal from the telomere, leading to 
replication fork stalling in telomeric DNA, activating ATR which then acts as a trigger for 
telomerase recruitment. 
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Figure 4.13: Model for ATM and ATR involvement in human telomerase recruitment to telomeres 
During S phase, ATM and/or other PIKKs phosphorylates TRF1 at S367, which leads to partial dissociation of TRF1 from telomeres (McKerlie 
et al., 2012; Wu et al., 2007). Depletion of TRF1, together with its protein partners Tin2, TPP1 and Pot1, causes telomeric replication forks to 
stall, leading to recruitment of RPA and ATR (Sfeir et al., 2009; Martinez et al., 2009; Zimmermann et al., 2014). ATR phosphorylates an 
unknown substrate to mediate telomerase recruitment. Replication fork stalling caused by aphidicolin treatment also leads to telomerase 
recruitment (this study) and telomere elongation (Sfeir et al., 2009). 
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Chapter 5 
ATM and ATR in regulating 
telomerase assembly 
Chapters 4 and 5 were published in the journal Cell Reports: 
Tong AS, Stern JL, Sfeir A, Kartawinata M, de Lange T, Zhu XD, Bryan TM. ATM and ATR 
Signaling Regulate the Recruitment of Human Telomerase to Telomeres, Cell Reports (2015), 
http://www.cell.com/cell-reports/references/S2211-1247(15)01211-5. 
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5. Results: ATM and ATR in regulating telomerase assembly 
Abstract 
Chapter 4 implicated ATM and ATR in the positive regulation of human telomerase 
recruitment to the telomeres. I presented evidence that ATM partially mediates this process 
through the shelterin component TRF1. To explore other TRF1-independent pathways of 
regulating telomerase, the ability of ATM and ATR to mediate initial telomerase assembly 
was examined by measuring the amount of hTR immunoprecipated with an antibody against 
hTERT. The results from this chapter demonstrate that ATM and ATR depletion reduce 
assembly of the telomerase complex, without affecting the levels of total hTR. These data 
reveal another way in which ATM and ATR can regulate telomerase activity in human cells. 
5.1 Introduction 
The assembly of telomerase represents another post-translational mechanism that 
can affect telomerase action at the telomeres, since only assembled hTERT and hTR 
complexes are able to locate to telomeres (Tomlinson et al., 2008). The identification of 
factors involved in telomerase assembly and shuttling to the telomeres poses a challenge 
due to the inherent transient nature of such interactions. Regardless, several components 
involved in telomerase assembly have been identified; they include the chaperone proteins 
p23 and Hsp90 (Forsythe et al., 2001) as well as the ATPases reptin and pontin (Venteicher 
et al., 2008). The roles of ATM and ATR in telomerase assembly, if any, have not been 
demonstrated.  
In this chapter, hTR dot blots were used to measure the levels of hTR in extracts 
from HEK 293T cells depleted for ATM and ATR, before and after immunoprecipitation (IP) 
with an hTERT antibody. This enabled the visualisation of telomerase complex assembly 
defects resulting from the knockdown of ATM or ATR. Direct telomerase activity assays 
allowed me to examine if these PIKKs have any role in affecting telomerase catalytic activity. 
In this study, I report that both ATM and ATR are required for the assembly of human 
telomerase, while not affecting the specific activity of telomerase. 
  
122 
 
5.2 Results 
5.2.1- ATM and ATR depletion affects human telomerase complex assembly 
The inability of TRF1 depletion to completely rescue telomerase recruitment after 
ATM silencing (Figure 4.7D) implies that ATM can affect other TRF1-independent pathways 
of telomerase regulation. I therefore investigated the levels of cellular telomerase 
components and their assembly capabilities. To this end, HEK 293T cells depleted for ATM 
or TRF1 were thymidine/aphidicolin synchronised into the various cell cycle stages (Figures 
5.1A and B). Measurement of total cellular hTR levels with a dot blot using an hTR specific 
probe revealed a slight inhibitory effect of TRF1 siRNA on hTR abundance across all cell cycle 
phases (Figures 5.1C and D). The amount of hTR recovered after immunoprecipitation with 
an antibody against hTERT (Figure 5.1E) reflected the levels of hTR in crude lysates, 
indicating that TRF1 depletion did not impact assembly of hTERT and hTR into an active 
complex. Conversely, treatment with ATM siRNA did not affect cellular hTR abundance 
(Figures 5.1C and D), but reduced telomerase complex assembly by ~50% across all phases 
of the cell cycle (Figure 5.1E).  
To determine if the effect of ATM in mediating telomerase complex assembly 
involves TRF1, HEK 293T cells were treated with control siRNA or simultaneous siRNAs 
targeting ATM and TRF1, and thymidine/aphidicolin synchronised to different cell cycle 
phases (Figures 5.2A and B). Measurement of hTR abundance with a dot blot using an hTR 
specific probe (Figures 5.2C) also revealed the inhibitory effect of TRF1 depletion on cellular 
hTR abundance (Figure 5.2D). Measuring the levels of hTR in complex with hTERT also 
observed a defect in assembly (Figure 5.2E), indicating that TRF1 is unlikely to be the ATM 
target responsible for this effect of telomerase assembly. 
Telomerase activity, measured by a direct non-PCR assay using immunopurified 
telomerase (Cohen and Reddel, 2008), was decreased in cells depleted for ATM compared 
to control or TRF1 silencing (Figure 5.3A and B). To ensure that this decrease in telomerase 
activity was due to the corresponding decrease in the levels of assembled telomerase 
(Figure 5.1E) and not due to a decrease in specific activity, the overall levels of telomerase 
activity were normalised against the amount of hTR recovered in the hTERT 
immunoprecipitates used in the assay (Figure 5.1E). No significant changes in the specific 
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activity of telomerase were observed after depletion of either ATM or TRF1 (Figures 5.3C), 
indicating that the decrease in overall telomerase activity can be attributed solely to the 
assembly defect resulting from ATM silencing.  
HEK 293T cells treated with a double knockdown of ATM and TRF1 also displayed a 
decrease in telomerase activity (Figure 5.4A and B). Calculation of the telomerase specific 
activity by normalising the levels of telomerase activity to the abundance of assembled 
telomerase complex again revealed no differences in the levels of telomerase specific 
activity (Figure 5.4C).This confirms that the decrease in telomerase activity observed is 
solely due to a decrease in assembled telomerase abundance rather than a change in 
specific activity. 
The effects of ATR silencing on levels of cellular telomerase RNA and telomerase 
assembly were also examined. Treatment with two different ATR siRNAs (Figure 5.5A) did 
not affect the levels of cellular hTR (Figure 5.5B and C). Again, measurement of hTR after 
hTERT IP revealed a reduction in telomerase complex assembly by up to ~50% in 
unsynchronised and G1 phase cells (Figures 5.5B and D).  
The effects of ATR silencing on telomerase activity were also measured with the 
direct non-PCR assay (Cohen and Reddel, 2008), revealing a reduction in telomerase activity 
in cells treated with ATR siRNA compared to controls (Figure 5.6A and B). Normalising these 
activity levels to the levels of assembled telomerase complex (Figure 5.5D) revealed no 
significant changes in the levels of specific activities of telomerase (Figure 5.6C), indicating 
that the decrease in telomerase activity (Figure 5.6B) is due to the reduction in levels of 
assembled telomerase rather than an effect on telomerase specific activity. 
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Figure 5.1: ATM is required for the assembly of human telomerase 
A: Cell cycle analysis by flow cytometry of propidium iodide-stained 293T cells treated with 
control, ATM, and TRF1 siRNA. 
B: Immunoblot to determine ATM and TRF1 abundance in 293T cells after treatment with 
control, ATM and TRF1 siRNA. Vinculin was probed as a control. 
C: Dot blot for hTR in 293T cells treated with control, ATM or TRF1 siRNA and synchronised 
with thymidine/aphidicolin. Crude cell lysates (top panel) contain total levels of cellular hTR 
while hTERT immunoprecipitated samples (IP) contain only hTR that has assembled with 
hTERT. Top row: in vitro-transcribed hTR standard. 
D: Quantitation of total hTR levels following control (grey), ATM (red) or TRF1 (blue) siRNA 
treatments (fmol of hTR in 1 × 106 cells) from Figure 5.1C; *p = 0.032 
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E: Quantitation of hTR assembled with hTERT (fmol of hTR in 2 × 106 cells) from Figure 
5.1C, following control (grey), ATM (red) or TRF1 (blue) siRNA treatments; *p < 0.05, ***p < 
0.005. 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 5.2: Requirement of ATM for the assembly of human telomerase is TRF1 
independent 
A: Immunoblot to determine ATM and TRF1 abundance in 293T cells after treatment with 
control siRNA, and simultaneous siRNA knock down of ATM and TRF1. Vinculin was probed 
as a control. 
B: Cell cycle analysis by flow cytometry of propidium iodide-stained 293T cells treated with 
control siRNA, or simultaneous ATM and TRF1 siRNA. 
C: Dot blot for hTR in 293T cells treated with control or ATM/TRF1 siRNA before and after 
immunoprecipitation with hTERT antibody. Crude cell lysates (top panel) contain total levels 
of cellular hTR while hTERT immunoprecipitated samples (IP) contain only hTR that has 
assembled with hTERT. Top row: in vitro-transcribed hTR standard. 
D: Quantitation of dot blot for hTR in 293T cells in Figure 5.2C. Total levels of hTR in control 
(black) and ATM/TRF1 (green) siRNA cells were quantitated using the hTR standard; **p < 
0.01, ***p < 0.005. 
E: Quantitation of hTR assembled with hTERT after treatment with combined ATM and 
TRF1 siRNAs (green); *p < 0.05, ***p < 0.005. 
In all panels, data is presented as the mean of three independent experiments ± SD.
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Figure 5.3: ATM depletion does not affect telomerase specific activity 
A: Direct telomerase activity assay of immunoprecipitated telomerase from cells treated with 
control, ATM and TRF1 siRNA, synchronised to the indicated cell cycle stages. LC 
represents an 18 nt loading control. 
B: Relative telomerase activity levels from Figure 5.3A, normalised to cell number and 
loading control, but not normalised to levels of hTR recovered. 
C: Telomerase specific activity, derived from total telomerase activity (Figure 5.3B) 
normalised to levels of hTR after hTERT immunoprecipitation (Figure 5.1E). 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 5.4: Simultaneous ATM and TRF1 depletion does not affect telomerase 
specific activity 
A: Direct telomerase activity assay of immunoprecipitated telomerase from 293T cells 
treated with control or ATM/TRF1 siRNA. LC represents an 18 nt loading control. 
B: Quantitation of telomerase activity of telomerase (Figure 5.4A) treated with control (black) 
or ATM/TRF1 (green) siRNA cells, normalised to control siRNA unsync; *p < 0.05. 
C: Quantitation of specific activity of telomerase treated with control (black) or ATM/TRF1 
(green) siRNA cells. Levels of relative specific telomerase activity were derived from total 
telomerase activity (Figure 5.4B) normalised to levels of hTR after hTERT 
immunoprecipitation (Figure 5.2E). 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 5.5: ATR is required for the assembly of human telomerase 
A: Immunoblot to determine ATR abundance in 293T cells after ATR knockdown. Vinculin 
was probed as a control. 
B: Dot blot for hTR in 293T cells treated with control or two different ATR siRNAs and 
synchronised with thymidine/aphidicolin. The combination of ATR siRNA and 
thymidine/aphidicolin treatment perturbs progression of the cells through S phase, so this 
experiment could only be performed on unsynchronised or G1 cells. Crude cell lysates (top 
panel) contain total levels of cellular hTR while hTERT immunoprecipitated samples (IP) 
contain only hTR that has assembled with hTERT. Top row: in vitro-transcribed hTR 
standard. 
C: Quantitation of total hTR levels after ATR siRNA; *p < 0.05. 
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D: Quantitation of hTR assembled with hTERT after treatment with two different ATR 
siRNAs; *p < 0.05. 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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Figure 5.6: ATR depletion does not affect telomerase specific activity 
A: Direct telomerase activity assay of immunoprecipitated telomerase from 293T cells 
treated with control or ATR siRNA. LC represents an 18 nt loading control. 
B: Relative telomerase activity levels from Figure 5.6A, normalised to cell number and 
loading control, but not normalised to levels of hTR recovered; *p < 0.05. 
C: Telomerase specific activity, derived from total telomerase activity (Figure 5.6B) 
normalised to levels of hTR after hTERT immunoprecipitation (Figure 5.5D). 
 
In all panels, data is presented as the mean of three independent experiments ± SD. 
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5.3- Discussion 
Data from this chapter demonstrate the necessity of both ATM and ATR for 
telomerase assembly in human cell lines. The observation in Chapter 4 showing that the lack 
of TRF1 does not completely rescue the telomerase recruitment defect caused by ATM 
depletion (Figure 4.7D) suggests there must be other TRF1-independent mechanisms by 
which ATM mediates telomerase localisation at telomeres.  
I demonstrated that one TRF1-independent function of ATM is its impact upon the 
ability of hTR and hTERT to assemble into a functional enzyme complex (Figures 5.1 and 
5.2), which is a prerequisite for localisation of hTR to telomeres (Tomlinson et al., 2008). 
ATR also plays a role in assembly of human telomerase; it is not known at this point if the 
substrates of these two kinases in this process are the same. This role is reflected in a 
substantial decrease in the amount of hTR recovered after hTERT IP, and in the total 
immunoprecipitated telomerase activity following ATM and ATR knockdown. Telomerase 
specific activity remains unchanged, demonstrating that neither ATM nor ATR have an effect 
on telomerase catalytic activity, consistent with results in yeast (Chan et al., 2001). No 
consensus PIKK phosphorylation motifs exist in the RNA binding domain of hTERT, implying 
either that ATM or ATR can mediate telomerase assembly by targeting regions not in the 
RNA binding domain, or that they can regulate telomerase assembly by phosphorylating 
unknown substrates (Figure 5.7B). The identity of potential substrates will be discussed in 
Chapter 6. 
The data from chapters 4 and 5 support a model incorporating multiple roles for 
ATM and ATR in the presence of human telomerase at telomeres (Figure 5.7). One pathway 
(A) involving both ATM and ATR is mediated by phosphorylation of TRF1 and its removal 
from the telomere, resulting in replication fork stalling and triggering telomerase 
recruitment. A second pathway (B), as demonstrated in this chapter, involves the role of 
ATM and ATR in facilitating telomerase assembly; additional phosphorylation targets of 
ATM, ATR and other PIKKs in the telomerase recruitment process may remain to be 
identified. These data reveal that, although it is important for telomeres to repress DNA 
damage signalling in order to avoid deleterious fusions, telomeres have also evolved the 
ability to carefully exploit aspects of DNA damage signalling pathways to regulate 
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telomerase presence at the telomere. Understanding of these regulatory pathways of 
telomerase assembly, recruitment and access to the telomere may provide valuable insight 
in the process of developing highly specific cancer therapeutics. 
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Figure 5.7: Model for ATM and ATR involvement in human telomerase recruitment to telomeres 
(A) The process of ATM and ATR in modulating telomerase recruitment during S phase, discussed in chapter 4. (B) An independent role of 
ATM and ATR involving the stimulation of telomerase assembly, which is a prerequisite for telomerase localisation to telomeres. This model 
does not preclude involvement of other unidentified substrates of ATM, ATR and other PIKKs. 
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Chapter 6 
General discussion and future 
directions 
  
136 
 
6. General discussion and future directions 
Highlights of this work: 
 ATM and ATR are required for telomerase recruitment to telomeres in human cells 
 Replication fork stalling triggers ATR-dependent telomerase recruitment to 
telomeres 
 Phosphorylation of TRF1 at an SQ site contributes to telomerase recruitment 
6.1 Summary of results 
This PhD project aimed to elucidate the roles of phosphorylation in mediating 
aspects of human telomerase regulation. By using a range of cellular and molecular 
techniques, I have made fundamental discoveries regarding the effects of phosphorylation 
on telomerase activity, recruitment, and assembly.  
To summarise the results from this project, I initially found that four previously-
identified hTERT phosphorylation sites did not affect telomerase regulation, at least for the 
parameters measured; some possible reasons for this have been discussed (Chapter 3).  
Therefore, we decided to investigate other kinase pathways that have been 
postulated to regulate telomerase. The ATM and ATR DNA damage pathways are involved in 
telomerase-mediated telomere length maintenance in S. cerevisiae and S. pombe (Moser et 
al., 2009; Moser et al., 2011; Yamazaki et al., 2012; Churikov et al., 2013). In mammals, ATM 
and ATR have been shown to affect telomere stability and regulate telomere length 
(Metcalfe et al., 1996; Smilenov et al., 1997; Wong et al., 2003; Wu et al., 2007; Pennarun et 
al., 2010), although they were also reported to be dispensable for elongation of the shortest 
mouse telomeres (Feldser et al., 2006; McNees et al., 2010). To address these conflicting 
results, we investigated the requirement for both ATM and ATR in human telomerase 
recruitment. 
Chapter 4 demonstrated that ATM and ATR are essential in mediating human 
telomerase recruitment to telomeres, with ATM exerting its regulatory effects in part 
through TRF1. TRF1 phosphorylation at S367 affects its telomere binding, and I 
demonstrated for the first time that this directly leads to changes in telomerase 
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recruitment. Additionally, this chapter also directly demonstrated the involvement of stalled 
replication forks and ATR signalling in human telomerase recruitment. 
Lastly, chapter 5 revealed a novel role for ATM and ATR in regulating telomerase 
complex assembly. The ATM-mediated pathway of telomerase assembly is TRF1-
independent, although the substrates involved in both ATM and ATR pathways of 
telomerase assembly remain to be identified.  
These results highlight the similar roles for DNA damage signalling in regulating 
telomerase between yeast and mammalian species, demonstrating surprising conservation 
between evolutionary distant human and yeast species (Yamazaki et al., 2012; Moser et al., 
2011; Tseng et al., 2006; Wu and Zakian, 2011). This conclusion is further supported by a 
recent independent study using complementary approaches, in which ATM was 
demonstrated to be necessary for telomerase-mediated telomere addition in both human 
and mouse cells (Lee et al., 2015). Together these studies have finally resolved the apparent 
discrepancies between the requirement for ATM and ATR in regulating telomerase 
recruitment and telomere lengths in S. cerevisiae and S. pombe, and the dispensability of 
ATM for telomerase presence at the shortest mouse telomeres. Here we have shown that in 
humans, ATM and ATR are required for telomerase recruitment and assembly but not its 
specific activity, and ATM exerts its regulatory effects partly through TRF1.  
6.2 Is there any biological significance for the phosphorylation of hTERT at residues S206, 
S523, T1113 and S1125? 
These phosphorylation sites were identified by either phospho-proteome studies in 
activated human lymphocytes (Tao et al., 2005), or by phospho-enrichment and mass 
spectrometry in HEK 293T cells (Scott Cohen, unpublished; see Appendix). Experiments 
performed with mutant telomerase mimicking differential phosphorylation states on all of 
these sites did not reveal effects on any parameters that were measured, including 
telomerase activity, recruitment and assembly. 
To be certain that these phosphorylation sites mediate telomerase regulation, or 
determine whether they are involved in the non-canonical functions of hTERT (as discussed 
in chapter 3), a CRISPR knock in of non-phosphorylated (A) or phospho-mimetic (D) hTERT 
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should be performed. The resulting clones containing hTERT with the desired mutations 
should be passaged over an extended period of time, before performing telomere length 
analysis (by Southern blot or quantitative FISH) to determine if mutant telomerase 
expression results in telomere length changes compared to WT telomerase controls. This 
experiment will fulfil two goals - to introduce mutant hTERT at physiological levels to avoid 
artefactual effects possible with over-expression systems, and secondly, to enable a longer-
term view on whether these mutations that mimic changes in phosphorylation states can 
affect hTERT to regulate telomerase. If there are no differences in telomere length between 
controls and mutants over multiple population doublings, it would be reasonable to 
conclude that these phosphorylation sites do not have roles in mediating telomerase action 
at the telomeres, although the non-canonical functions of hTERT still cannot be discounted. 
If there are changes in telomere length, then the various assays used in chapter 3 could be 
utilised to investigate telomerase activity levels, telomerase recruitment to the telomere, 
assembly and primer binding, but in this case in the presence of endogenous levels of 
telomerase expression. 
6.3 Are there other potential hTERT phosphorylation sites that may mediate aspects of 
telomerase regulation? 
An analysis of identified hTERT phosphorylation sites reported on 
www.phosphosite.org revealed the presence of other phosphorylation sites; those that are 
published are listed in table 6.1. There are also 6 additional sites (T26, Y122, S134, T767, 
S948 and Y949) listed on www.phosphosite.org that have been identified in 
phosphoproteomic screens by Cell Signaling Technology using a variety of cancer tissue 
samples and cell lines, although these are not published and no confirmatory data is 
presented.  
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Table 6.1: List of hTERT phosphorylation sites with observed phenotypes 
Residue Location in hTERT Reported effects (+ reference) 
Serine 227 Just downstream of 
TEN domain 
Increase affinity for importin-α (Jeong et al., 2015) 
Nuclear localisation (Chung et al., 2012) 
Increase in telomerase activity (Kang et al., 1999) 
Tyrosine 707 Reverse 
transcriptase domain 
Decrease in mitochondrial hTERT (Buchner et al., 2010) 
Nuclear export of hTERT (Jakob et al., 2008; Haendeler et al., 
2003a) 
Serine 824 Reverse 
transcriptase domain 
Increase in telomerase activity (Kang et al., 1999) 
 
Table 6.1 lists phosphorylation sites that have been reported to exhibit a phenotype 
in published studies. However, whether phosphorylation on these sites has any effects on 
telomerase regulation in terms of telomere recruitment, assembly, DNA binding or telomere 
length remains to be determined. Phosphorylation on residues S227 and K707 of hTERT by 
Akt kinase and Src kinase, respectively, has been shown to have opposing effects of either 
regulating nuclear import of hTERT, or facilitating nuclear export (Chung et al., 2012; Jakob 
et al., 2008; Haendeler et al., 2003a). Phosphorylation on S227 by Akt kinase may 
concentrate telomerase components in the nucleus and could potentially enhance 
telomerase assembly levels, activity and recruitment, while phosphorylation of K707 by Src 
kinase to decrease nuclear hTERT levels may impose a negative regulatory pressure on 
telomerase assembly and recruitment to the telomeres. Alternatively, the location of S227 
within hTERT may enhance the interaction between the TEN domain and the RBD or the 
catalytic active site (Jurczyluk et al., 2011; Moriarty et al., 2002; Moriarty et al., 2004), or 
facilitate telomerase assembly resulting in increased telomerase activity levels. Additionally, 
phosphorylation at S227 may also regulate the DNA binding capabilities or telomere 
recruitment function of the TEN domain (Sealey et al., 2010; Wyatt et al., 2007; Wyatt et al., 
2009; Jurczyluk et al., 2011; Lue, 2005; Stern et al., 2012; Armbruster et al., 2001; 
Armbruster et al., 2003) to either increase the interactions between telomerase and 
telomeric DNA, or regulate the presence of telomerase at telomere ends. Similarly, 
phosphorylation on K707 may regulate the activity or processivity of telomerase, since the 
site is located within the catalytic domain (Table 6.1). 
Phosphorylation of hTERT on S227 and S824 has been postulated to increase 
telomerase activity (Kang et al., 1999). The reasons behind these increases in telomerase 
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activity was not explored; factors such as telomerase localisation, assembly, and DNA 
binding can all affect the readout from a telomerase activity assay. Verification of an 
increase in telomerase activity due to phosphorylation on these residues should first be 
performed using the direct (i.e. non-PCR based) telomerase activity assay using WT, S227 
and S824 hTERT mutants. A direct telomerase activity assay is more quantitative than the 
PCR-based TRAP assay that was used, and will be able to provide information on whether 
phosphorylation of hTERT on these residues has any direct effect on telomerase activity or 
processivity. If phosphorylation at S824 is shown to increase telomerase activity, one 
plausible explanation could be that S824 lies in the catalytic domain of hTERT. Therefore, 
phosphorylation on this site may induce the active site to adopt a more ‘open’ configuration 
for primer binding or catalysing telomeric repeats. Alternatively, since S824 can be 
phosphorylated by the kinase Akt, at least in vitro (Kang et al., 1999), and this kinase has 
also been shown to be involved in regulating the nuclear localisation of hTERT (Chung et al., 
2012), the simultaneous phosphorylation of hTERT at S227 and S824 may localise hTERT to 
the nucleus and facilitate telomerase assembly, increasing the abundance of assembled 
telomerase and thus increasing telomerase activity levels. To investigate these aspects of 
telomerase regulation, hTERT containing non-phosphorylated or phospho-mimetic 
mutations should be expressed in cells at physiological levels using a CRISPR knock in. The 
levels of telomerase nuclear localisation, telomere recruitment, assembly and activity can 
then be compared between telomerase containing WT, phospho-mimetic or non-
phosphorylated hTERT using the techniques discussed above. 
Understanding the mechanistic reasons behind the phenotypes resulting from hTERT 
phosphorylation will improve our knowledge regarding the multiple factors that regulate 
telomerase, and potentially suggest ways to control or regulate telomerase in disease.  
6.4 Does dyskerin phosphorylation regulate telomerase? 
The mass spectrometry and phospho-analysis performed by Dr. Scott Cohen to 
reveal phosphorylation sites on hTERT also revealed two phosphorylation sites on dyskerin, 
S485 and S494 (see Appendix). The functional significance of dyskerin phosphorylation and 
how it affects telomerase regulation remains unknown. One of the main telomerase-related 
functions of dyskerin is in hTR stabilisation (Mitchell et al., 1999); phosphorylation might 
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represent a post-translational modification that regulates dyskerin interaction with hTR to 
modulate hTR stability, and hence the assembly of the telomerase complex. The 
telomerase-specific effects on assembly, recruitment and activity from such 
phosphorylation events on dyskerin could be examined in more detail using CRISPR clones 
expressing endogenous amounts of WT, non-phosphorylated or phospho-mimetic dyskerin.  
6.5 How do ATM and ATR regulate telomerase recruitment?  
I have demonstrated the regulatory role of both ATM and ATR in telomerase 
recruitment to the telomere (Chapter 4). Co-immunopurification and immunofluorescence 
experiments have identified S367 of TRF1 as a target of ATM phosphorylation (McKerlie et 
al., 2012; Wu et al., 2007). Phosphorylation at this site facilitates TRF1 displacement from 
the telomeres, resulting in telomere elongation (Wu et al., 2007; McKerlie et al., 2012). 
While I have provided a mechanistic explanation for this observation, and demonstrated 
that both ATM and TRF1 function in the same pathway (Chapter 4), there is a possibility that 
other PIKKs may also phosphorylate S367 since they have identical consensus recognition 
sequence. A mass spectrometry analysis of changes in TRF1 phosphorylation states 
following ATR depletion or inhibition should be performed to investigate if TRF1 is a target 
for ATR, whether at S367 or other sites; this can be done in tandem with a mass 
spectrometry analysis on cells with ATM knockdown to confirm if S367 of TRF1 can be 
phosphorylated in the presence of other PIKKs. Alternatively, in vitro kinase assays and gel 
shift assays can also be used to investigate whether TRF1 is phosphorylated by ATR 
(McKerlie et al., 2012). 
Telomerase recruitment across the cell cycle could also be observed in cells with a 
combined TRF1 and ATR knockdown. Since only ATM has been identified as a regulator of 
TRF1, and our model predicts that telomerase recruitment after ATM-mediated TRF1 
knockdown is ATR and replication fork stalling-dependent (Figure 5.7), we would 
hypothesise that there will be no greater telomerase recruitment resulting from a double 
TRF1/ ATR knockdown than after knockdown of ATR alone, confirming our model that ATR 
activation is downstream of TRF1 dissociation and replication fork stalling, resulting in an 
increase in telomerase recruitment at G2/M after TRF1 loss. 
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To further confirm that part of the ATM effect is upstream of the replication fork, 
measurement of fragile telomeres after ATM depletion or inhibition should be performed. A 
decrease in abundance of stalled replication forks following ATM knockdown compared to 
controls would support our hypothesis that ATM functions upstream of stalled forks. 
Neither ATM- nor ATR-mediated telomerase recruitment can be attributed to the 
regulation of telomerase assembly alone, since the levels of assembled telomerase were 
only reduced by half, in contrast to the dramatic decrease in telomerase recruitment in the 
absence of ATM or ATR (Chapters 4 and 5). Also, the fact that both ATM and ATR are non-
redundantly required for telomerase recruitment, even though they target the same 
consensus sequences, could mean they mediate telomerase recruitment through the 
phosphorylation of different substrates. To determine the downstream substrate(s) of ATR 
in mediating telomerase recruitment, a mass spectrometry analysis on 293T cells after ATR 
depletion using siRNA knockdown or inhibition with VE-822 should be performed. This will 
allow the identification of residues on shelterin components or chaperone proteins whose 
phosphorylation states change in the absence of ATR (Table 6.2). For example, TCAB1, which 
has roles in mediating telomerase recruitment, has five potential PIKK phosphorylation sites, 
one of which has been identified through phospho-proteome studies (Zhou et al., 2013; 
Kettenbach et al., 2015; Matsuoka et al., 2007). The shelterin components also contain 
multiple PIKK consensus sequences, some of which were identified from proteomic studies 
(Table 6.2). Following mass spectrometry analysis, the sites on any telomere-related 
proteins that have altered phosphorylation states after ATR inactivation or depletion should 
then be mutated, and the mutated proteins introduced into 293T cells using over-
expression or CRISPR knock in. Measuring the resulting telomerase recruitment levels will 
help confirm the identity of any ATR-specific substrates involved in mediating telomerase 
recruitment. 
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Table 6.2: PIKK consensus sequences in shelterin components and TCAB1 
Protein 
name 
No. of S/T-Q sites * No. of S/T-Q sites identified 
in proteomics studies 
References for 
proteomic studies 
TRF2 5 (23SQ24, 230TQ231, 359TQ360, 
410SQ411, 422SQ423) 
3 (230TQ231, 410SQ411, 422SQ423) (Her and Chung, 2013; 
Tanaka et al., 2005; 
Zhou et al., 2013; 
Matsuoka et al., 2007) 
TPP1 3 (116TQ117, 213SQ214, 224SQ225)  0  
POT1 1 (96TQ94)  0  
TIN2 2 (270SQ271, 297TQ298)  1 (297TQ298) (Yang and Counter, 
2013; Chen et al., 2009) 
Rap1 1 (89TQ90) 0  
TCAB1 5 (6TQ7, 64SQ65, 151SQ152, 
166TQ167, 290SQ291) 
1 (64SQ65) (Zhou et al., 2013; 
Kettenbach et al., 2015; 
Matsuoka et al., 2007) 
 
* S/T-Q sites identified by manual inspection of the amino acid sequences 
 
6.6 How does the absence of TRF1 induce telomerase recruitment outside of S phase? 
It remains to be determined how the removal of TRF1 elevates the levels of 
telomerase occupancy at telomeres outside S phase (Chapter 4). The most probable 
hypothesis, one which is also incorporated in our working model (Figure 5.7), is that TRF1 
dissociation from telomeres results in the presence and retention of stalled forks and ATR 
activation into G2/M, resulting in continual telomerase recruitment. Therefore, the double 
TRF1 and ATR depletion experiment discussed above should be performed to also 
investigate if the continuous signalling from ATR resulting from stalled replication forks is 
the major signal in allowing elevated telomerase recruitment across the cell cycle, 
particularly in G2/M phase.  
Another plausible hypothesis is that TRF1 removal leads to a conformational change 
in telomeric structure or changes in telomeric accessibility, permitting the access of 
telomerase. It has been demonstrated that TRF2 is the only shelterin component needed to 
maintain a t-loop, at least at mouse telomeres (Doksani et al., 2013), implying that any 
change in structure from TRF1 dissociation is not t-loop unwinding.  However, it is not 
known whether the level of telomere-bound TRF2 fluctuates in response to depleted TRF1 
levels in human cells, allowing the unwinding of t-loops to facilitate telomerase recruitment. 
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A ChIP experiment probing for telomeric DNA that is bound to TRF2 should be performed 
following TRF1 knockdown, to determine whether changes in telomerase recruitment 
following TRF1 depletion could result from changes in bound TRF2 levels, which in turn can 
affect telomere secondary structure.  
The shelterin components TPP1, POT1 and TIN2 have been shown to mediate 
telomerase activity, processivity and recruitment (Nandakumar et al., 2012; Wang et al., 
2007; Zhang et al., 2013; Zhong et al., 2012; Abreu et al., 2010; Frank et al., 2015). One way 
in which TRF1 depletion from the telomere could enhance telomerase recruitment is by 
altering protein-telomerase interactions at the telomere. Therefore, a ChIP experiment to 
probe for the levels of TPP1, POT1 and TIN2 at the telomere should be performed to 
investigate if the telomere occupancy of any of these shelterin components is altered 
following removal of TRF1 from the telomeres. The TPP1/ POT1 complex, tethered to TIN2, 
recruits telomerase through the TEL patch in the OB fold of TPP1 (Nandakumar et al., 2012; 
Wang et al., 2007; Zhang et al., 2013; Zhong et al., 2012; Abreu et al., 2010); it is possible 
that TRF1 removal increases the likelihood of interactions between the TEL patch of TPP1 
and telomerase, allowing for elevated levels of telomerase occupancy at the telomeres 
outside of S phase. To confirm the hypothesis that the effects of stalled replication forks 
resulting from the phosphorylation of TRF1 at S367 is due to the localisation of TRF1 and not 
other regulatory pathways, 293T cells could be depleted for endogenous TRF1 while 
overexpressing and tethering TRF1-S367D to the telomeres. Phenotypes of stalled 
replication fork can then be observed by quantitating the fragile telomere phenotype. 
To test the hypothesis that TRF1 can compete for TPP1 binding to sequester its 
interactions with telomerase, the increase in telomerase processivity that results from the 
interaction between telomerase and TPP1 could be examined with an in vitro direct 
telomerase activity assay using a telomeric primer in the presence or absence of TRF1, 
either by introducing recombinant TRF1 into the telomerase activity assay or by depleting 
cellular TRF1 prior to performing such assays (Nandakumar et al., 2012). Additionally, any 
possible TRF1 binding motif in TPP1 should be identified and mutated, and the resulting 
telomerase activity and processivity measured using the same telomerase assay mentioned 
above. Any enhancement of telomerase processivity resulting from either TRF1 depletion or 
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abolished TPP1-TRF1 interactions would support the argument that TRF1 can act as a 
negative telomerase regulator through competitive binding to TPP1. 
TIN2 is another shelterin component with roles in facilitating telomerase 
recruitment, possibly by tethering TPP1 to telomere ends (Abreu et al., 2010). However, 
mutation of R282 of TIN2 showed that, while this did not perturb the telomere binding of 
the other shelterin components, it reduced telomerase recruitment and telomere 
elongation, suggesting a direct role of TIN2 in mediating telomerase recruitment and 
telomere length regulation that is separate from its TPP1-tethering role (Frank et al., 2015; 
Abreu et al., 2010). It is plausible that TRF1 is a competitive inhibitor of interactions 
between TIN2 and telomerase; with TRF1 occupancy at the telomeres diminished, TIN2 
could be free to bind telomerase. This hypothesis will need to be rigorously tested in a 
human cell line because in a murine context, telomeric association of TIN2 is partially 
dependent upon TRF1, and a fivefold decrease in TIN2 telomeric association occurred when 
its binding with TRF1 was abolished (Frescas and de Lange, 2014). Since there are 
considerable differences between mouse and human telomere biology, TIN2 abundance at 
human telomeres should be tested with ChIP following TRF1 knockdown to determine if the 
levels of telomeric TIN2 change with decreasing levels of TRF1. 
POT1 is a shelterin component identified as a binding partner of TRF1 (Loayza and de 
Lange, 2003). The dissociation of telomeric TRF1 following S367 phosphorylation may 
abrogate POT1-mediated telomere length feedback control by diminishing the loading of 
POT1 on the single-stranded 3’ telomeric DNA, allowing for increased levels of telomerase 
recruitment and telomere lengthening (Loayza and de Lange, 2003).  
To test the levels of telomerase interaction with TIN2, TPP1 and POT1, the in vivo 
visualisation of these interactions can be observed using either a proximity ligation assay or 
the bimolecular fluorescence complementation assay. These assays work on the principle 
that when two candidate proteins interact with each other, their close proximity allows 
special probes or sections of fluorescent proteins to interact and give a fluorescent signal 
(Kerppola, 2006; Soderberg et al., 2006). The visualisation of telomerase interactions with 
TIN2, TPP1 and POT1 could then be repeated in the presence of TIN2 that is defective in 
binding to TRF1 (Kim et al., 2004), to simulate TRF1 depletion. If the levels of fluorescence, 
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and hence interactions between telomerase and shelterin components, are higher in the 
absence of TRF1 binding, then the mechanism of sequestration of protein interactions by 
TRF1 should be investigated in more detail. 
The loss of TRF1 also leads to sister telomere associations (Sfeir et al., 2009), which 
may affect telomerase association with the telomere. Another shelterin component that is 
important for sister telomere cohesion during S phase is TIN2 (Canudas and Smith, 2009); 
the DC-causing mutation cluster within TIN2 contains a binding site for the non-histone 
chromosomal protein HP1 (Canudas et al., 2011). This binding site in TIN2 and its interaction 
with HP1 is required for sister telomere cohesion and affects telomerase-mediated telomere 
length maintenance (Canudas et al., 2011). Further evidence supporting this view comes 
from a TIN2 allele (TIN2-C) with increased binding to HP1 that leads to an increase in 
telomere cohesion, resulting in increased telomere elongation by telomerase. Conversely, 
the decrease in cohesion due to a different TIN2 allele (TIN2.RD) reduced HP1 interaction 
and diminished cohesion, which led to a decrease in telomerase-mediated telomere 
elongation (Houghtaling et al., 2012). These results illustrate a correlation between the 
abundance and persistence of sister telomere associations and telomere elongation, leading 
to the hypothesis that sister telomere associations are needed during S phase for 
telomerase action (Houghtaling et al., 2012). Under this model, TRF1 re-association with 
telomeres at the end of S phase may suppress sister telomere association and telomerase 
recruitment in G2/M in a TIN2-TPP1-Pot1 dependent manner. To test this hypothesis, the 
levels of sister telomere associations could be manipulated by expressing TIN2 mutants that 
are either proficient (TIN2-C) or defective (TIN2.RD) in HP1 binding (Houghtaling et al., 
2012), leading to the establishment or abolishment of cohesion respectively. If sister 
telomere associations are required for the presence of telomerase at telomeres, then the 
introduction of the TIN2-C mutant should increase telomerase recruitment across all phases 
of the cell cycle when measured directly with hTR/ telomere FISH. Conversely, cells stably 
expressing TIN2.RD should show reduced telomerase presence at the telomeres, since 
according to the model, telomerase is not able to elongate single sister telomeres 
(Houghtaling et al., 2012). 
6.7 Does the MRN complex play any role in ATM mediated telomerase recruitment? 
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The MRN complex - MRE11, RAD50 and NBS1 - plays a vital role in the recognition of 
DNA double strand breaks and is required for the optimal activation and recruitment of 
ATM to damage sites. The resulting propagation of the DNA damage signalling cascade 
mediates cellular responses for DNA repair, cellular survival or apoptosis (Shiloh and Ziv, 
2013; Lamarche et al., 2010). Both the MRN complex and ATM have also been found to co-
operatively regulate TRF1 in mediating telomere length control (Wu et al., 2007). To test if 
the involvement of MRN complex in this process affects telomerase recruitment, 
components of the MRN complex should be depleted individually and collectively, followed 
by analysis of telomerase recruitment with hTR/telomere FISH. To further confirm that MRN 
and ATM function in the same pathway in regulating telomerase recruitment, a knockdown 
of both MRN and TRF1 (the downstream target of ATM) should be performed, with the 
hypothesis that this will alleviate the inhibition of telomerase recruitment imposed when 
only MRN is depleted. 
6.8 The role of ATM and ATR in mediating telomerase assembly 
Both kinases have been found to play a role in telomerase assembly, with the levels 
of assembled telomerase decreasing by ~50% after ATM or ATR knockdown (Chapter 5). 
How these PIKKs mediate telomerase assembly remains unknown. Broadly, the possibilities 
can be categorised into two groups: by mediating the phosphorylation states of the core 
telomerase components hTERT or dyskerin, thereby influencing the assembly capabilities of 
active telomerase, or by regulating the numerous proteins along the telomerase assembly 
pathway. 
A visual examination of putative PIKK phosphorylation sites on hTERT reveals two 
residues: 182TQ183 and 1101TQ1102. Two things were noted about these potential PIKK 
phosphorylation sites: neither of them are found within the RNA binding domain of hTERT, 
which is where they may be expected to reside if they affect the association of hTERT and 
hTR. In addition, neither of these sites were identified in phospho-proteome or mass 
spectrometry studies; this seems surprising given that ~12 studies have identified other 
phosphorylation sites on hTERT 
(http://www.phosphosite.org/proteinAction.do?id=3829&showAllSites=true), indicating 
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that although these sites contain the consensus motif for PIKK phosphorylation, they are 
likely not to be biologically active. 
The other core telomerase component is dyskerin (Mitchell et al., 1999; Cohen et al., 
2007). The protein sequence of dyskerin contains 4 PIKK consensus motifs, one of which 
(387SQ388) has been identified through in vivo mass spectrometry studies (Weber et al., 2012; 
Zhou et al., 2013; Sharma et al., 2014). Although the only known role of dyskerin in 
telomerase so far involves the stabilisation of hTR (Mitchell et al., 1999), it is known that 
telomerase can only associate with telomeres once it has been assembled (Tomlinson et al., 
2008). This would strongly suggest that the stabilisation of hTR by dyskerin plays an 
important role in maintaining levels of cellular hTR to mediate telomerase assembly and 
subsequent recruitment to the telomeres. It will be interesting to examine if any one of the 
potential PIKK phosphorylation sites on dyskerin play a role in regulating interactions with 
hTR and hence telomerase complex formation. Dyskerin could be mutated with a single 
residue change or a combination of mutations, and either exogenously expressed or 
knocked in using CRISPR to measure any defects in telomerase assembly with an hTR dot 
blot before and after hTERT immunopurification.  
Table 6.3: PIKK consensus sequences in telomerase components and assembly factors 
Protein 
name 
No. of S/T-Q sites * No. of S/T-Q sites identified 
in proteomics studies 
References for 
proteomics studies 
TERT 2 (182TQ183, 1101TQ1102) 0  
Dyskerin 4 (50SQ51, 145SQ146, 167TQ168, 
387SQ388)  
1 (387SQ388) (Sharma et al., 2014; 
Zhou et al., 2013; 
Weber et al., 2012) 
Reptin 5 (43SQ44, 120TQ121, 220SQ221, 
254TQ255, 440TQ441) 
2 (220SQ221, 254TQ255) (Kettenbach et al., 
2015; Matsuoka et al., 
2007) 
Pontin 1 (12TQ13)  0  
 
* S/T-Q sites identified by manual inspection of the amino acid sequences 
In order to determine the roles of ATM and ATR in regulating telomerase assembly, 
the search for potential PIKK phosphorylation sites should be expanded to proteins that are 
involved in the process of telomerase protein assembly. The ATPases reptin and pontin are 
required for telomerase assembly (Venteicher et al., 2008) and they contain five and one 
PIKK consensus sequence, respectively (Table 6.3). Of these, 220SQ221 and 254TQ255 on reptin 
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have been identified by mass spectrometry on 293T cells (Matsuoka et al., 2007) and HeLa 
cells (Kettenbach et al., 2015), respectively. Perhaps the most efficient way to determine if 
these ATPases play a role in telomerase assembly would involve examining any changes in 
the phosphorylation states of the five putative sites on reptin and one site on pontin with 
mass spectrometry following the depletion of ATM or ATR. Differences in phosphorylation 
states would imply a functional significance for ATM/ATR regulation; these sites should then 
be mutated and replaced in the cells, either by transient over-expression or CRISPR knock in 
for a more physiologically relevant context. Any defects in telomerase assembly can be 
measured with an hTR dot blot before and after hTERT immunoprecipitation.   
6.9 The upstream signal of ATM in mediating telomerase recruitment and assembly 
Table 6.4: PIKK consensus sequences in ATM 
Protein 
name 
No. of S/T-Q sites * No. of S/T-Q sites 
identified in proteomics 
studies 
References for 
proteomics studies 
ATM 30 (86TQ87, 160SQ161, 179SQ180, 200SQ201, 
267TQ268, 297TQ298, 367SQ368, 373TQ374, 
403SQ404, 417TQ418, 440SQ441, 475SQ476, 
875SQ876, 1075TQ1076, 1360SQ1361, 
1499SQ1500, 1577TQ1578, 1635SQ1636, 
1878SQ1879, 1905SQ1906, 1981SQ1982, 
2209SQ2210, 2242SQ2243,  2268TQ2269, 
2396TQ2397, 2592SQ2593, 2636TQ2637, 
2640TQ2641, 2761SQ2762, 2941SQ2942) 
9 (86TQ87, 200SQ201, 
297TQ298, 367SQ368, 373TQ374, 
440SQ441, 1878SQ1879, 
1981SQ1982, 2592SQ2593) 
(Matsuoka et al., 
2007; Sharma et 
al., 2014; 
Kettenbach et al., 
2015; Zhou et al., 
2013; Stiff et al., 
2006; Bakkenist 
and Kastan, 2003; 
Kim et al., 1999) 
 
* S/T-Q sites identified by manual inspection of the amino acid sequences 
An interesting observation about the activation of ATM in mediating TRF1 
phosphorylation at S367 is that ATM has the potential to phosphorylate TRF1 at multiple 
sites, some of which reportedly do not result in any changes in telomere length (Kishi et al., 
2001; Wu et al., 2007). What is different about the upstream signalling that activates ATM 
when telomerase action is needed, resulting in the differential activation of downstream 
pathways?  
Our working model suggests that the partial removal of TRF1 due to ATM 
phosphorylation at S367 increases the tendency for stalled replication forks, which then 
activates ATR to facilitate telomerase recruitment and telomere extension (Figure 5.7). The 
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activation of ATM during S phase may be induced by the unwinding of t-loops, causing an 
‘intermediate’ state telomere which has been shown to activate ATM (Cesare and Karlseder, 
2012). ATM could also be activated when telomere lengths reach a critical point where 
bound shelterin complexes are unable to form a t-loop. ATM has the potential to be 
phosphorylated on various different sites by multiple upstream signals, some of which are 
additional to its canonical response to DNA damage and double strand breaks, such as the 
phosphorylation of S1403 by Aurora B during the mitotic spindle checkpoint (Yang et al., 
2011). Identification of sites that are phosphorylated on ATM in response to the cell cycle or 
short telomeres may help identify the upstream signal in mediating ATM activation for 
telomere length maintenance.  ATM has 30 PIKK phosphorylation sites, with 9 identified 
through proteomic studies and others that do not fall within the canonical PIKK 
phosphorylation motif but were identified with phosphoproteomic screens (unpublished) by 
Cell Signaling Technology (Table 6.4, 
http://www.phosphosite.org/proteinAction.do?id=1393&showAllSites=true). It is plausible 
that sites other than S1981 are regulated by the MRN complex (or other upstream signals) 
to dictate the differential downstream phosphorylation of ATM targets.  
A mass spectrometry analysis will provide the most comprehensive overview of sites 
on ATM that can be mediated by MRN phosphorylation, or by other signals activated due to 
short telomeres. Identical cell lines but with different telomere lengths such as HT1080 or 
HeLa transduced with hTR (Pickett et al., 2009), or cells cultured in the presence of the 
telomerase inhibitor BIBR1532 to induce short telomeres (Damm et al., 2001), should be 
used to elicit a differential ATM response resulting from telomere length and analysed with 
mass spectrometry. If there are differences in the phosphorylation states of ATM residues, 
then these sites should be mutated, introduced back into cells and the possible 
phosphorylation of different residues on TRF1 or other downstream ATM targets observed 
using  phosphosite-specific antibodies. It is possible that phosphorylation induced by 
shortened telomeres targets different residues on ATM compared to other forms of DNA 
damage, allowing differential ATM activation of different downstream substrates.  
6.10 Does our working model support the preferential recruitment of telomerase to the 
shortest telomeres? 
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It has been hypothesised in S. pombe and mouse models that short telomeres are 
more likely to experience stalled replications forks due to the loss of Taz1 or TRF1 (Rog and 
Cooper, 2008; Dehe et al., 2012; Sfeir et al., 2009), and short telomeres are known to elicit 
an ATR response (d'Adda di Fagagna et al., 2003). Additionally, the preferential elongation 
of short telomeres has been observed in mouse and S. cerevisiae (Hemann et al., 2001; 
Samper et al., 2001; Teixeira et al., 2004; Sabourin et al., 2007; Marcand et al., 1997b; Chang 
et al., 2007). These results suggest that short telomeres and the resultant ATR signalling are 
required for telomerase recruitment. 
The data from human cells have been more controversial. Some studies have 
demonstrated the preference of human telomerase for extension of short telomeres 
(Tomlinson et al., 2006; Ouellette et al., 2000; Steinert et al., 2000; Britt-Compton et al., 
2009), while it has also been shown that human telomerase can extend every telomere 
during S phase under telomere length-maintenance conditions (Zhao et al., 2009). It is also 
plausible that in addition to an ATR-mediated response, short telomeres will elicit an ATM 
response independent of replication fork stalling, due to insufficient shelterin complex 
binding or the inability to form protective structures such as t-loops. Therefore, to test if our 
working model supports the notion that recruitment of telomerase displays a preference for 
the shortest telomeres and requires ATM or ATR (as in S. pombe (Yamazaki et al., 2012; 
Moser et al., 2011) and  S. cerevisiae (Chang et al., 2007)), a quantitative analysis of the 
lengths of telomeres  associated with telomerase should be performed using quantitative 
hTR/telomere FISH (Martens et al., 2000). This analysis will reveal if telomerase is 
preferentially localised at shorter telomeres in human cells, and whether this preference is 
altered after ATM or ATR depletion or inhibition.  
6.11 Does the ATM/ATR kinase pathway mediate telomerase recruitment in normal cells 
with telomerase expression?  
We have demonstrated the requirement for ATM and ATR in mediating telomerase 
recruitment in cancer cells. An intriguing question is whether this pathway for mediating 
telomerase recruitment is also essential in normal cells that use telomerase, such as 
activated lymphocytes or stem cells (Hiyama et al., 1995; Norrback et al., 1996; Morrison et 
al., 1996). To examine this, ATM and ATR could be depleted individually in activated 
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lymphocytes or stem cells, and telomerase recruitment measured with telomere/ hTR FISH. 
A potential caveat to this might be that endogenous levels of telomerase expression might 
be too low in these cell types to obtain robust signals. If so, the hTR probes could be 
modified to contain more fluorophores in order to increase signal sensitivity and robustness 
of the procedure. 
If ATM and ATR are demonstrated to not be required for telomerase recruitment in 
normal cells, then this pathway of telomerase recruitment may represent a gain of function 
by which cancer cells achieve replicative immortality, which may provide promising drug 
targets specific for cancer cells. 
6.12 Conclusion 
153 
 
 
Figure 6.1: Summary of ATM and ATR in regulating telomerase recruitment and 
assembly 
ATM/ ATR mediate the phosphorylation of downstream substrates to mediate telomerase 
recruitment to telomeres. Part of the kinase pathway of ATM involves the shelterin 
component TRF1 (top panel). Both ATM and ATR regulate telomerase assembly through as 
yet unknown substrates (bottom panel). 
Phosphorylation by ATM and ATR plays a major role in regulating telomerase 
recruitment and assembly (Figure 6.1). This project demonstrated the direct influence of 
ATM and ATR phosphorylation on telomerase recruitment and how TRF1 is a substrate for 
ATM in this process. The direct induction of telomerase recruitment following replication 
fork stalling and ATR activation has also been demonstrated. This project also revealed a 
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novel involvement of ATM and ATR in regulating telomerase assembly. A detailed 
mechanistic understanding of processes leading to these observations should be pursued, to 
increase our knowledge of the roles DNA damage proteins play in telomerase regulation, 
and allow for development of potential new cancer therapeutic targets. 
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Appendix: Mass Spectrometry data for hTERT 
 
 
 
 
 
 
A) ms/ms data for peptide hTERT201-209, showing the difference in mass of 80 for the non-phosphorylated and phosphorylated peptide obtained 
after titanium dioxide enrichment. 
B) ms/ms data for peptide hTERT522-536, showing the difference in mass of 80 for the non-phosphorylated and phosphorylated peptide obtained 
after titanium dioxide enrichment. 
C) ms/ms data for peptides dyskerin478-500 and titanium dioxide enriched dyskerin480-501, showing the difference in mass of 80 for the non-
phosphorylated and phosphorylated peptide obtained after titanium dioxide enrichment, taking into account the extra alanine (Mr 71) on the 
non-phosphorylated peptide. 
D) ms/ms data for peptide dyskerin478-500, showing the difference in mass of 80 for the non-phosphorylated and phosphorylated peptide 
obtained after titanium dioxide enrichment. 
Group Protein Peptide Mr (calc) Mr (expt) Observed (m/z) ppm 
A hTERT201-209  R.AWNHSVR.E 868.4304 868.4302 435.2224 -0.21 
A hTERT201-209 (TiO2 enriched) R.AWNHSVR.E 948.3967 948.3959 475.2052 -0.88 
B hTERT522-536 R.SPGVGCVPAAEHR.L 1278.6139 1278.6134 640.3140 -0.41 
B hTERT522-536 (TiO2 enriched) R.SPGVGCVPAAEHR.L 1358.5707 1358.5703 680.2925 -0.28 
C Dyskerin478-500 K.AKAGLESGAEPGDGDSDTTKK.K 2032.9549 2032.9543 678.6587 -0.29 
C Dyskerin480-501(TiO2 enriched) K.AGLESGAEPGDGDSDTTKKK.K 2041.8841 2041.8843 681.6354 0.08 
D Dyskerin478-500 K.AKAGLESGAEPGDGDSDTTKK.K 2032.9549 2032.9543 678.6587 -0.29 
D Dyskerin478-500(TiO2 enriched) K.AKAGLESGAEPGDGDSDTTKK.K 2112.9212 2112.9210 705.3143 -0.13 
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